DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 1 of 97  
A Phase 1/2 Study of Delayed Heterologous SARS -CoV -2 Vaccine Dosing (Boost) after 
Receipt of EUA Vaccines   
 
DMID Protocol Number: 21-0012  
 
IND Sponsor: Division of Microbiology and Infectious Diseases (DMID)  
 
Version Number: 10.0 
 
06 April 2023   
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 2 of 97 STATEMENT OF COMPLIANCE  
Each institution engaged in this research will hold a current Federal  wide Assurance (FWA) 
issued by the Office of Human Research Protection (OHRP) for federally funded research.  The 
Institutional Review Board ( IRB)/Independent or Institutional Ethics Committee  (IEC) must be 
registered with OHRP as applicable to the research.  
 
The study will be carried out in accordance with the following as applicable:  
• United States (US) Code of Feder al Regulations (CFR) 45 CFR Part 46: Protection of 
Human Subjects  
• Food and Drug Administration (FDA) Regulations: 21 CFR Part 50 (Protection of 
Human Subjects), 21 CFR Part 54 (Financial Disclosure by Clinical Investigators), 21 
CFR Part 56 ( IRBs), 21 CFR Part 11, and 21 CFR Part 312 (Investigational New Drug 
Application), and/or 21 CFR 812 (Investigational Device Exemptions)  
• The International Council for Harmonisation (ICH) of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) E 6(R2) Good Clinical Practice  
(GCP) , and the Belmont Report: Ethical Principles and Guidelines for the Protection of 
Human Subjects of Research, Report of the National Commission for the Protection of 
Human Subjects of Biomedical and Behavioral Research  
• The policies and procedures of National Institutes of Health (NIH) Office of Extramural 
Research and Division of Microbiology and Infectious Diseases ( DMID ) 
• The National Institute of Allergy and Infectious Diseases (NIAID) Terms of Award  
• Any additional Federa l, State, and Local Regulations and Guidance  
 
The signature below provides the necessary assurance that this study will be conducted 
according to all stipulations of the protocol , including statements regarding confidentiality, and 
according to local legal  and regulatory requirements , US federal regulations , and ICH E6 (R2) 
GCP guidelines.  
 
Site Investigator  Signature : 
 
Signed:   Date:   
 Name, Credentials  
Title  
   
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 3 of 97 TABLE OF CONTENTS  
 
STATEMENT OF COMPLIANCE  ................................ ................................ ................................  2 
TABLE OF CONTENTS  ................................ ................................ ................................ ................  3 
LIST OF TABLES  ................................ ................................ ................................ ..........................  8 
LIST OF FIGURES  ................................ ................................ ................................ ........................  8 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...... 9 
1.1 Synopsis  ................................ ................................ ................................ ..........................  9 
1.2 Schedule of Activities (SOA)  ................................ ................................ .......................  18 
2 INTRODUCTION  ................................ ................................ ................................ ................  22 
2.1 Background and Study Rationale ................................ ................................ ..................  22 
2.1.1  Public Readiness and Emergency Preparedness Act  ................................ ............  23 
2.2 Risk/Benefit Assessment  ................................ ................................ ..............................  24 
2.2.1  Known Potential Risks  ................................ ................................ ..........................  24 
2.2.2  Known Potential Benefits  ................................ ................................ .....................  29 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ......................  30 
4 STUDY DESIGN ................................ ................................ ................................ ..................  32 
4.1 Overall Design  ................................ ................................ ................................ ..............  32 
4.2 Scientific Rationale for Study Design ................................ ................................ ...........  37 
4.3 Justification for D oses................................ ................................ ................................ ... 37 
5 STUDY POPULATION  ................................ ................................ ................................ ....... 39 
5.1 Inclusion Criteria  ................................ ................................ ................................ ..........  39 
5.2 Exclusion Criteria  ................................ ................................ ................................ .........  39 
5.2.1  Exclusion of specific populations  ................................ ................................ .........  39 
5.3 Inclusion of Vulnerable Subjects  ................................ ................................ ..................  39 
5.4 Lifestyle Considerations  ................................ ................................ ...............................  39 
5.5 Screen Failures  ................................ ................................ ................................ ..............  40 
5.5.1  Strategies for Recruitment and Retentio n ................................ .............................  40 
5.5.2  Retention  ................................ ................................ ................................ ...............  40 
5.5.3  Compe nsation Plan for Subjects  ................................ ................................ ...........  40 
5.5.4  Costs  ................................ ................................ ................................ ......................  40 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 4 of 97 6 STUDY PRODUCT ................................ ................................ ................................ ..............  41 
6.1 Study Product(s) and Administration ................................ ................................ ............  41 
6.1.1  Study Product Description  ................................ ................................ ....................  41 
6.1.2  Dosing and Administration  ................................ ................................ ...................  42 
6.1.3  Dose Modifications  ................................ ................................ ...............................  43 
6.2 Accountability/Handling/Storage/Preparation  ................................ ..............................  43 
6.2.1  Acquisition and Accountability  ................................ ................................ ............  43 
6.2.2  Formulation and Appearance  ................................ ................................ ................  44 
6.2.3  Product Storage and Stability ................................ ................................ ................  45 
6.2.4  Preparation  ................................ ................................ ................................ ............  47 
6.3 Measures to Minimize Bias: Randomization an d Blinding  ................................ ..........  47 
6.3.1  Treatment Assignment Procedures  ................................ ................................ ....... 47 
6.3.2  Randomization and Blinding  ................................ ................................ ................  47 
6.3.3  Blinding and Masking Procedures  ................................ ................................ ........  47 
6.4 Study Intervention Compliance  ................................ ................................ ....................  47 
6.5 Concomitant Therapy ................................ ................................ ................................ .... 47 
6.5.1  Rescue Medicine  ................................ ................................ ................................ ... 48 
6.5.2  Non-Research Standard of Care ................................ ................................ ............  48 
7 STUDY INTERVENTION DISCONTINUATION AND SUBJECT 
DISCONTINUATION/WITHDRAWAL ................................ ................................ .....................  49 
7.1 Halting Criteria and Discontinuation of Study Intervention  ................................ .........  49 
7.1.1  Halting Criteria  ................................ ................................ ................................ ..... 49 
7.1.2  Criteria for Continuation of Dosing and Redosing  ................................ ...............  49 
7.1.3  Discontinuation of Study Intervention  ................................ ................................ .. 49 
7.1.3.1  Delay of Study Vaccination  ................................ ................................ ..............  50 
7.1.4  Follow -up for Subjects that Discontinued Study Intervention  .............................  50 
7.2 Subject Withdrawal from the Study and Replacement  ................................ .................  50 
7.3 Lost to Follow -Up ................................ ................................ ................................ .........  51 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ................................  52 
8.1 Screening and Immunogenicity Assessments  ................................ ...............................  52 
8.1.1  Screening or Enrollment/Baseline Procedures ................................ ......................  52 
8.1.2  Immunogenicity Evaluations  ................................ ................................ ................  53 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 5 of 97 8.1.3  Samples for Illness Visit  ................................ ................................ .......................  54 
8.1.4  Samples for Genetic/Genomic Analysis  ................................ ...............................  54 
8.1.4.1  Genetic/Genomic Analysis  ................................ ................................ ...............  54 
8.1.4.2  Genetic Privacy and Confidentiality  ................................ ................................ . 54 
8.1.4.3  Management of Results ................................ ................................ .....................  55 
8.2 Safety and Other Assessments  ................................ ................................ ......................  55 
8.2.1  Procedures to be Followed in the Event of Abnormal Clinical Findings  .............  60 
8.3 Adverse Events and Serious Adverse Events  ................................ ...............................  60 
8.3.1  Definition of Adverse Event (AE)  ................................ ................................ ........  60 
8.3.1.1  Solicited Adverse Events  ................................ ................................ ..................  60 
8.3.1.2  Unsolicited Adverse Events  ................................ ................................ ..............  61 
8.3.1.3  Special Reporting of Adverse Events  ................................ ...............................  61 
8.3.2  Definition of S erious Adverse Event (SAE)  ................................ .........................  61 
8.3.3  Suspected Unexpected Serious Adverse Reactions (SUSAR) ..............................  62 
8.3.4  Classification of an Adverse Event  ................................ ................................ ....... 62 
8.3.4.1  Severity of Adverse Events  ................................ ................................ ...............  62 
8.3.4.2  Relationship to Study  Intervention  ................................ ................................ ... 63 
8.3.5  Time Period and Frequency for Event Assessment and Follow -Up .....................  63 
8.3.6  Adverse Event Reporting  ................................ ................................ ......................  63 
8.3.6.1  Investigators Reporting of AEs  ................................ ................................ .........  64 
8.3.7  Serious Adverse Event Reporting  ................................ ................................ .........  64 
8.3.7.1  Investigators Reporting of SAEs  ................................ ................................ ...... 64 
8.3.7.2  Regulatory Reporting of SAEs  ................................ ................................ .........  64 
8.3.8  Reporting Events to Subjects  ................................ ................................ ................  65 
8.3.9  Adverse Events of Special Interest (AESIs)  ................................ .........................  65 
8.3.10  Reporting of Pregnancy  ................................ ................................ ........................  66 
8.4 Unanticipated Problems  ................................ ................................ ................................  67 
8.4.1  Definition of Unanticipated Pro blems (UPs)  ................................ ........................  67 
8.4.2  Unanticipated Problem Reporting ................................ ................................ .........  67 
8.4.3  Reporting Unanticipated Problems to Subjects  ................................ ....................  67 
9 STATISTICAL CONSIDERATIONS ................................ ................................ ..................  68 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 6 of 97 9.1 Statistical Hypotheses  ................................ ................................ ................................ ... 68 
9.2 Sample Size Determination ................................ ................................ ...........................  68 
9.2.1  Sample Size Calculation for the Safety Endpoint  ................................ .................  68 
9.2.2  Sampl e Size Calculation for the Immunogenicity Endpoints  ...............................  68 
9.3 Populations for Analyses  ................................ ................................ ..............................  71 
9.4 Statistical Analyses  ................................ ................................ ................................ ....... 71 
9.4.1  General Approach  ................................ ................................ ................................ . 71 
9.4.2  Analysis of the Primary Endpoint(s) ................................ ................................ ..... 71 
9.4.3  Analysis of the Co -Primary Endpoint(s) ................................ ...............................  71 
9.4.4  Safety Analyses  ................................ ................................ ................................ ..... 72 
9.4.5  Baseline Descriptive Statistics  ................................ ................................ ..............  72 
9.4.6  Planned Interim and Early Analyses  ................................ ................................ ..... 72 
9.4.6.1  Interim Safety Analyses  ................................ ................................ ....................  73 
9.4.6.2  Interim Immunogenicity Re view  ................................ ................................ ...... 73 
9.4.6.3  Interim Immunogenicity and Safety Review  ................................ ....................  73 
9.4.7  Sub-Group Analyses  ................................ ................................ .............................  73 
9.4.8  Tabulation of Individual Subject Data  ................................ ................................ .. 73 
9.4.9  Exploratory Analyses  ................................ ................................ ............................  73 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ....... 75 
10.1  Regulatory, Ethical, and Study Oversight Considerations ................................ ............  75 
10.1.1  Informed Consent Process  ................................ ................................ ....................  75 
10.1.1.1  Requirements for Permission by Parents/Guardians and Assent by Children 
(in case of a minor)  ................................ ................................ ................................ ...........  76 
10.1.1.2  Other Informed Consent Procedures  ................................ .............................  76 
10.1.2  Study Termination and Closure  ................................ ................................ ............  78 
10.1.3  Confidentiality and Privacy  ................................ ................................ ..................  78 
10.1.4  Secondary Use of Stored Specimens and Data  ................................ .....................  80 
10.1.4.1  Samples for Secondary Research  ................................ ................................ .. 80 
10.1.4.2  Data Sharing for Secondary Research  ................................ ..........................  80 
10.1.5  Key Roles and Study Governance  ................................ ................................ ........  81 
10.1.6  Safety Oversight ................................ ................................ ................................ .... 81 
10.1.6.1  Safety Monitoring Committee (SMC)  ................................ ..........................  81 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 7 of 97 10.1.7  Clinical Monitoring  ................................ ................................ ...............................  81 
10.1.8  Quality Control (QC) and Quality Assurance (QA)  ................................ .............  82 
10.1.9  Data Handling and Record Keeping  ................................ ................................ ..... 82 
10.1.9.1  Data Collection and Management Responsibilities  ................................ ...... 82 
10.1.9.2  Study Record Retention  ................................ ................................ ................  83 
10.1.9.3  Source Records  ................................ ................................ .............................  83 
10.1.9.4  Protocol Deviations  ................................ ................................ .......................  84 
10.1.9.5  Publication and Data Sharing Policy  ................................ ............................  84 
10.1.9.6  Human Data Sharing Plan  ................................ ................................ .............  84 
10.1.9.7  Genomic Data Sharing (GDS) Plan  ................................ ..............................  84 
10.1.9.8  Publication  ................................ ................................ ................................ .... 85 
10.1.9.9  Conflict of Interest Policy  ................................ ................................ .............  85 
10.2  Additional Considerations  ................................ ................................ ............................  85 
10.2.1  Research Related Injuries  ................................ ................................ .....................  85 
10.3  Abbreviations  ................................ ................................ ................................ ................  85 
10.4  Protocol Amendment History  ................................ ................................ .......................  90 
11 REFERENCES  ................................ ................................ ................................ .....................  90 
12 APPENDIX A: Adverse Events of Special Interest (AESIs) Terms  ................................ .... 94 
 
  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 8 of 97 LIST OF TABLES  
Table 1: EUA -dosed Cohort 1  ................................ ................................ ................................ ...... 13 
Table 2 : Prospective Cohort 2 ................................ ................................ ................................ ....... 16 
Table 3: SOA for EUA -dosed Cohort 1  ................................ ................................ ........................  18 
Table 4: SOA for Prospective Cohort 2 (prior to 2nd booster dose):  ................................ ............  19 
Table 5: SOA for Prospective Cohort 2 (2nd booster dose)  ................................ ..........................  20 
Table 6: SOA for Cohort 2 Volunteers who do not proceed to first Study Booster  .....................  21 
Table 7: Objectives and Endpoints (Outcom e Measures) ................................ .............................  30 
Table 8: Cohort 1 Treatment Arms  ................................ ................................ ...............................  34 
Table 9: Cohort 2 Treatment Arms  ................................ ................................ ...............................  36 
Table 10: Venipuncture Volumes for Cohort 1 (One Vaccination – EUA Dosed Cohort)  ..........  57 
Table 11: Venipuncture Volumes for Cohort 2: (Up to Three Vaccinations)  ..............................  58 
Table 12: Venipuncture Volumes for Cohort 2: (Fourth Vaccination) ................................ .........  59 
Table 13: Probability of Observing an Adverse Event for Various Event Rates in one vaccine 
schedule group (or age subgroup), assuming no attrition (N = 50 or N = 25) or approximately 
10% attrition (N = 45 or N = 22).  ................................ ................................ ................................ . 69 
Table 14: Two -sided 95% confidence intervals based on observing a particular average loge -
antibody titer in subjects’ vaccine groups and age subgroups.  ................................ .....................  70 
Table 15: Abbreviations  ................................ ................................ ................................ ................  85 
Table 16: Protocol Amendment History  ................................ ................................ .......................  90 
 
LIST OF FIGURES  
No table of figures entries found.  
  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 9 of 97 1 PROTOCOL SUMMARY  
1.1 Synopsis  
 
Title:   A Phase 1/2 Study of Delayed Heterologous SARS -CoV -2 Vaccine Dosing 
(Boost) after Receipt of EUA Vaccines.  
Phase:   Phase 1/2 
Population:   Approximately 1130 healthy individuals aged ≥ 18 years  
Sites:    Approximately 10 clinical research sites.  
 
Rationale:  
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS -CoV -2), causative agent of the 
coronavirus disease of 2019 (COVID -19) pandemic,  has infected over 182 million people 
worldwide and resulted in over 3.9 million deaths, including > 605,000 in the Unite d States ( July 
02, 2021, WHO; (www.who.int ). Multiple Phase 3 efficacy trials of SARS -CoV -2 vaccine 
constructs are underway or in long -term follow -up in the U.S, and these studies have supported 3 
Emergency Use Authorizations (EUAs) for COVID vaccines. The emergence of variant strains 
has raised concerns about the breadth of immunity and protection achieved by the current 
vaccines. WHO SAGE and CDC ACIP have identified the safety and immunogenicity of mixed 
schedules as a critical and immediate research pri ority to inform policy on the use of mixed 
schedules.  
Knowledge of the safety, tolerability, and immunogenicity of a boost vaccine using a  
heterologous platform with the homologous or variant spike lineage administered after an  EUA 
prim ary dosing is a critical piece of information needed to inform public health decisions . The 
heterologous boost strategy will also provide an opportunity to thoroughly evaluate innate, 
cellular, and hum oral immune responses elicited from the multiple prime boost combinations 
using very similar immunogens, utilizing mRNA, adenovirus - vectored, and protein -based 
platforms. As new vaccines  are manufactured to emerging variants, these foundational data will 
be key to the evaluation of future variant and heterologous prime -boost strategies. This phase 1/2 
clinical trial will evaluate the safety and immunogenicity of different heterologous delayed doses 
(boosts) in those who received an EUA vaccine (either prio r to participation in this trial, or as 
part of this trial).  
Objectives:  
Primary:  
1. To evaluate the safety and reactogenicity of delayed heterologous or homologous 
vaccine doses after EUA dosed vaccines:   
• Local and systemic solicited adverse events for 7 da ys following the delayed boost 
dose.   
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 10 of 97 • Adverse Events from Dose 1 to 28 days following each vaccination and delayed boost 
dose.   
• MAAEs, SAEs, NOCMCs, and AESI s from Dose 1  to end of planned study 
participation .  
2. To evaluate humoral immunogenicity of hetero logous booster vaccines following 
EUA dosing.  
Exploratory:   
1. To assess, in at least a subset of samples, the B cell immune response following 
EUA vaccination and delayed boost;  
2. To assess, in at least a subset of samples, the SARS -CoV -2 protein -specific T ce ll 
responses following EUA vaccination and delayed boost ; 
3. To evaluate breakthrough symptomatic SARS -CoV -2 infection and sequence 
strains to assess for variant spike lineage.   
4. To assess , in at least a subset of samples,  mucosal (salivary and nasal) SARS -
CoV -2 spike protein -specific IgG and IgA responses  and assess correlation with serologic 
responses . 
Study Design:   
This Phase 1/2 study will evaluate the safety, tolerability, immunogenicity of different SARS -
CoV -2 vaccine delayed boost at >12 weeks. This study will be composed of two different 
cohorts:  
1. A cohort of persons previously vaccinated with an EUA vaccine who  will be 
boosted with a homologous  or heterologous  vaccine strain on a homologous or a 
heterologous platform (  
Group  Sample 
Size*  EUA Dosing 
Scheme  Interval(weeks)  Delayed 
Boost er 
Vaccination  Strategy Tested  
1E 50 Previously 
dosed Janssen – 
Ad26.COV2 -S ≥12 Moderna - 
mRNA -1273   Same Strain  
Heterologous 
platform  
2E 50 Previously 
dosed Moderna 
– mRNA -1273  ≥12 Moderna - 
mRNA -1273  Control - 
Same Strain  
& platform  
3E 50 Previously 
dosed 
Pfizer/BioNTech 
–BNT162b2  ≥12 Moderna - 
mRNA -1273  Same Strain  
Similar  
platform  
4E 50 Previously 
dosed Janssen – 
Ad26.COV2 -S ≥12 Janssen – 
Ad26.COV2 .S Control - 
Same Strain  
& platform  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 11 of 97 Group  Sample 
Size*  EUA Dosing 
Scheme  Interval(weeks)  Delayed 
Boost er 
Vaccination  Strategy Tested  
5E 50 Previously 
dosed Moderna 
– mRNA -1273  ≥12 Janssen – 
Ad26.COV2 .S  Same Strain  
Heterologous 
platform  
6E 50 Previously 
dosed 
Pfizer/BioNTech 
–BNT162b2  ≥12 Janssen – 
Ad26.COV2 .S  Same Strain  
Heterologous 
platform  
7E 50 Previously 
dosed Janssen – 
Ad26.COV2 -S ≥12 Pfizer/BioNTech 
–BNT162b2   Same Strain  
Heterologous 
platform  
8E 50 Previously 
dosed Moderna 
– mRNA -1273  ≥12 Pfizer/BioNTech - 
BNT162b2  Same Strain  
Similar  
platform  
9E 50 Previously 
dosed 
Pfizer/BioNTech 
–BNT162b2  ≥12 Pfizer/BioNTech 
–BNT162b2  Control - 
Same Strain  
& platform  
10E 50 Previously 
dosed Janssen – 
Ad26.COV2 -S ≥12 Moderna - 
mRNA -1273.211  Variant Strain  
Heterologous 
platform   
11E 50 Previously 
dosed 
Pfizer/BioNTech 
–BNT162b2  ≥12 Moderna - 
mRNA -1273.211  Variant Strain  
Similar  
platform   
12E 50 Previously 
dosed Janssen – 
Ad26.COV2 -S ≥12 Moderna - 
mRNA -1273  50 
mcg   Same Strain  
Heterologous 
platform  
13E 50 Previously 
dosed Moderna 
– mRNA -1273  ≥12 Moderna - 
mRNA -1273  50 
mcg  Control - 
Same Strain  
& platform  
14E 50 Previously 
dosed 
Pfizer/BioNTech 
–BNT162b2  ≥12 Moderna - 
mRNA -1273  50 
mcg  Same Strain  
Similar  
platform  
15E 60 Previously 
dosed  +/- 
boosted  Janssen 
– Ad26.COV2 -S ≥12 NVX -CoV2373  
5 mcg SARS -CoV-
2 rS 
50 mcg Matrix -
M Same Strain 
Heterologous 
platform  
16E 60 Previously 
dosed Moderna 
– mRNA -1273  ≥12 NVX -CoV2373  
5 mcg SARS -CoV-
2 rS 
50 mcg Matrix -
M Same Strain  
Heterologous 
platform  
17E 60 Previously 
dosed ≥12 NVX -CoV2373  
5 mcg SARS -CoV-
2 rS Same Strain  
Heterologous 
platform   
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 12 of 97 2. ); and  
3. A cohort of persons who are prospectively vaccinated with EUA standard dosing 
and who will be available for rapid assessment of a heterologous boost at s ome 
point in the future ( Table 2). 
EUA-dosed Cohort:  Cohort 1 will recruit persons who have previously received COVID -19 
vaccine under EUA dosing guidelines, completing their regimen at least 12 weeks  prior to 
enrollment . Eligible individuals will be stratified by age group (18-55 years or > 56 years) in a 
1:1 ratio (N = 25/group *). Subjects  will be sequentially enrolled to receive one of the available 
delayed boost options (  Group  Sample 
Size*  EUA Dosing 
Scheme  Interval(weeks)  Delayed 
Boost er 
Vaccination  Strategy Tested  
Pfizer/BioNTech 
–BNT162b2  50 mcg Matrix -
M 
Group  Sample 
Size*  EUA Dosing 
Scheme  Interval(weeks)  Delayed 
Boost er 
Vaccination  Strategy Tested  
1E 50 Previously dosed 
Janssen – 
Ad26.COV2 -S ≥12 Moderna - mRNA -
1273   Same Strain  
Heterologous 
platform  
2E 50 Previously dosed 
Moderna – 
mRNA -1273  ≥12 Moderna - mRNA -
1273  Control - Same 
Strain  
& platform  
3E 50 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 Moderna - mRNA -
1273  Same Strain  
Similar  platform  
4E 50 Previously dosed 
Janssen – 
Ad26.COV2 -S ≥12 Janssen – 
Ad26.COV2 .S Control - Same 
Strain  
& platform  
5E 50 Previously dosed 
Moderna – 
mRNA -1273  ≥12 Janssen – 
Ad26.COV2 .S  Same Strain  
Heterologous 
platform  
6E 50 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 Janssen – 
Ad26.COV2 .S  Same Strain  
Heterologous 
platform  
7E 50 Previously dosed 
Janssen – 
Ad26.COV2 -S ≥12 Pfizer/BioNTech –
BNT162b2   Same Strain  
Heterologous 
platform  
8E 50 Previously dosed 
Moderna – 
mRNA -1273  ≥12 Pfizer/BioNTech - 
BNT162b2  Same Strain  
Similar  platform  
9E 50 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 Pfizer/BioNTech –
BNT162b2  Control - Same 
Strain  
& platform  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 13 of 97 ).  A total of approximately 50* per group will be recruited for each group (combination of EUA 
primary vaccination plus booster)  in Cohort 1.  *Note: Due to the surge in Omicron variant cases, 
vaccinated individuals  may be prone to asymptomatic breakthrough infections. Stage 6 (Groups 
15E-17E) sample size will be expanded to N  = 60/group (approximately 1:1 age strata). This 
study is designed to be adaptive, and as more vaccines become available either under EUA  (or 
anticipated to have an EUA  in the next few months ), or new variants of available EUA vaccine s 
become available,  the number of groups may be expanded.  Particip ants will be assessed for 
safety and tolerability endpoints following administration of a delayed boost.  
Table 1: EUA -dosed Cohort 1  Group  Sample 
Size*  EUA Dosing 
Scheme  Interval(weeks)  Delayed 
Boost er 
Vaccination  Strategy Tested  
10E 50 Previously dosed 
Janssen – 
Ad26.COV2 -S ≥12 Moderna - mRNA -
1273.211  Variant Strain  
Heterologous 
platform   
11E 50 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 Moderna - mRNA -
1273.211  Variant Strain  
Similar  platform   
12E 50 Previously dosed 
Janssen – 
Ad26.COV2 -S ≥12 Moderna - mRNA -
1273  50 mcg   Same Strain  
Heterologous 
platform  
13E 50 Previously dosed 
Moderna – 
mRNA -1273  ≥12 Moderna - mRNA -
1273  50 mcg  Control - Same 
Strain  
& platform  
14E 50 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 Moderna - mRNA -
1273  50 mcg  Same Strain  
Similar  platform  
15E 60 Previously dosed  
+/- boosted  
Janssen – 
Ad26.COV2 -S ≥12 NVX -CoV2373  
5 mcg SARS -CoV-2 
rS 
50 mcg Matrix -M Same Strain 
Heterologous 
platform  
16E 60 Previously dosed 
Moderna – 
mRNA -1273  ≥12 NVX -CoV2373  
5 mcg SARS -CoV-2 
rS 
50 mcg Matrix -M Same Strain  
Heterologous 
platform  
17E 60 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 NVX -CoV2373  
5 mcg SARS -CoV-2 
rS 
50 mcg Matrix -M Same Strain  
Heterologous 
platform   
Group  Sample 
Size*  EUA Dosing 
Scheme  Interval(weeks)  Delayed 
Boost er 
Vaccination  Strategy Tested  
1E 50 Previously dosed 
Janssen – 
Ad26.COV2 -S ≥12 Moderna - mRNA -
1273   Same Strain  
Heterologous 
platform  

DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 14 of 97 Group  Sample 
Size*  EUA Dosing 
Scheme  Interval(weeks)  Delayed 
Boost er 
Vaccination  Strategy Tested  
2E 50 Previously dosed 
Moderna – 
mRNA -1273  ≥12 Moderna - mRNA -
1273  Control - Same 
Strain  
& platform  
3E 50 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 Moderna - mRNA -
1273  Same Strain  
Similar  platform  
4E 50 Previously dosed 
Janssen – 
Ad26.COV2 -S ≥12 Janssen – 
Ad26.COV2 .S Control - Same 
Strain  
& platform  
5E 50 Previously dosed 
Moderna – 
mRNA -1273  ≥12 Janssen – 
Ad26.COV2 .S  Same Strain  
Heterologous 
platform  
6E 50 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 Janssen – 
Ad26.COV2 .S  Same Strain  
Heterologous 
platform  
7E 50 Previously dosed 
Janssen – 
Ad26.COV2 -S ≥12 Pfizer/BioNTech –
BNT162b2   Same Strain  
Heterologous 
platform  
8E 50 Previously dosed 
Moderna – 
mRNA -1273  ≥12 Pfizer/BioNTech - 
BNT162b2  Same Strain  
Similar  platform  
9E 50 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 Pfizer/BioNTech –
BNT162b2  Control - Same 
Strain  
& platform  
10E 50 Previously dosed 
Janssen – 
Ad26.COV2 -S ≥12 Moderna - mRNA -
1273.211  Variant Strain  
Heterologous 
platform   
11E 50 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 Moderna - mRNA -
1273.211  Variant Strain  
Similar  platform   
12E 50 Previously dosed 
Janssen – 
Ad26.COV2 -S ≥12 Moderna - mRNA -
1273  50 mcg   Same Strain  
Heterologous 
platform  
13E 50 Previously dosed 
Moderna – 
mRNA -1273  ≥12 Moderna - mRNA -
1273  50 mcg  Control - Same 
Strain  
& platform  
14E 50 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 Moderna - mRNA -
1273  50 mcg  Same Strain  
Similar  platform  
15E 60 Previously dosed  
+/- boosted  
Janssen – 
Ad26.COV2 -S ≥12 NVX -CoV2373  
5 mcg SARS -CoV-2 
rS 
50 mcg Matrix -M Same Strain 
Heterologous 
platform  
16E 60 Previously dosed 
Moderna – 
mRNA -1273  ≥12 NVX -CoV2373  
5 mcg SARS -CoV-2 
rS Same Strain  
Heterologous 
platform  

DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 15 of 97 *Sample cohort size, N = approximately 50, two age strata: 18 -55 years (n ≈ 25), ≥ 56 years (n ≈ 25), and N= 
approximately 60, two age strata (N~ 30) for Groups 15E -17E. 
Prospective Cohort:  Cohort 2 will recruit persons who are naïve to COVID -19 vaccine and 
infection (by history). These individuals will be given a vaccine as part of the study that matches 
the vaccine/dose available under a n EUA. Cohorts from this pool will then be available to be 
boosted with a novel homologo us or heterologous variant lineage spike proteins or heterologous 
platform delayed boost as part of an adaptive design meant to respond quickly to circulating 
SARS -CoV -2 variants.  As booster vaccines have been approved for individuals at an interval of 
6 months from the primary series, under EUA, all Cohort 2 volunteers will be offered a booster 
of mRNA -1273 at the approved 50 mcg dose. Due to the surge of the Omicron variant and 
breakthrough infections, volunteers who contract symptomatic or asymptomatic COVID -19 
between completion of their EUA primary series and the scheduled booster dose will be allowed 
to continue in the study. The interval between the COVID -19 infection and booster dosing 
should be a minimum of 28 days. This pool of participants will th en be followed to assess the 
immunogenicity of a 4th dose of bivalent vaccine.  The Moderna mRNA -1273. 222 vaccine that 
contains 25 -mcg of the prototype strain and 25 -mcg of the Omicron BA.4/BA.5 variant (total 50 -
mcg)  will be administered as a  second  booste r 4 to 12 months after  administration of  the first 
booster vaccin e.   
Prioritization of Cohort 1 versus Cohort 2 enrollment will be determined by availability of EUA -
dosed vaccines , status of distribution , and current epidemiology . Cohort s 1 and 2 may enroll 
simultaneously.Group  Sample 
Size*  EUA Dosing 
Scheme  Interval(weeks)  Delayed 
Boost er 
Vaccination  Strategy Tested  
50 mcg Matrix -M 
17E 60 Previously dosed 
Pfizer/BioNTech –
BNT162b2  ≥12 NVX -CoV2373  
5 mcg SARS -CoV-2 
rS 
50 mcg Matrix -M Same Strain  
Heterologous 
platform   

DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 16 of 97 Table 2: Prospective Cohort 2    
Group  Sam -
ple 
Size*  First 
Vaccina -
tion** Inter -
val Second 
Vaccina -
tion** Inter -
val Delayed 
Booster 
Vaccina -
tion 1 Interval  Booster 
Vaccination 
2 
1 250 Moderna - 
100 mcg 
mRNA -
1273  28 
days Modern a- 
100 mcg 
mRNA -
1273  ~6 
months  Moderna  - 
50 mcg 
mRNA -
1273  4-12 
months  Moderna - 
50 mcg 
mRNA -
1273.2 22 
*Aged ≥ 18 years  
** As part of an adaptive design, products newly awarded EUA can be added as programmatically needed .  
Duration of Study:    Approximately 4 years   
Duration of participation per subject:  Up to 2 years (approximately ~6 months after second 
boost er inoculation)   
Criteria for Inclusion/Exclusion:   
Inclusion Criteria:  
Participants must meet all of the following criteria to be eligible to participate in this study:  
1. Individuals ≥ 18 years of age at the time of consent.   
2. Received and completed primary mRNA COVID -19 vaccine under EUA dosing 
guidelines and one or two doses of Ad26.COV2.S at least 12 weeks prior to enrollment 
(Cohort 1 only).  
3. Willing and able to comply with all scheduled visits, vaccination plan, laboratory tests 
and other study procedures.   
4. Determined by medical history, targeted physic al examination and clinical judgement  of 
the investigator to be in good health.   
Note:   Healthy volunteers with pre-existing stable disease, defined as disease not   
 requiring significant change in therapy or hospitalization for worsening disease during 
 the 6 weeks before enrollment, can be included.  
5. Female participants of childbearing potential may be enrolled in  the study, if all of the 
following apply:   
• Practiced adequate contraception for 28 days prior to the first dose of vaccine (Day 
1),  
• Has agreed to continue adequate contraception through 3 months following the 
booster dose,  
• Has a negative pregnancy test at screening and on the day of the first study vaccine 
dose (Day 1),  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 17 of 97 • Is not currently breastfeeding.  
Exclusion Criteria:   
Participants meeting any of the following criteria will be excluded from the study :  
1. Known history of SARS -CoV -2 infection  (for Cohort 1 and the primary series of Cohort 
2).  
2. Prior administration of an investigational coronavirus (SARS -CoV, MERS -CoV) vaccine 
or SARS -CoV -2 monoclonal antibody in the preceding 90 days or current/planned 
simultaneous participation in another int erventional study.  
3. Receipt of SARS CoV -2 vaccine prior to study entry  (Cohort 2 only).  
4. A history of anaphylaxis, urticaria, or other significant adverse reaction requiring medical 
intervention after receipt of a vaccine or nanolipid particles.  
5. Receipt of any investigational study product within 28 days prior to enrollment.  
6. Received or plans to receive a vaccine within 28 days prior to the first dose (Day 1) or 
plans to receive a non -study vaccine within 28 days prior to or after any dose of study 
vaccine (with exception for seasonal influenza vaccine within 14 days of study vaccine).   
7. Bleedi ng disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet 
disorder requiring special precautions) or significant bruising or bleeding difficulties with 
intramuscular injections or blood draws , or previously experienced thrombosi s with 
thrombocytopenia (TTS) or heparin -induced thrombocytopenia .  
8. Current or previous diagnosis of immunocompromising condition, immune -mediated 
disease, or other immunosuppressive condition.   
9. Received systemic immunosuppressants or immune -modifying dru gs for >14 days in 
total within 6 months prior to Screening (for corticosteroids ≥ 20 mg/day of prednisone 
equivalent). Topical tacrolimus is allowed if not used within 14 days prior to Day 1.   
10. Received immunoglobulin, blood -derived products, within 90 da ys prior to first study 
vaccination.  
11. An immediate family member or household member of this study’s personnel.   
12. Is acutely ill or febrile 72 hours prior to or at vaccine dosing (fever defined as ≥ 
38.0°C/100.4°F). Participants meeting this criterion may b e rescheduled within the 
relevant window periods. Afebrile participants with minor illnesses can be enrolled at the 
discretion of the investigator.  
Safety  
• The study will use halting  rules for booster vaccination in the study overall and not  EUA 
dosed  vaccinations to individual subjects. See Section 7.1 for details.  
• This study will use a Safety  Monitoring Committee (SMC) for objective oversight of the 
study. SMC  reviews are required for study halting.  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost           06 April 2023   
DMID/NIAID/NIH  CONFIDENTIAL  Page 18 of 97 1.2 Schedule of Activities  (SOA) 
Table 3: SOA for EUA -dosed Cohort 1  
Study Day  D-28 
to D-1 1 8b 15 29 91 181 273 366 Illness/ 
Unscheduled 
Visit Early 
Termination 
Visit  
Visit Number  00a 1 2 3 4 5 6 7 8   
Window (+/ -)  0 1 2 2 7 14 28 28   
Informed Consenta X           
Eligibility Criteria  X X          
Medical History  X X          
Vaccinationc  X          
Concomitant Meds   X X X X       
Interim History   X X X X X X X X X X 
Physical Exam - Targeted  X X  X X X X X X X X 
Vital Signsd X X  X X     X X 
Height/Weight (BMI)a X           
Urine -HCGe  X          
Memory Aid, Solicited AEs   X X X f        
Unsolicited AEs   X X X X       
SAEs, Protocol specified AESIs, MAAEs, and 
NOCMCs    X X X X X X X X X 
Nasal or NP swab for PCR & Sequencing           Xg  
Immunoassays             
Serum - Humoral Assays   32  32 32 32 32 32 32  32 
PBMC Cellular Assays & plasma   64  64   64  64  64 
Daily Volume (mL)   96  96 32 32 96 32 96  96 
Cumulative Volume (mL)   96  192 224 256 352 384 480   
a Optional screening visit – informed consent and height/weight only performed at screening or Day 1  
b Telephone visit  
c Delayed booster dose based upon assignment to Groups 1E -3E (and/or future groups added as adaptive design)  
d Vital signs before and after booster vaccination. Otherwise, only as clinically indicated  
e For women of childbearing potential, a negative urine pregnancy on Day 1 will be performed with negative results confirmed before dosing  
f Review  7-day Memory Aid  data .  
g Collect nasal or NP swab for PCR  (x2). Sequencing will be performed on all Illness visit -confirmed SARS -CoV-2 specimens.  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost           06 April 2023   
DMID/NIAID/NIH  CONFIDENTIAL  Page 19 of 97 Table 4: SOA for Prospective Cohort 2  (prior to 2nd booster dose) : 
Study Day  D-28 
to D-1 1 8b 29 36b 43 
Delayed Boost to occur ≥ 181 days (window +/ - 30 days) from Dose 2  1B 8Bb 15B 29B 91B 181B 366B  Illness/
Unsch 
Visit Early 
Term 
Visit 
Visit Number  00a 1 2 3 4 5 6 7 8 9 10 11 12   
Window (+/ -)  0 1 2 3 3 0d 1 2 2 7 14 28   
Informed Consenta X               
Eligibility Criteria  X X  X   X         
Medical History  X               
Vaccination   Xc  Xc   Xd         
Concomitant Meds  X X X X X X X X X X      
Interim History   X X X X X X X X X X X X X X 
Physic al Exam - Targeted  X X  X  X X  X X X X X X X 
Vital Signse X X  X   X  X X    X  
Height/Weight (BMI) a X               
Urine -HCGf  X  X   X         
Memory Aid, Solicited AEs   X X X X  X X Xg       
Unsolicited AEs   X X X X X X X X X      
SAEs, Protocol specified AESIs, 
MAAEs, and NOCMCs    X X X X X X X X X X X X X 
Nasal  or NP  swab for PCR & 
Sequencing               Xh  
Immunoassays                 
Serum - Humoral Assays   32  32  32 32  32 32 32 32 32  32 
PBMC Cellular Assays & plasma   64*  64*  64* 64  64  64 64 64  64 
Daily Volume (mL)   96  96  96 96  96 32 96 96 96  96 
Cumulative Volume (mL)   96  192 192 288 384  480 512 608 704 800   
a Optional screening visit – informed consent and height/weight only performed at screening or Day 1  
b Telephone visit  
c EUA -dosing with 28 -day interval – new constructs may be added as EUA is awarded  and vaccine available  
d Delayed booster dose  will be the 50 mcg dose of Moderna mRNA -1273.  It will be administered on study day 1B which is 181 days with a window of +28  days  after the second vaccine dose . If no  booster administered; safety visits will continue as per Table 6.  If 
Covid -19 infection is detected in the interval between the primary series and the estimated time of booster administration, volunte ers may remain in the study (with a minimum 28 day interval between infection and boost)  
e Vital signs before and after vaccination.  Otherwise, only as clinically indicated.  
f  For women of childbearing potential, a negative urine pregnancy test on Day s 1 and 1B (delayed boost) will be performed with negative results confirmed   prior to each dosing  
g Review  7-day Memory Aid data for delayed booster dose .  
h Collect nasal or NP swab s (x 2)  for PCR. Sequencing will be performed on all Illness visit -confirmed SARS -CoV-2 specimens.  
*Collection of PBMC for cellular assays  is performed a t the discretion of the site, based on the capacity for PBMC processing  
 
 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost           06 April 2023   
DMID/NIAID/NIH  CONFIDENTIAL  Page 20 of 97 Table 5: SOA  for Prospective Cohort 2 (2nd booster dose)  
Study Day  
Boost to 
occur ≥ 120 
days and ≤ 
366 days 
from Dose 3  1C 8Cb 15C 29C 91C 181C  Illness/Unsch 
Visit Early Term Visit  
Visit Number  13 14 15 16 17 18   
Window (+/ -) 0 1 2 2 7 14   
Informed Consent  X        
Eligibility Criteria  X        
Vaccination  Xa        
Concomitant Meds  X X X X     
Interim History  X X X X X X X X 
Physical Exam - Targeted  X  X X X X X X 
Vital Signsc X  X X   X  
Saliva Mucosal Sample  X  X X X X  X 
Nasal Mucosal Sample  X  X X X X  X 
Urine -HCGd X        
Memory Aid, Solicited AEs  X X Xe      
Unsolicited AEs  X X X X     
SAEs, Protocol specified AESIs, MAAEs, and 
NOCMCs  X X X X X X X X 
Nasal or NP swab for PCR & Sequencing        Xf  
Immunoassays          
Serum - Humoral Assays  32  32 32 32 32  32 
PBMC Cellular Assays & plasma  64  64   64  64 
Daily Volume (mL)  96  96 32 32 96  96 
Cumulative Volume (mL)  800  896 928 960 1056    
a Second B ooster dose will be the 50 mcg dose of Moderna mRNA -1273.222. It will be administered on study day 1 C which is ≥ 120 and ≤ 270 days  after the third  vaccine dose . If no booster administered; safety visits will continue as per Table 6. 
b Telephone visit   
c Vital signs before and after vaccination. Otherwise, only as clinically indicated.  
d  For women of childbearing potential, a negative urine pregnancy test on Day 1 C (Second  boost) will be performed with negative results confirmed prior to each dosing  
e Review 7 -day Memory Aid data for second booster dose.  
f Collect nasal or NP swabs (x 2) for PCR. Sequencing will be performed on all Illness visit -confirmed SARS -CoV-2 specimens.  
 
  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost           06 April 2023   
DMID/NIAID/NIH  CONFIDENTIAL  Page 21 of 97 Table 6: SOA for Cohort 2 Volunteers who  do not proceed to  first Study Booster  
Study Day  181a 366a Early Term Visit  
Visit Number  6 12  
Window (+/-) 28 28  
Informed Consent     
Eligibility Criteria     
Medical History     
Vaccination     
Concomitant Meds     
Interim History  X X X 
Physical Exam - Targeted  X X X 
Vital Signs     
Height/Weight (BMI)     
Urine -HCG    
Memory Aid, Solicited AEs     
Unsolicited AEs     
SAEs, Protocol specified AESIs, MAAEs, and 
NOCMCs  X X X 
 
a From the date of the last study vaccine  
 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 22 of 97 2 INTRODUCTION  
2.1 Background and Study Rationale  
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS -CoV -2) was first detected in 
Wuhan, Hubei Province, China in December 2019. The corresponding illness designation, 
coronavirus disease 2019 (COVID -19), was declared as  a pandemic respiratory illness on March 
2020.1 As of 20 January 2022 , it has infected over 339 million people worldwide and resulted in 
over 5.6 million deaths, including > 858,000 in the United States.1,2 
Five Phase 3 effic acy trials of SARS -CoV -2 vaccine constructs are underway or in long -term 
follow -up in the U.S., through U.S. government efforts funded by the Biomedical Advanced 
Research and Development Authority (BARDA) and National Institutes of Health (NIH). 
Vaccine te sting centers have prioritized research studies as part of three Phase 3, 2 -dose trials in 
various stages of conduct (Moderna, AstraZeneca/Oxford, Novavax), one Phase 3 single -dose 
trial (Janssen – 2-dose testing underway internationally) and one privately  funded, 2 -dose trial 
(Pfizer/BioNTech). The ModernaTX, Inc mRNA‑1273 and Pfizer/BioNTech BNT162b2 mRNA 
platforms encode for the full -length spike (S) protein of SARS -CoV -2, modified to introduce 2 
proline residues to stabilize the S protein (S -2P) in a pr efusion conformation, derived from the 
Wuhan -Hu-1 strain.3 The Janssen Pharmaceutical/Johnson  & Johnson COVID -19 Vaccine 
(Ad26 .COV .2) is composed of recombinant,  replication -incompetent human adenovirus type 26, 
encoding a prefusion -stabilized  SARS -CoV -2 spike antigen.4 Studies of the Pfizer and Moderna 
mRNA vaccines demonstrated high efficacy against all symptom atic and severe disease and 
received Emergency Use Authorization (EUA) on December 12 and 18, 2020, respectively.  The 
Pfizer mRNA vaccine received approval on April 23, 2021, and will  be marketed as Comirnaty, 
for the prevention of COVID -19 disease in individuals 16 years of age and older.  The Moderna 
mRNA vaccine received approval on January 31, 2022 , and will be marketed as Spikevax for the 
prevention of COVID -19 in individuals 18 years of age and older . Similarly, Janssen 
Pharmaceuticals reported 66%  vaccine efficacy with a single dose and high -level protection 
against severe disease and death. FDA EUA was issued on February 26, 2021. Novavax  (NVX -
CoV2373), a recombinant nanoparticle vaccine containing the full -length spike glycoprotein plus 
Matrix -M adjuvant, showed 86.3% and 90.4% vaccine efficacy in phase 2b -3 trials in the UK 
and North America (but prior to the delta and omicron surges, respectively).5,6 . In October 2022, 
the U.S. has COVID -19 products from  4 different manufacturers  approved or available under 
EUA.  
The optimization and distribution of SARS -CoV -2 vaccines is of critical public health priority. 
The inability to mass -vaccinate the world’s population in a timely fashion is resulting in ongoing 
high-level transmission and accelerated emergence of variants with mutations in the S protein. 
Moreover, the evolution of variant strains may favor immune escape or reinfecti on among 
previously infected or vaccinated individuals. A variant first identified in South Africa (B.1.351) 
is associated with increased transmission, higher viral burden, and possibly increased mortality 
in infected persons .7 The emergence of variant strains has raised concerns about the breadth of 
immunity and protection achieved by the current vaccines. Pivotal studies testing both viral 
vector and adjuvanted protein technologies had lower efficacy in regions where B.1.351 was 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 23 of 97 known to be circulating.8,9 Sera from individuals vaccinated with mRNA -based vaccines had a 6 -
to-9-fold reduction in neutralizing activity against a B.1.351 -matched pseudovirion relative to a 
Wuhan -matched pseudovirion .10,11 WHO SAGE and CDC ACIP have identified the safety and 
immunogenicity of mixed schedules as a critical and immediate research priority to inform 
policy on the use of mixed schedules. Vaccine manufacturers are working on variant booster 
candidates to o ptimize efficacy against the B.1.1.7, B.1.351 and Brazilian P1 and P2 rapidly 
emerging  variants with receptor binding domain mutations. For example, mRNA -1273. 211, like 
mRNA -1273, encodes the prefusion stabilized S protein  (S-2P) of SARS -CoV -2, but also 
incorporates the key mutations present in the B.1.351 viral strain  (S-2P) in a 1:1 ratio with the 
wildtype Wuhan -Hu-1 strain . A phase 1 clinical trial to examine the immunological benefit of 
boosting subjects previously vaccinated with mRNA -1273 (DMID 20 -0003) with the B.1.351 
strain -specific S protein is underway.  Similarly, mRNA -1273.2 22 encodes the prefusion stabilize 
S protein (S -2P) of SARS -CoV -2 along with the key mutations of the Omicron BA.4/BA.5 
subvariants (S -2P) in a 1:1 ratio with the wildtype (prototype) Wuhan -Hu-1 strain.  
Prime -boost strategies may enhance immunogenicity through complementary stimulation of 
humoral and T cell immune pathways. In contrast, the immune response to booster doses  of 
certain vaccines, such as the adenovirus vector vaccines, may be limited by pre -existing antibody 
and/or enhanced by longer dosing intervals. Thus, the order of delivery of heterologous SARS -
CoV -2 vaccine platforms may result in immune responses that are greater or less than 
homologous regimens of the same vaccine. In a murine model, a self -amplifying RNA vaccine 
followed by the adenovirus vectored vaccine (ChAdOx1 -nCoV -19/AZD1222) was shown to 
induce high titers of neutralizing antibodies (although was not tested against a two -dose 
homologous regimen).12 In humans, the Gam -COVID -Vac combined vector vaccine consisting 
of rAD26 c arrying the full -length glycoprotein S (rAD26 -S) (prime) and rAd5 -S administered 
after 21 days as a boost, demonstrated 91.6% efficacy in adults < 60 years of age and illustrates 
the potential vaccine efficacy with a heterologous prime/boost strategy.13 The United Kingdom 
(UK) announced plans (4 Feb 2021) to test a mix -and-match approach (at 4 - and 12 -week 
intervals) with currently UK -approved vaccines. Testing of the heterolo gous prime boost strategy 
with Pfizer/BioNTech’s (BNT162b2) followed by AstraZeneca/Oxford’s (ChAdOx -2) and vice 
versa is underway  in the UK .  
Knowledge of the safety, tolerability, and immunogenicity of a delayed heterologous boost 
vaccine incorporating a  similar or variant spike administered following EUA dosing regimens 
might induce immunity to variant circulating strains and improve upon breadth and durability of 
protection. Utilizing the EUA -dosed  COVID -19 vaccines available  (currently mRNA -1273, -
BNT1 62b2, and AD26 .COV2 .S), we propose to evaluate innate, mucosal, cellular, and humoral 
immune responses elicited from different boost er vaccines. As part of an adaptive design, we 
anticipate adding groups with variant -lineage spike proteins and other vaccine platforms , subject 
to availability.   
2.1.1 Public Readiness and Emergency Preparedness Act  
The study vaccine s, mRNA -1273 , mRNA -1273. 211, mRNA -1273.2 22, BNT162b2, 
Ad26 .COV .2, and NVX -CoV237 3, and the efforts for th is clinical trial are covered under the 
Public Readiness and Emergency Preparedness Act (PREP Act) and the Declaration issued by 
the Secretary of the U.S. Department of Health and Human Services under that Act. Under the 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 24 of 97 PREP Act and the Declaration, cover ed persons (such as manufacturers, distributers, program 
planners, and other qualified persons who prescribe, administer,  or dispense study product) are 
immune from liability from the administration, or use of a covered countermeasure, such as 
mRNA -1273 , mRNA -1273. 211, mRNA -1273.2 22, BNT162b2,  Ad26.COV2 .S, and NVX -
CoV2373 . The PREP Act provides immunity for covered persons from liability unless  the injury 
was caused by willful misconduct. The Declaration invoking the PREP Act for COVID -19 
covered countermeasures was made on March 10, 2020 and is retroactively effective from 
February 4, 2020.  
The PREP Act also established the Countermeasures Inju ry Compensation Program (CICP) to 
provide compensation for serious injuries or death that occur as the direct result of the 
administration or use of certain countermeasures. Any requests for compensation must be filed 
within one year of the administration or use of the covered countermeasure. Requests for 
Benefits must be made to the Health Resources and Services Administration’s (HRSA) 
Countermeasures Injury Compensation Program ( http://www.hrsa.gov/cicp/ ) by filing a Request 
for Benefits Form and all requ ired medical records and supporting documentation. Additional 
information on filing a Request for Benefits is available on the CICP’s website at 
http://www.hrsa.gov/cicp/ . Compensation may then be available for reasonable and necessary 
medical benefits, lo st wages and/or death benefits to eligible individuals for certain injuries in 
accordance with regulations published by the Secretary of HHS (found at 42 CFR part 110).  
If an individual suffers a serious physical injury or death from the administration or use of a 
covered countermeasure in this study, the individual, the individual’s legal or personal 
representative, the administrator/executor of a deceased individual’s estate, or certain survivors 
may request benefits from the CICP. A serious physical inju ry means an injury that warranted 
hospitalization (whether or not the person was actually hospitalized) or that led to a significant 
loss of function or disability. The CICP is the payer of last resort. This means that it only covers 
expenses or provides b enefits that other third -party payers (such as health insurance, the 
Department of Veterans Affairs, or Workers’ Compensation programs) do not have an obligation 
to pay.  
If the Secretary of DHHS does not make a final determination on the individual’s reque st within 
240 days, or if the individual decides not to accept the compensation, the injured individual or 
his representative may pursue a tort claim in the US District Court for the District of Columbia, 
but only if the claim involves willful misconduct a nd meets the other requirements for suit under 
the PREP Act. Any award is reduced by any public or private insurance or worker’s 
compensation available to the injured individual. Awards for non -economic damages, such as 
pain, suffering, physical impairment , mental anguish, and loss of consortium are also limited. If 
the individual accepts compensation, or if there is no willful misconduct, then the individual does 
not have a tort claim that can be filed in a US Federal or a State court.  
2.2 Risk/Benefit Assessm ent 
2.2.1 Known Potential Risks  
The potential risks of participating in this trial are those associated with having blood drawn, IM 
injection, possible reactions to the initial immunization with mRNA -1273 vaccine and delayed 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 25 of 97 booster inoculation of mRNA -1273 , mRN A-1273. 211, mRNA -1273.2 22, BNT162b2 , 
Ad26.COV2.S  and NVX -CoV 2373 , and breach of confidentiality.  
Drawing blood may cause transient discomfort and fainting. Fainting is usually transient and 
managed by having the subject lie down and elevate his/her legs. Bruising at the blood draw site 
may occur but can be prevented or lessened by applying pressure to the blood draw site for a few 
minutes after the blood is taken. IM injection may also cause transient discomfort and fainting. 
Drawing blood and IM inj ection may cause infection. The use of aseptic (sterile) technique will 
make infection at the site where blood will be drawn or where the vaccination will be given 
extremely unlikely.  Collection of nasal and salivary fluids may be associated with transient  
discomfort due to placement of the absorptive material in the nares and mouth, respectively.  
Risks of mRNA vaccines ( mRNA -1273 , mRNA -1273. 211, mRNA -1273.2 22 and BNT162b2)  
Immediate systemic allergic reactions ( e.g., anaphylaxis) can occur following any va ccination. 
These reactions are very rare and are estimated to occur once per 450,000 vaccinations for 
vaccines that do not contain allergens such as gelatin or egg protein.14 
Anaphyla ctic reactions have occurred after administration of the Moderna and the Pfizer mRNA 
COVID -19 vaccines in vaccination campaigns under Emergency Use Authorization (EUA) in 
the United States. Most  of these reactions had onset within 30 minutes of vaccination, most of 
these events occurred in persons with a prior history of allergy, and nearly all were women. The 
currently estimated risk of an anaphylactic reaction to the mRNA EUA COVID -19 vaccine s is 
about 2-5 events per million vaccinations.  
As a precaution, all subject s will remain under observation at the study site for at least 30 
minutes after injection.  
Infrequently, people who have received dermal fillers might experience swelling at or near the 
site of filler injection (usually face or lips) following administration of a dose of an mRNA 
COVID -19 vaccine. The swelling appears to be temporary and resolves with medical treatment, 
including corticosteroid therapy. COVID -19 vaccines can be ad ministered to people who have 
received injectable dermal fillers who have no contraindications or precautions for vaccination.  
Vasovagal syncope (fainting) can occur before or after any vaccination, is usually triggered by 
the pain or anxiety caused by the  injection and is not related to the substance injected. Therefore, 
it is important that standard precautions and procedures be followed to avoid injury from 
fainting.  
Intramuscular injection with other mRNA vaccines manufactured by ModernaTX, Inc . 
contain ing the SM -102 lipid formulation commonly results in a transient and self -limiting local 
inflammatory reaction. This typically includes pain, erythema (redness), or swelling (hardness) at 
the injection site, which are mostly mild to moderate in severity an d usually occur within 24 
hours of injection.  A small percentage of participants may experience late local inflammatory 
reactions, with onset seven or more days after , usually the first,  vaccination, and characterized by 
redness in the deltoid area of the upper ar m and/or pain or itching.15 These reactions are self -
limited and are no t a contraindication to subsequent vaccinations in t he vaccination series.  
The majority of local and systemic solicited adverse events  (AEs) observed after injection with 
mRNA -1273 at the 100 -mcg dose level or BNT162b2 at the 30 -mcg dose level have been mi ld to 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 26 of 97 moderate in severity. The most commonly reported systemic AEs were headache, myalgia, 
fatigue, chills, and fever.15-17 In the majority of cases, the reactions resolved spontaneously 
within several days. Laboratory abnormalities (including increases in liver function tests and 
serum lipase le vels) following injection were observed in clinical studies with similar mRNA -
based vaccines. These abnormalities were without clinical symptoms or signs and returned 
toward baseline, pre -vaccination (Day 1) values over time. The clinical significance of t hese 
observations is unknown.  
There is limited experience with administration of a third dose of the mRNA COVID -19 
vaccines , and it is possible that the third dose may be associated with more frequent or more 
severe adverse events . Myocarditis and pericard itis have been reported following mRNA 
vaccines, particularly after the second dose , in a younger population (age < 30 years), and more 
common in males . Symptoms can include chest pain, shortness of breath , or palpitations. 
Typically, onset of symptoms has  been within a few days following receipt of the mRNA 
COVID -19 vaccines. Whilst some severe cases have been reported, most cases have been 
associated with full resolution of symptoms in the short term;  however, long -term follow -up is 
limited. It is not kno wn whether the risk of myocarditis or pericarditis is increased following 
additional doses of the vaccine, e.g., following a booster dose.  
Further details are provided in the FDA -approved fact sheet  and current IB s for mRNA -1273 , 
mRNA -1273. 211, mRNA -1273.2 22 and BNT162b2 . mRNA -1273. 211 has not been  extensively  
tested clinically, but based on its similarity to mRNA -1273, the risks are expected to be similar.  
Similarly , mRNA -1273.2 22 has not been tested extensively, but it has received EUA for use as a 
booster in adults.  
Risks of Ad26.COV2.S.  
Immediate systemic allergic reactions (e.g., anaphylaxis) can occur following any vaccination 
but no cases of anaphylaxis were noted in the Phas e 3 trial. Hypersensitive reactions, not 
classified as anaphylaxis, are a rare occurrence within the Ad26 platform but have been reported.  
The most common solicited adverse events were injection site pain, headache, fatigue and 
myalgia. Intramuscular injec tion with Ad26.COV2.S can cause local pain, erythema (redness), or 
swelling at the injection site, which are mostly mild to moderate in severity, transient, and 
usually occur within 24 hours of injection.  
Pyrexi a (fever defined as body temperature > 38.0°C ) was reported and generally dissipated 
within 24 hours of vaccination. Other solicited events systemic signs and symptoms included 
headache, myalgia, chills and nausea.  
Grade 2 facial paralysis (Bell’s Palsy) has been reported although the incidence of Bell’s  Palsy 
was not above known background prevalence rates. Tinnitus has been reported following 
vaccination with Ad26.COV2.S but it is unclear if these were due to vacci ne or underlying 
medical conditions.  
Thrombosis in combination with thrombocytopenia (thrombosis with thrombocytopenia 
syndrome [TTS]), in some cases accompanied by bleeding, has been observed very rarely 
following vaccination with Ad26.COV2.S. Reports in clude severe cases of venous thrombosis at 
unusual sites such as cerebral venous sinus thrombosis (CVST), splanchnic vein thrombosis and 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 27 of 97 arterial thrombosis, in combination with thrombocytopenia. These cases occurred approximately 
3 weeks following vaccina tion. The reporting rate of thrombosis with thrombocytopenia 
following administration of the Janssen COVID -19 Vaccine has been highest in females ages 18 
through 49 years; some have been fatal . Thrombosis in combination with thrombocytopenia can 
be fatal. The exact physiology of TTS is unclear. TTS is considered an important identified risk 
for Ad26.COV2.S.  It is unknown if this risk changes (increase or decreases) when this vaccine 
is used as a delayed booster vaccine. Participants should be instructed to  seek immediate medical 
attention if they develop symptoms such as shortness of breath, chest pain, leg swelling, 
persistent abdominal pain, severe or persistent headaches, blurred vision, and skin bruising 
and/or petechiae beyond the site of vaccination. The medical management of thrombosis with 
thrombocytopenia is different from the management of isolated thromboembolic diseases. Study 
site personnel and/or treating physicians should follow available guidelines for treatment of 
thrombotic thrombocytopenia  (e.g., from the American Society of Hematology, British Society 
of Haematology - Expert Haematology Panel10, and the CDC). The use of heparin may be 
harmful and alternative treatments may be needed. Consultation with a hematologist is strongly 
recommended .  Refer to the latest version of the IB and its addenda (if applicable) for further 
details. Due to the possibility of the occurrence of TTS after vaccination with Ad26.COV2.S, 
additional reporting and data collection procedures have been included in the study for 
thrombotic events, thrombocytopenia, and TTS (see Section 8.3.9 ), which may facilitate 
diagnosis and clinical management of the event.  
Rare cases of Guillain Barré syndrome have occurred in some people who have received the 
Janssen COVID -19 Vaccine. The FDA requested (12 Jul 2021 ) that this risk be added to the Fact 
Sheet .  In most circumstances, symptoms began within 42 days following re ceipt of dosing. 
Reported s ymptoms include d weakness or tingling sensations in the extremities, difficulty 
ambulating, difficulty with facial movements to include chewing, swallowing or speaking, 
diplopia or inability to move eyes, or difficulty with bowel  or bladder control.  
While there is a theoretical risk of vaccine -associated enhanced diseases (VAED) with SARS -
CoV -2 vaccines, there has been no evidence of VAED following Ad26.COV2.S or mRNA 
vaccine dosing.  
There is limited evidence of the effects of adm inistering an adenovirus -vectored vaccine before 
or after an mRNA COVID -19 vaccine, and it is possible that a delayed booster dose may result 
in more frequent or more severe adverse events.   
Risks of NVX -CoV2373  
Across age strata, there were higher frequen cies of solicited local and systemic treatment 
associated AEs among NVX -CoV2373 recipients than among placebo recipients following each 
vaccination. In the NVX -CoV2373 group, the frequency and intensity of solicited local and  
systemic AEs increased after s econd vaccination relative to the first vaccination, but the study  
vaccine remained well tolerated. Participants in the older age cohort (≥ 65 years of age) reported  
a lower frequency and intensity of solicited local and systemic AEs than participants in t he 
younger age cohort (18 to ≤ 64 years of age). Across both age strata, frequencies of unsolicited  
AEs, severe AEs, and treatment -related AEs within 28 days after second vaccination  
(e.g., Day 49) were higher in the NVX -CoV2373 group than in the placebo g roup, but most were 
mild to moderate in severity.  The majority of the reactogenic responses ( i.e., injection site pain, 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 28 of 97 fatigue, headache, pyrexia, and myalgia) were mild in severity. The most frequent solicited 
systemic TEAEs following each vaccination were headache, fatigue, and muscle pain, which had 
a median duration of ≤ 1.5 days following first vaccination and a media n duration of ≤ 2.0 days 
following second vaccination. Across the two age strata, participants in the older age cohort (65 
to 84 years of age) reported a lower frequency and intensity of solicited local and systemic AEs 
than participants in the younger age  cohort (18 to 64 years of age).  Of the three deaths detected 
in the U.K. Phase 3 study, none were deemed related to study product.  One SAE in the NVX -
CoV2373 U.K. group had  an SAE (myocarditis) that was assessed by the investigator as related 
to study v accine but  assessed by the Sponsor as not related to study vaccine. This event occurred 
in a 19 -year-old male 3 days after the second dose and was also reported as a Potential Immune -
Mediated Medical Conditions (PIMMC). The case was also  reviewed by an ind ependent Safety 
Monitoring Committee that considered the event most likely  viral myocarditis. Two SAEs in the 
North American Phase 3 trial were assessed as related to study treatment (angioedema and 
central nervous system inflammation).  No difference in f atal events was noted between the 
study and placebo groups.  
The fully -analyzed human experience to date with Matrix -M adjuvants is confined to adults who 
have received 1 - to 3-dose series of IM doses of 25 to 75 mcg. Local injection site reactogenicity 
comprising pain, redness, bruising, and swelling have occurred up to approximately twice as 
commonly following Matrix -M adjuvant -containing vaccine doses than following unadjuvanted 
vaccine antigen doses when a comparable antigen preparation is used. Persist ent nodules, skin 
breakdown, or ulceration at injection sites have never been reported. Systemic reactogenicity 
complaints comprising headache, myalgia, arthralgia, fatigue, and chills are similarly 1.5 - to 2-
fold more frequent following adjuvanted doses, while nausea, diarrhea, and vomiting are only 
slightly increased. Notably, more than 95% of subjects reporting any solicited reactogenicity 
events indicate that they are mild to moderate in intensity (i .e., they do not cause major 
interference with daily a ctivities) and that they are transient (i .e., resolve during the 7 -days post -
injection follow -up period). When multiple doses of Matrix -M-adjuvanted vaccines are given at 
a relatively short interval (3 to 4 weeks), the incidence rate of local and systemic reactogenicity 
events may increase after the second dose, although these remain predominantly mild to 
moderate in severity, and transient. In older adults, the difference in reactogenicity for Matrix -M-
adjuvanted influenza vaccines in contrast to licensed high-dose inactivated or recombinant 
influenza vaccines has been minimal.  
Risks to Privacy  
Subjects will be asked to provide personal health information (PHI). All attempts will be made to 
keep this PHI confidential within the limits of the law. However, t here is a chance that 
unauthorized persons will see the subject’s PHI. All study records will be kept in a locked file 
cabinet or maintained in a locked room at the participating site . Electronic files will be password 
protected . Only people who are involv ed in the conduct, oversight, monitoring, or auditing of 
this trial will be allowed access to the PHI that is collected. Any publications from this trial will 
not use information that will identify subjects by name. Organizations that may inspect and/or 
copy research records maintained at the participating site  for quality assurance (QA) and data 
analysis include groups such as the IRB, NIAID and the FDA.  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 29 of 97 A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by US Law. This web site will not include information that can identify subjects.  
There may be other risks, discomforts or side effects that are unknown at this time.  
Risks of Genetic Testing  
Any genetic data generated will be kept private. There may be a risk that information resulting 
from research genetic testing could be misused for discriminatory purposes. However, state and 
federal laws provide protections against genetic discrimination. Researchers will need to 
maintain confidentiality in order to be granted access to genetic information . 
2.2.2 Known Potential Benefits  
In cohort 2, there is the potential for protection against symptomatic SARS -CoV -2 infection  
following receipt of an EUA vaccine . There is no known direct benefit expected to the subjects  
in Cohort 1 or from the booster vaccination in Cohort 2 . There is potential benefit that the 
vaccine will boost the participant’s  immunity to a SARS -CoV -2 infection and the benefit to 
society resu lting from insights gained from participation in this study due to the emerging threat 
of the SARS -CoV -2 outbreak. Data from the Phase 3 placebo -controlled clinical trial of mRNA -
1273 demonstrated 94.1% efficacy of the vaccine  as a two-vaccination series versus placebo 
against symptomatic SARS -CoV -2 infection.  The Phase 3 placebo -controlled trial of  BNT162b2 
provided 95% vaccine efficacy as a two -vaccination series versus placebo against symptomatic 
SARS -CoV -2 infection.17 The Phase 3 placebo -controlled clinical trial of Ad26.COV.2 
demonstrated 66% efficacy against mild -mode rate SARS -CoV -2 infection and 85% against 
severe disease as a one -dose vaccination. The doses and vaccination strategies used in this trial 
may or may not alter this protection. It is unknown if the mRNA -1273. 211 vaccine will provide 
protection against inf ection with the B.1.351 variant.  It is anticipated that the mRNA -1273.2 22 
strain will provide protection against the currently circulating BA.4 and BA.5 strains.   
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 30 of 97 3 OBJECTIVES AND ENDPOINTS  
Table 7: Objectives and Endpoints (Outcome Mea sures)  
OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
Primary   
• To evaluate the safety and reactogenicity 
of delayed heterologous or homologous 
vaccine doses after EUA dosed vaccines.  • Local and systemic solicited adverse 
events for 7 days following the delayed 
boost dose . 
• Adverse Events from Dose 1 to 28 days 
following each vaccination and delayed 
boost dose .  
 
• MAAEs, SAEs, NOCMCs, and AESI s 
from Dose 1  to end of planned study 
participation . 
• To evaluate the breadth of the humoral 
immune responses of heterologous and 
homologous delayed boost regimens 
following EUA dosing  
  Response rate, and magnitude of SARS -
CoV -2-specific antibody binding and 
neutralization titers in serum samples as 
assessed via a range of assays at all 
timepoints . 
Secondary   
• None  • None  
*Exploratory   
• To assess, in at least a subset of samples, 
the B cell immune response following 
EUA vaccination and delayed boost  • Magnitude, phenotype and percentage of 
SARS -CoV -2 specific B cells, as 
measured by flow cytometry and targeted 
B cell subset analysis at time points post -
vaccination and/or delayed boost.  
• To assess, in at least a subset of samples, 
the SARS -CoV -2 protein -specific T cell 
responses following EUA vaccination and 
delayed boost  • Magnitude, ph enotype, and percentage of 
cytokine producing S protein T cells as 
measured by flow cytometry at time 
points post -vaccination and/or delayed 
boost.  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 31 of 97 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
• To evaluate breakthrough symptomatic 
SARS -CoV -2 infection and sequence 
strains to assess for variant spike lineage  • To perform sequence analysis on 
breakthrough NAAT -confirmed COVID -
19 strains to assess for variant spike 
lineage  
 
• To assess, in at least a subset of samples, 
mucosal (salivary and nasal) SARS -CoV -
2 spike protein -specific IgG and IgA 
responses  • Magnitude and percentage of SARS -CoV -
2 spike protein specific IgA and IgG and 
correlation with serologic antibody 
response  
 
*Assays for exploratory endpoints may be performed and the data provided as described in 
Section 9.4, if available from the research laboratory.  
 
  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 32 of 97 4 STUDY DESIGN  
4.1 Overall Design  
This is a phase 1 /2, open -label clinical trial in individuals , 18 years of age and older, who are in 
good health, have no known history of COVID -19 or SARS -CoV -2 infection , and meet all other 
eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and 
immunogenicity of a delayed ( >12 weeks) vaccine boost on a range of EUA -dosed COVID -19 
vaccines (mRNA -1273 manufactured by ModernaTX, Inc.; B NT162b2 manufactured by 
Pfizer/BioNTech; or Ad26.COV2.S manufactured by Janssen Pharmaceuticals/Johnson & 
Johnson) . This is an adaptive design and may add arms (and increase sample size) as vaccines 
are awarded EUA and/or variant lineage spike vaccines are  manufactured  or become available . 
Enrollment will occur at up to twelve domestic clinical research sites.  
This study includes two cohorts. Cohort 1 will provide rapid information about the  safety, 
reactogenicity, and  immunogenicity of delayed boost  in a p reviously EUA -dosed group. This 
cohort can inform near term public health decisions if the variant virus becomes more 
widespread. Cohort 2 is an adaptive cohort that will evaluate , in a prospective fashion, the safety, 
reactogenicity and immunogenicity of  EUA -dosed vaccine followed by delayed boost. Pools of 
subjects will be recruited to receive EUA -dosed vaccine  and will be assigned, at a later date, to a 
delayed booster vaccine based on av ailability of vaccine product, to enable rapid implementation 
based  on situational assessment of need.  This cohort will take longer to provide information on 
the immunogenicity of delayed boost , but it may assume priority in enrollment as  it is important 
to inform future public health strategies  and as access to COVID -19 vaccine becomes more 
widespread . As Cohorts 1 and 2 are in different populations, they can be enrolled in parallel or 
prioritized as determined by DMID/ IDCRC needs . 
Cohort 1 will include subjects greater than 18 years of age and older , stratified into two age strata 
(18-55 years and > 56 years)  who received previously  received  COVID -19 vaccine at EUA 
dosing ( two vaccinations of mRNA -1273 at the 100 mcg  dose, two vaccinations of  BNT162b2 at 
the 30 mcg dose, or one vaccination of Ad 26.COV2 .S at the 5x1010 vp dose) . Those subjects will 
be offered enrollment into this study >12 weeks after they received the last dose of their EUA  
vaccin e.  Subjects will receive an open -label delayed boost that is assigned to each of the 
approximately twelve domestic trial sites.  
1. Previously EUA -dosed vaccination with Janssen  (one or two doses for Group 15E)  – 
Ad26.COV2.S  at 5x1010 vp followed by:  
Group 1E – A 100 -mcg dose of mRNA -1273  
Group 4E – A 5x1010 vp dose of Ad26.COV2.S * 
Group 7E - A 30 -mcg dose of BNT162b2  
Group 10E –A 100 -mcg dose of mRNA -1273. 211 
Group 12E – A 50 -mcg dose of mRNA -1273  
Group 15E – A dose of NVX -CoV237 3 (5 mcg Prototype SARS -CoV -2 rS vaccine with 
50 mcg Matrix -M)* 
 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 33 of 97 2. Previously EUA -dosed vaccination with Moderna – mRNA -1273  at 100 mcg for two 
doses followed by:  
Group 2E – A 100 -mcg dose of mRNA -1273  
Group 5E – A 5x1010 vp dose of Ad26.COV2.S  
Group 8E - A 30 -mcg dose of BNT162b2  
Note: There will be no boost with mRNA -1273.211 to avoid duplication of trial 
efforts with DMID 21-0003. 
Group 13E – A 50 -mcg dose of mRNA -1273  
Group 16E – A dose of NVX -CoV237 3 (5 mcg  Prototype  SARS -CoV2  rS vaccine with 
50 mcg Matrix -M)* 
 
3. Previously EUA -dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two 
doses followed by:  
Group 3E – A 100 -mcg dose of mRNA -1273  
Group 6E – A 5x1010 vp dose of Ad26.COV2.S  
Group 9E - A 30 -mcg dose of BNT162b2  
Group 11E – A 100 -mcg dose of mRNA -1273. 211 
Group 14E – A 50 -mcg dose of mRNA -1273  
Group 1 7E – A dose of NVX -CoV237 3 (5 mcg Prototype SARS -CoV2  rS vaccine with 
50 mcg Matrix -M)* 
The anticipated sample size of each group  is approximately 25 subjects 18 through 55 years of 
age and approximately 2 5 subjects 56 years of age and older  for a total of 50 subjects per group .  
*Note – Groups 15E -17E will enroll 60 subjects, split  (approximately  evenly ) between age strata  
as able . As the use of 2 dose s of Ad26COV2.S without additional vacci nes is relatively 
infrequent in the population  (and 1 dose without additional vaccines is even less frequent) , 
participants  who were  enrolled and remain active  in Group 4E (homologous prime -boost with 
Ad26C OV2.S ) will be offered the opportunity to roll int o Group 15E , if eli gible . 
Subjects in Cohort 1 will receive a single intramuscular (IM) injection of the designated delayed 
booster vaccine and will be followed through 12 months after vaccination. A telephone visit will 
occur at Day 8 and in -person f ollow -up visits will occur on Days  15 and 29, as well as 3, 6, 9, 
and 12 months after the vaccination.  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 34 of 97 Table 8: Cohort 1 Treatment Arms  
Arm  Sample Size  Booster Vaccination  
Product and Dose  
1E ~50 100 mcg mRNA -1273  
2E ~50 100 mcg mRNA -1273  
3E ~50 100 mcg mRNA -1273  
4E ~50 5x1010 vp dose Ad26.COV2.S  
5E ~50 5x1010 vp dose Ad26.COV2.S  
6E ~50 5x1010 vp dose Ad26.COV2.S  
7E ~50 30 mcg BNT162b2  
8E ~50 30 mcg BNT162b2  
9E ~50 30 mcgBNT162b2  
10E ~50 100 mcg mRNA -1273. 211 
11E ~50 100 mcg mRNA -1273. 211 
12E ~50 50 mcg mRNA -1273  
13E ~50 50 mcg mRNA -1273  
14E ~50 50 mcg mRNA -1273  
15E ~60 NVX -CoV2373 (5 mcg Prototype SARS -
CoV -2 rS with 50 mcg Matrix -M) 
16E ~60  NVX -CoV2373 (5 mcg Prototype SARS -
CoV -2 rS with 50 mcg Matrix -M) 
17E ~60  NVX -CoV2373 (5 mcg Prototype SARS -
CoV -2 rS with 50 mcg Matrix -M) 
Summary of Treatment Arms:  
• 1E – Evaluates a  hetero logous platform booster  dose of mRN A-1273  among  persons who 
previously received an Ad26.COV2.S EUA vaccination series  
• 2E- As a bridging arm evaluates a homologous platform third boosting dose of mRNA -
1273 among persons who previously rec eived a mRNA -1273 EUA vaccination series  
• 3E – Evaluates a homologous mRNA platform of mRNA -1273 booster dose among 
persons who previously received a BNT162b2  EUA vaccination series  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 35 of 97 • 4E - Evaluates Ad26.COV2.S EUA vaccination series followed by a homologou s 
platform delayed dose of Ad26.COV2.S * 
• 5E - Evaluates mRNA -1273 EUA vaccination series followed by a heterologous platform 
delayed dose of Ad26.COV2.S  
• 6E - Evaluates BNT162b2 EUA vaccination series followed by a heterologous platform 
delayed dose of Ad26.COV2.S  
• 7E - Evaluates Ad26.COV2.S EUA vaccination series followed by a heterologous 
platform delayed dose of BNT162b2  
• 8E - Evaluates mRNA -1273 EUA vaccination series followed by a homologous platform 
delayed dose of BNT162b2  
• 9E - Evaluates BNT162b2 EU A vaccination series followed by a homologous platform 
delayed dose of BNT162b2  
• 10E- Evaluates Ad26.COV2.S EUA vaccination series followed by a heterologous 
platform delayed dose of  a combined homologous and  variant  spike lineage  mRNA -
1273. 211 
• 11E - Evalua tes BNT162b2 EUA vaccination series followed by a homologous platform 
delayed dose of a combined homologous and variant spike lineage mRNA -1273. 211 
o Note – the homologous comparator for groups 10E and 11E ( Moderna EUA 
vaccination with the mRNA 1273.211  homologous and  variant vaccine is being 
conducted in another trial ( NIAID DMID 21 -0002) and not done here to avoid 
duplication.  
• 12E – Evaluates a heterologous platform  50 mcg  booster of mRNA -1273 among persons 
who previously received an Ad26.COV2. S EUA vaccination series  
• 13E- Evaluates a homologous platform  50 mcg  booster of mRNA -1273 among persons 
who previously received a mRNA -1273 EUA vaccination series  
• 14E – Evaluates a homologous mRNA platform of mRNA -1273 50 mcg  booster among 
persons who previously received a BNT162b2 EUA vaccination series  
• 15E - Evaluates Ad26.COV2.S EUA vaccination series  (one or two doses) * followed by 
a heterologous platform delaye d dose of NVX -CoV237 3 (5 mcg SARS -COV -2) 
• 16E - Evaluates mRNA -1273 EUA vaccination series followed by a heterologous 
platform delayed dose of NVX -CoV237 3 (5 mcg SARS -COV -2) 
• 17E - Evaluates BNT162b2 EUA vaccination series followed by a heterologous platform  
delayed dose of NVX -CoV237 3 (5 mcg SARS -COV -2) 
*Since t he regimen of one or two doses of Ad26.COV2.S is less prevalent than other EUA 
dosing regimens , it will make this group harder to recruit.  Therefore, Group 4E participants 
who have received two doses of Ad26.COV2.S will be offered the opportunity to roll into 
Group 15E. Newly recruited volunteers who have received a single dose of Ad26.COV2.S 
will also be recruited.  Subset analysis will be p erformed on the one and the two dose arms.  
Data is needed as to the best means of boosting this under -evaluated regimen.  
 
Cohort 2 will include approximately 250 participants  per group aged > 18 years of age who have 
not received a COVID -19 vaccine and  have no known history of COVID -19 or SARS -CoV -2 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 36 of 97 infection. They will be assigned to receive COVID -19 vaccine under EUA dosing (as 
programmatically outlined in Table 9. Additional pools of subjects can be included if needed as 
additional COVID -19 vaccines are awarded EUA.  These pools of participants were to be  
assigned a novel homologous or heterologous variant boost or heterologous platform boost at a 
minimum of 12 weeks  following receipt of EUA dosing and  followed through 12 months after 
the last vaccination. As booster vaccines have been approved for individuals at an interval of 6 
months from the primary series, under EUA, all Cohort 2 volunteers will be offered a boos ter of 
mRNA -1273 at the approved 50 mcg  dose at Day 181 (+/ - 30 days following dose 2 of their 
primary series . A telephone visit will occur one week after each primary EUA vaccination  and 
one week after the booster dose . In person follow -up visits will occur on 14 days following  
completion of  EUA vaccination s and on days  14, and 28 days after the booster dose , as well as 3, 
6, and 12 months post the booster vaccination.  A fourth dose of COVID -19 vaccine will be 
administered to partic ipants using the Moderna mRNA -1273.2 22 bivalent vaccine at an interval 
of 4 to 12 months after the third dose (1st booster). In addition to the other immunologic assays 
planned for earlier  parts of the study (including innate, cellular and humoral response s), samples 
also will be collected to measure mucosal immune responses before  the booster dose  and on days 
14 and 28, and at 3 months  and 6 months  after the  fourth dose ( 2nd booster ). Due to the surge of 
the Omicron variant and breakthrough infections, volunteers who contract symptomatic or 
asymptomatic COVID -19 between completion of their EUA primary series and the scheduled 
booster dose will be allowed to continue in the study. The i nterval between the COVID -19 
infection and booster dosing should be a minimum of 28 days.  
Table 9: Cohort 2 Treatment Arms  
Group  Sample 
Size First 
Vaccination  Second 
Vaccination  Booster 
Vaccination  1 Booster 
Vaccination 2  
Product 
and Dose  Inter -
val Product 
and 
Dose  Inter -
val Product 
and 
Dose  Inter -
val Product 
and Dose  
1 250 100 mcg 
mRNA -
1273  28 
days 100 
mcg 
mRNA -
1273  ~6 
months  50 mcg 
mRNA -
1273  4-12 
months  50 mcg 
mRNA -
1273.2 22 
 
For both Cohorts 1 and 2, reactogenicity will be assessed at the above -mentioned visits and 
blood will be drawn for immunogenicity assays  at the in -person follow -up visits . 
After the IND is in effect, IRB review  and approval,  and site activation, the participating sites 
will begin recruitment outreach efforts, which can include fliers, letters, telephone calls, etc. 
Information regarding this trial may be provided to potential subjects who have previously 
participated in other vaccine trials conducted at th e participating site. Other forms and/or 
mechanisms of recruitment may also be used. The IRB will approve the recruitment process and 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 37 of 97 all materials prior to use.  Screening can occur up to 2 8 days prior to the first dose  or on Day 1 
prior to administration of Dose 1.  
Schedule s of assessments are found in Section 1.2, Schedule  of Activities . 
4.2 Scientific Rationale for Study Design  
This phase 1/2 clinical trial  is designed as an open -label study, without administration of a 
placebo  formulation . An open -label  study will facilitate the need for rapid review and 
dissemination of study data for public health reasons.  
4.3 Justification for Dose s 
The dosages selected are those authorized under EUA.  
In the Phase 1 clinical trial, DMID 20 -0003,  mRNA -1273, admi nistered as two injections 28 
days apart, was investigated at dos ages of 25, 50, 100 and 250 mcg in subject s 18 through 55 
years of age , and at dosages of 25, 50, and 100 mcg in older cohorts (56 -70 years of age  and >71  
years of age ).18,19 The 100-mcg dose induced higher antibody titers than the 25-mcg dose, 
whereas the 250-mcg dose did not lead to significant increases . The Phase 2 trial of mRNA -1273 
evaluated doses of 50 mcg and 100 mcg,  administered as a two -vaccination series, in 600 adults 
≥18 years of age. The safety profile of both for mulations was acceptable.20 Anti-SARS -CoV -2 S 
binding and neutralizing antibodies were induced by both dose  levels  of mRNA -1273 within 28 
days after the first vaccination and  rose substantially to peak titers by 14 days after the second 
vaccination, exceeding leve ls of convalescent sera from COVID -19 patients. The antibodies 
remained elevated through the last timepoint assessed at 57 days. Binding and neutralizing 
antibody responses were generally comparable in participants who received the 100 -mcg 
mRNA -1273 and th e 50-mcg dose at all time points and across the age groups of ≥18 to <55 
years and ≥55 years. These findings support the evaluation of mRNA -1273 and mRNA -1273.351 
at total dosages of 50 or 100 mcg per vaccination . For this reason, mRNA -1273.211 consists of  a 
combined 50 -mcg of mRNA -1273 encoding the S -2P of Wuhan -Hu-1 and 50 -mcg of mRNA -
1273.351  encoding the S -2P of the South African (Beta) variant strain . Further, the 50mcg dose 
of mRNA -1273 will be tested as a dose -sparing booster option separate from the  admixture 
(mRNA -1273 and mRNA -1273.351) dosing. The primary efficacy analysis from the Phase 3 trial 
evaluating a two -dose schedule of a 100 -mcg mRNA -1273 vaccine led to the issuance of the 
EUA and initiation of a vaccination campaign in the United States . The mRNA -1273.2 22 
vaccine has received EUA to be used as a booster vaccine in adults in the US beginning in 
September 2022.  
The Phase 1 study of BNT162b1 (which encodes the RBD) vs. BNT162b2  (which encodes the 
full-length spike protein)  produced by Pfizer/BioNTech admin istered at two injections 21 days 
apart, was investigated at dosages of 1 0, 20, 30 and 100 mcg in subjects 18 through 55 years of 
age and 65 through 85 years of age .16 BNT162b2 was associated with lower incidence and 
severity of systemic reactions com pared to BNT162 b1, and both produced  similar levels of 
neutralizing antibody  which super seded convalescent serum  results. The lower incidence of 
systemic reactions was particularly apparent in older subjects. The 50% and 90% neutralizing 
antibody titers exce eded convalescent serum  at 7 and 14 d after the second dose.  Based upon 
these data, the 30 -mcg dose was taken in to Phase 2 a/3 trials.  The results of the Phase 2a/3 trial 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 38 of 97 demonstrated thatBNT162b2 administered as two injections, 21 days apart, at a 30 -mcg dose, 
conferred 95% protection against C OVID -19 in persons >16 years of age.17 The primary efficacy 
analys is from the Phase 3 trial led to the issuance of the EUA and initiation of a vaccination 
campaign in the United States.    
Although current vaccines prov ide high levels of protection against severe illness and death, the 
increased transmission of the Delta variant resulted in increasing numbers of contagious 
breakthrough infections in fully vaccinated individuals.21-23 This coincided with evidence of 
waning of immunity in some vac cinated populations.22-24 Based upon a full review of risks, 
benefits, and immunogenicity of booster vaccines, the VRBPAC advisory group to the FDA  (14 
October 2021) , affirmed by the ACIP  (21 October 2021) , recommended booster vaccines for 
BNT162b2 and mRNA -1273 (the latter at a reduced dose of 50 mcg ),25-27 6 months after 
completion of the primary series in those aged >65 years or in those vulnerable populations 
considered at risk for Covid -19 acquisition.   Furthermore, heterologous booster vaccines were 
deemed permissible.  
The Phase 1/2a study of the AD2 6.COV 2.S vaccine evaluated two dosage levels (5x1010 vp and 
1x1011 vp) based upon prior vaccine studies with the Ad26 platform .28 Both formulations  
administered as a single dose had favorable safety and immunogenicity profiles,29 yielding high 
and comparable humoral and cellular immune response rates. The low er dose had a more 
favorable reactogenicity profile an d was selected for Phase 3 trial evaluation  that demonstrated 
its protective efficacy .28 As with the mRNA vaccines, upon review of risks, benefits, and 
immunogenicity of a second dose of Ad26.COV2.S,30 the VRBPAC advisory group to the FDA  
(15 October 2021) , affirmed by the ACIP  (21 October 2021) , recommended a homologous 
booster vaccine or a heterologous booster vaccine for Ad26.COV2.S, 2 months after completion 
of the primary vaccine in those aged 18 years or greater . 
 
Novavax received EU A from  the FDA for use as a two -dose priming vaccine  in persons 18 and 
older in July 2022 and for 12 -17 year olds the following month  (August 2022) . On October 19,  
2022 the FDA authorized EUA  use of Novavax  first booster  dose in persons 18 years and older  6 
months  after compl etion of  primary vaccination . Phase 1 (Part 1) of the SARS -CoV -2 rS product 
with or without Matrix -M adjuvant was conducted in Australia (2019nCoV -101) in adults aged 
19-59 inclusive and  determined the safety  and immunogenicity of the 5 g vs. 25 g dose of the 
SARS -CoV -2 rS recombinant protein with or without 50 g of Matrix -M. The adjuvant clearly 
enhanced anti -Spike IgG , anti -ACE2 inhibition and neutralizing antibody  and the 5 g dose of 
protein was non -inferior to the 25 g dose of SARS -CoV -2 rS in all assays. Additionally, the 
study established that a two -dose arm was superior to a one dose design (at an interval of 21 
days).31 The 2019nCoV -101 (Part 2) examined the vaccine constructs in persons up to age 84 
years as a one -dose, two -dose or two -dose with a 6 -month booster dose (three dose). Data 
analysis for the booster dosing has not been performed. It was found to be safe, well -tolerated 
and immunogenic in younger and older individuals with similar trends as to Part 1 of the study. 
Based upon these data, the Phase 3 trials of NVX -CoV2373 examined the safety, 
immunogenicity and efficacy of the vaccine with 5 g of SARS -CoV -2 rS a djuvanted with 50  g 
of Matrix -M.5,6  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 39 of 97 5 STUDY POPULATION  
Two cohorts will be enrolled. For Coh ort 1, approximately  880 individuals (50 subjects/group; 
Groups 1E -14E, and 60 subjects/group; Groups 15E -17E) 18 years of age and older , stratified 
into two age groups (18 -55 years and >56 years at 1:1 ratio) , who are in good health and received 
EUA dosed vaccinations of mRNA -1273 , BNT162b2 or Ad26.COV2.S  will be invited to 
participate in this study.  
For Cohort 2, approximately 250 individuals  (250 subjects/ group ), >18 years of age, who have 
never been vaccinated against SARS -CoV -2 or are not known to  have been infected with SARS -
CoV -2 and  meet all eligibility criteria will be enrolled. The target population should reflect the 
community at large.  Future groups may be added as additional EUA vaccines become available.  
The estimated time from initiation of enrollment to complete enrollment in each group within  
this clinical trial is approximately 2-4 weeks  (though could take longer ). However, owing to the 
adaptive nature of the design, new groups may be added to Cohort 1 or 2 dependent upon 
manufacture of variant lineage spike protein -based vaccine constructs or vaccines newly 
awarded EUA.  An optional s creening period can occur up to 28 days prior to the first 
vaccination , or can be completed on Day 1, prior to dosing . 
Subject Inclusion and Exclusion Criteria must be confirmed by a study clinician, licensed to 
make medical diagnoses and listed on the Form FDA 1572. No exemptions are gr anted on 
Subject Inclusion or Exclusion Criteria in DMID -sponsored studies.  
5.1 Inclusion Criteria  
See Inclusion Criteria  in Synopsis  
5.2 Exclusion Criteria  
See Exclusion Criteria  in Synopsis . 
5.2.1 Exclusion of specific populations  
The effects on the fetus are not known; therefo re, pregnant women will not be eligible for the 
trial. Children will not be included in this trial as presently there are no safety or efficacy data in 
adults for the variant strain. Should the outcome of this trial be deemed acceptable, additional 
trials may be initiated, including these populations.  
5.3 Inclusion of Vulnerable Subjects  
Not Applicable  
5.4 Lifestyle Considerations  
During this study subjects  are asked to:  
• Follow public health guidance on preventing SARS -CoV -2 infection.  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 40 of 97 • Subjects must avoid eating or drink ing anything hot or cold within 10 minutes prior to 
taking oral temperature.  
5.5 Screen Failures  
A screening visit is optional. However, if  screening assessments  are performed , the participating 
site PI or qualified designee is to review the inclusion  and exclusion criteria and determine the 
subject’s eligibility for the study.  
Only the following information will be collected on screen failures: demographics (age, screen 
number, sex, ethnicity, and race) and reason for ineligibility. Subjects who are f ound to be 
ineligible will be told the reason for ineligibility.  
5.5.1 Strategies for Recruitment and Retention  
Potential subjects will learn about the study via IRB -approved recruitment strategies, including 
direct mailing , recruitment from an IRB -approved tria l registry a nd local advertisements/flyers . 
Screening will begin with a brief IRB -approved telephone call from study staff. Information 
about the study will be presented to potential subjects and questions about their health and ability 
to comply with the study visit schedule will be asked of potential subjects  to presumptively 
determine eligibility. Appointments will be made at the research clinic  for potential subjects who 
are interested in the study for further screening procedures and additional protoco l-specific 
information.  
5.5.2 Retention  
Study retention strategies will include education and explanation of the study schedule and 
procedures during screening and enrollment /baseline  visits and restriction of enrollment to 
persons who can attend all study visits . Participating subjects will be reminded of subsequent 
visits during each visit, and study staff will contact subjects prior to appointments. Study staff 
will contact subjects who miss appointments to encourage them to return for completion of 
safet y evaluations.  
5.5.3 Compensation Plan for Subjects  
Subjects may be compensated for their participation in this trial. Compensation will be in 
accordance with local IRB requirements, and subject to local IRB approval. Reimbursements 
will be disbursed at specific  timepoints during the study with the amount contingent on 
completing study procedures.  
5.5.4 Costs  
There is no cost to subjects for the research tests, procedures/evaluations or study product while 
taking part in this trial. Procedures and treatment for clinica l care may be billed to the subject, 
subject’s insurance or third party.  
  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 41 of 97 6 STUD Y PRODUCT  
6.1 Study Product (s) and Administration  
6.1.1 Study Product  Description  
Product: mRNA -1273 , mRNA -1273.211 , and mRNA -1273.222   
mRNA -1273 (0.2 mg/mL) is an LNP dispersion containing an mRNA that encodes for the pre 
fusion stabilized S protein of the Wuhan -Hu-1 strain of SARS -CoV -2. mRNA -1273 consists of 
an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable 
lipid, SM -102, and 3 commercially available lipids, cholesterol, 1,2 -distearoyl -sn-glycero -3-
phosphocholine (DSPC), and PEG2000 DMG.  
mRNA -1273.211  (0.2 mg/mL)  is formulated in the same way as the mRNA -1273 vaccine but 
contains 1:1 mix of mRNAs that encodes for the prefus ion stabilized S protein of the B.1.351 
variant SARS -CoV -2 strain and the prefusion stabilized S protein of the Wuhan -Hu-1 strain used 
in mRNA -1273.  
mRNA -1273.2 22 (0.1 mg/mL)  is formulated in the same way as the mRNA -1273 vaccine but 
contains 1:1 mix of mR NAs that encodes for the prefusion stabilized S protein of the Omicron 
BA.4/BA.5 variant SARS -CoV -2 strain and the prefusion stabilized S protein of the Wuhan -Hu-
1 strain used in mRNA -1273.  
 
Product: Ad26.COV2.S  
Each 0.5 mL dose of the Ad26.COV2.S vaccine is formulated to contain 5x1010 virus particles of 
the Ad26 vector encoding the S glycoprotein of SARS -CoV -2. Each dose of the Ad26.COV2.S 
vaccine also includes the following inactive ingredients 2.19 mg sodium chloride, 0.14 mg citric 
acid monohydrate, 2.02 mg trisodium citrate dihydra te, 0.16 mg polysorbate -80, 25.5 mg 2 -
hydroxypropyl -β-cyclodextrin, 2.04 mg ethanol. Each dose may also contain residual amounts of 
host cell proteins (≤0.15 mcg) and/or host cell DNA (≤3 ng). The Ad26.COV2.S vaccine is a 
colorless to slightly yellow, clea r to very opalescent suspension. Each vial contains five doses . 
Product:  BNT162b2  
The Pfizer -BioNTech COVID -19 Vaccine  (250 mcg/0.5 mL)  contains a nucleoside -modified 
messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS -CoV -2. The 
vacci ne also includes the following ingredients: lipids ((4 -hydroxybutyl)azanediyl)bis(hexane -
6,1-diyl)bis(2 -hexyldecanoate), 2 -[(polyethylene glycol) -2000] -N,N-ditetradecylacetamide, 1,2 -
distearoyl -sn-glycero -3-phosphocholine, and cholesterol), potassium chlor ide, monobasic 
potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose.  Each 
vial contains  up to  six doses.  
This vaccine requires dilution .  The USP grade 0.9% NaCl or normal saline for injection is a 
sterile, nonpyrogenic, is otonic solution; each mL contains NaCl 9 mg. It contains no 
bacteriostatic agent, antimicrobial agent, preservatives, or added buffer and is supplied only in 
single -dose containers. The solution may contain hydrochloric acid and/or sodium hydroxide for 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 42 of 97 pH adjustment (pH 5.3, range 4.5 -7.0). This product should be used to dilute the BNT162b2 
vaccine to the desired concentration.  
Product: NVX -CoV237 3 
SARS -CoV -2 rS Drug Substance containing the prototype Wuhan  is formulated with saponin -
based Matrix -M adjuvant in a buffer of 25 mM sodium phosphate (pH 7.2), 300 mM sodium 
chloride, and 0.01%  (weight per volume [w/v]) polysorbate 80. Quantities of the Drug Substance 
strain(s) and the Matrix -M adjuvant are added to buffer, and then additional buffer is add ed to 
obtain the desired protein concentration. The DP (drug product) solution is filtered and 
aseptically filled into the United States Pharmacopeia (USP) type -I glass vials, stoppered, and 
sealed to produce SARS -CoV -2 rS Drug Product.  
 
The product will b e available in a co-formulated single or multi -dose vial for this study.  The 
IP consists of 10 mcg/mL SARS -CoV -2 rS vaccine adjuvanted with 100 mcg/mL Matrix -M. 
6.1.2 Dosing and Administration  
Product: mRNA -1273 , mRNA -1273.211 , and mRNA -1273.222   
mRNA -1273 (0. 2 mg/mL) will be administered in  0.5 mL dos es (100 mcg /0.5 mL ). 
mRNA -1273 (0.2 mg/mL) will be administered in 0.25 mL doses (50 mcg/0.25 mL).  
mRNA -1273.211 (0.2 mg/mL) will be administered in 0.5 mL doses (100 mcg/0.5 mL).  
mRNA -1273 .222 (0.1 mg/mL) will be  administered in 0.5 mL doses (50 mcg/0.5 mL)  
Product: Ad26.COV2.S  
Ad26.COV2.S will be used undiluted to obtain the specified vp content in 0.5 mL doses. Each 
dose is 0.5 mL.  
Product:  BNT162b2  
BNT162b2 ( 250 mcg/0.5 mL) will be administered in diluted 0. 3 mL doses (30 mcg/0.3 mL) . 
Product: NVX -CoV237 3 
NVX -Co-V2373 will be administered in 0.5 mL dose (5 mcg Prototype SARS -CoV -2 rS 
with 50 mcg Matrix -M adjuvant).  
For Cohort 2, the second dose of mRNA vaccine will be administered preferably in the same arm 
used for the first dose.  For Cohort 2, the booster dose of vaccine will also be administered 
preferably in the same arm used for the first dose.  
The pharmacist will prepare a single dose for each subject based on cohort assignment.   
See the protocol -specif ic Manual of Procedures ( MOP ) for detailed information on the 
preparation, labeling, storage, and administration of vaccine for each cohort. Vaccine  preparation 
will be performed by the participating  site’s research pharmacist on the same day of vaccine 
administration to the subject.  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 43 of 97 6.1.3 Dose Modifications  
A dose sparing 50 mcg mRNA -1273 booster (Groups 12E -14E) will be tested and compared to 
full dose booster dosing (Groups 1E -3E). As of 21 October 2021, this dose was also 
recommended and approved under EUA as  the booster mRNA -1273 dose offered.   
6.2 Accountability /Handling/Storage/ Preparation  
6.2.1 Acquisition and Accountability  
All the vaccines (and diluents as needed)  will be provided by the DMID repository : 
DMID Clinical Materials Services Contract  
Fisher BioServices  
20439 Seneca Meadows Parkway  
Germantown, MD 20876  
Phone: 240 -477-1350  
Fax: 240 -477-1360  
Email: DMID.CMS@thermofisher.com  
All study products will be shipped to the clinical research site upon request and approval from 
DMID.  
Accountability  
The participating  site PI is responsible for study product distribution and disposition and has 
ultimate responsibility for study product accountability. The participating  site PI may delegate to 
the participating site’s research pharmacist responsibility for st udy product ac countability. The 
participating  site’s research pharmacist will be responsible for maintaining complete records and 
documentation of study product receipt, accountability, dispensation, storage conditions, and 
final disposition of the study p roduct(s). Study product accountability records and dispensing 
logs should include, but are not limited to the following: DMID protocol number; name, dosage 
form, strength of the study product; capture vial numbers assigned sequentially by the 
pharmacists as vials/syringes are used (number uniquely, do not start over at 1 or repeat 
numbers), manufacturer or other source; control, lot number or other identification number; 
expiration or retest date; date of receipt of the study product; quantity received fro m supplier; 
subject identification number ; quantity dispense d as amount or dose per subject ; balance of study 
product currently available ; disposition of study product  if not dispensed to a study subject (e.g. , 
disposed/destroyed or retuned to supplier as per protocol or protocol -specific MOP or as directed 
by DMID) ; date of vaccine preparation/administration, time of vaccine preparation, expiration of 
vaccine preparation ; and amount of vaccine withdrawn for adm inistration. Time of vaccine 
administration to the subject will be recorded on the appropriate data collection form ( DCF ). All 
study product(s), including the amount of study product , and vial admixtures, whether 
administered or not, must be documented on the appropriate study product accountability record 
or dispensing log. The sponsor’s monitoring staff will verify the participating site’s study 
product accountability records and dispensing logs per the  DMID -approved  clinical  monitoring 
plan (CMP) . 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 44 of 97 Once a ll subject dosing is complete, the pharmacy staff should retain or dispose of used study 
products and complete study product accountability procedures in accordance with site -specific 
standard operating procedures (SOPs).  
All used supplies noted above may either  be sequestered from the unused supplies and retained 
until study conclusion or until study product accountability has occurred by the monitor and 
written notification stating retention is no longer required is received or  may be destroyed in 
accord ance with site -specific SOPs with a second pharmacy staff member’s observation and 
verification as documented in the pharmacy log . Refer to the protocol -specific MOP for details 
on storing used study product  vials . 
Destruction  
After the study treatment per iod has ended or as appropriate over the course of the study after 
study product  accountability has been performed, disposition of unused and used study product  
vials should occur as noted:  
Unused and used study product vials:  
Should be  destroyed on -site following applicable site procedures or by the site’s selected 
destruction vendor. Following the site’s procedure for the destruction of hazardous 
material or study product  destruction policy/SOP when destroying used and unused 
items.  
A certificate of destruction or documentation of destruction should be provided to the 
sponsor and retained in the Pharmacy Binder once completed.  
Used syringes may be destroyed in accordance with site -specific SOPs.  
6.2.2 Formulation  and Appearance  
Product: mRNA -1273, mRNA -1273.211 , and mRNA -1273.222   
mRNA -1273  is provided as a sterile liquid for injection, white to off -white dispersion in 
appearance . 
mRNA -1273.211  is provided as a sterile liquid for injection, white to off -white dispersion in 
appearance.  
mRNA -1273.222  is provided as a sterile liquid for injection, white to off -white dispersion in 
appearance.  
Product: Ad26.COV2.S  
Ad26.COV2.S is supplied as a sterile suspension in multi -dose vials. The Ad26COV2.S vaccine 
does not contain a preservative. The A d26.COV2.S vaccine is a colorless to slightly yellow, clear 
to very opalescent suspension.  
Product: BNT162b2  
BNT162b2 is white to off -white, sterile, preservative -free, frozen suspension for intramuscular 
injection.  
Product: NVX -CoV237 3 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 45 of 97 Prototype SARS -CoV -2 rS is a liquid solution formulated in 25 mM phosphate buffer (pH 7.2), 
300 mM sodium chloride, and 0.01% (w/v) polysorbate 80, and diluted with the same to 
specified concentrations co -formulated with Matrix -M adjuvant that also contains phosphate -
buffer ed saline. The SARS -CoV -2 rS vaccine with Matrix -M adjuvant will be supplied in single -
dose or multi -dose glass vials with latex -free stoppers; volume of fill to be specified in the study 
MOP  
Each of the study products will be labeled according to manufact urer specifications and include 
the statement “Caution: New Drug Limited by Federal Law to Investigational Use.”  
6.2.3 Product Storage and Stability  
Product: mRNA -1273   
mRNA -1273  vials are stored between -50°C to -15°C ( -58°F to 5°F) as per updated EUA Fact 
Sheet.  Store in the original carton to protect from light. Do not store on dry ice or below -50ºC ( -
58ºF). Use of dry ice may subject vials to temperatures colder than -50°C ( -58°F). Vials can be 
stored refrigerated between 2°C to 8°C (36° to 46°F) for up  to 30 days prior to first use. Do not 
refreeze. Vials may be stored between 8° to 25°C (46° to 77°F) for a total of 24 hours. After the 
first dose has been withdrawn, the vial should be held between 2° to 25°C (36° to 77°F). Vials 
should be discarded 12 h ours after the first puncture. Thawed vials can be handled in room light 
conditions. Do not refreeze once thawed . 
mRNA -1273.211  vials are stored frozen between -60°C to -90°C  (-76°F to -130°F). Stability and 
compatibility with the apparatus intended for ad ministration for up to 8 hours after preparation 
were assessed. The prepared doses were stable for clinical in -use for up to 8 hours at room 
temperature. Store in the original carton to protect from light.  
mRNA -1273.222  vials are stored frozen between -90°C to -60°C (-130°F to -76°F). Once a vial 
is fully thawed at room temperature for 20 -30 min, it must be used within 24 hours. After 
drawing a dose into a dosing syringe, the syringe may be stored at room temperature for up to 8 
hours, as long as the thawed  vial expiry (24 hours from thaw) is not exceeded.  
Product: Ad26.COV2.S  
Storage Prior to First Puncture of the Vaccine Vial   
Store unpunctured multi -dose vials of the Janssen COVID -19 Vaccine at 2°C to 8°C (36°F to 
46°F) and protect from light. Do not store frozen.  
Unpunctured vials of Ad26.COV2.S vaccine may be stored between 9°C to 25°C (47°F to 77°F) 
for up to 12 hours. The Ad26.COV2.S vaccine is initially stored frozen by the manufacturer, then 
shipped at 2°C to 8°C (36°F to 46°F). If vaccine is sti ll frozen upon receipt, thaw at 2°C to 8°C 
(36°F to 46°F). If needed immediately, thaw at room temperature (maximally 25°C/77°F). At 
room temperature (maximally 25°C/77°F), a carton of 10 vials will take approximately 2 hours 
to thaw, and an individual via l will take approximately 1 hour to thaw. Do not refreeze once 
thawed.  
Product: BNT162b2  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 46 of 97 BNT162b2  is a preservative -free, sterile dispersion of RNA formulated in LNP in aqueous 
cryoprotectant buffer for IM administration. The RNA Drug Substance is the only  active 
ingredient in the drug product. The vaccine is supplied as a frozen [between -80°C to -60°C ( -
112°F to -76°F)] multi -dose vial. Alternatively, vials may be stored at -25°C to -15°C ( -13°F to 
5°F) for up to 2 weeks.  Thaw and then store undiluted via ls in the refrigerator [2ºC to 8ºC (35ºF 
to 46ºF)] for up to 1 month. The vaccine must be thawed (room temperature [up to 25ºC (77ºF)]  
for 30 minutes  or at 2ºC to 8ºC (35ºF to 46ºF) for up to 1 month. ) and diluted in its original vial 
with 1.8 mL of steril e 0.9% Sodium Chloride Injection, USP prior to administration  and within 2 
hours of thaw . Before dilution, the vaccine vials should be inverted gently 10 times but not 
shaken. Do not refre eze. After dilution, the vial contains up to 6 doses of 0.3 mL per dose. After 
dilution, the multiple -dose vials must be stored between 2°C to 25°C (35°F to 77°F) and used 
within 6 hours from the time of dilution.  During storage, minimize exposure to room light and 
avoid exposure to direct sunlight an d ultraviolet light.  Any vaccine remaining in vials must be 
discarded after 6 hours.  Note : Vial  labels and cartons may state that after dilution, a vial contains 5 
doses of 0.3 mL. The information in  the EUA  this Fact Sheet regarding the number of doses p er vial 
after dilution supersedes the number of doses stated on vial labels and cartons.  For the purposes of 
this study, no more than 5 doses per vial will be used.  
Product: NVX -CoV237 3 
Prototype SARS -CoV -2 rS with Matrix -M adjuvant should be stored at 2 C  to 8 C.  
DO NOT FREEZE.  
Once a product vial has been punctured, all preformulated vaccine with Matrix -M adjuvant from 
the punctured vial should be administered within 6 hours.  
Study Product Temperature Accountability  
The temperature of the storage unit must be manually recorded daily (excluding non -business 
days and holidays, as applicable) and continuously monitored and recorded during the course of 
this trial per site-specific SOPs , and documentation will be maintain ed. If the temperature 
fluctuates outside of the required range, the affected study product(s) must be quarantined at the 
correct storage temperature and labeled as ‘Do Not Use’ (until further notice). The participating  
site’s research pharmacist must aler t the participating site PI, study coordinator, and the DMID  
Product Support Team  if the temperature fluctuates outside of the required range. In the event the 
temperature fluctuates outside of the required range, including accidental deep -freezing or 
disruption of the cold chain, the affected study product(s) must not be administered. The 
participating  site PI or responsible person should immediately contact the DMID Product 
Support Team at DMIDProductSupportTeam@niaid.nih.gov for further instructions befo re any 
additional vaccinations are administered. Based on the information collected, DMID and/or the 
manufacturer will determine whether the affected study product(s) can be used. If it cannot be 
used, the participating site will receive specific instructi ons on how to return the affected study 
product(s) to the DMID CMS or destroy it on -site. Additional instructions for quarantine and 
DMID contact information are provided in the protocol -specific MOP.  
Study p roduct  must  be stored in a secure area with limi ted access (pharmacy staff only ) and  must 
be stored as above . The storage areas  should have an automated temperature recording and alert 
system. There must be an available back -up storage location . The storage areas  must be 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 47 of 97 connected to a back -up generator,  or alternate plan in the event of a power failure . The pharmacy 
must have in place a 24 -hour alert system that allows for rapid response in case of storage area  
malfunctioning. In addition, vaccine accountability study sta ff (e.g., pharmacy staff) are required 
to keep a temperature log to establish a record of compliance with these storage conditions. Only 
vaccine accountability study staff (e.g., pharmacy staff) should have access to the product used 
in this study. The participating site is responsible for reporting any study product  that was not 
temperature controlled during shipment or during storage to the pharmacy staff. Such product  
will be retained for inspection by the pharmacy staff  and disposed of according to appr oved 
methods.  
6.2.4 Preparation  
Refer to the  protocol -specific MOP for details about preparation . 
6.3 Measures to Minimize Bias: Randomization and Blinding  
6.3.1 Treatment Assignment Procedures  
Per International Council for Harmonisation  of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) guideline E6: GCP, screening records will be kept at the participating site to 
document the reason why an individual was screened, but failed trial entry criteria. The reasons 
why individua ls failed screening will be recorded in the electronic data capture (EDC) system 
that the IDCRC Statistical and Data Science Unit (SDSU) develops and manages through the 
Statistical Center for HIV/AIDS Research (SCHARP) at the Fred Hutchinson Cancer Resear ch 
Center.  
Once consented and upon entry of demographic data and confirmation of eligibility for this trial, 
the subjects will be enrolled.  
6.3.2 Randomization and Blinding  
Subjects in Cohort s 1 and 2 will not  be randomized to study intervention.  The study will  be open 
label and study sites will administer product to which they have been assigned.  
6.3.3 Blinding and Masking Procedures  
This study is unblinded.  
6.4 Study Intervention Compliance  
Each dose of study product will be administered by a member of the clinical rese arch team  that is 
qualified and licensed to administer the study product . Administration and date, time, and 
location of injection will be recorded on the appropriate DCF . 
6.5 Concomitant Therapy  
Concomitant medications include only prescription medications  through 28 days after each  study  
vaccination and COVID -19 vaccines received outside  of the study  at any time during study  
participa tion. At each study visit , if there are new SAEs , Protocol Specified AESIs, MAAE s, or 
NOCMC s, concomitant medicat ions should be recorded  on the appropriate DCF . 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 48 of 97 6.5.1 Rescue Medicine  
Not Applicable  
6.5.2 Non-Research Standard of Care  
Not Applicable   
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 49 of 97 7 STUDY INTERVENTION DISCONTINUATION AND 
SUBJECT  DISCONTINUATION/WITHDRAWAL  
7.1 Halting  Criteria and Discontinuation of Study Intervention  
7.1.1 Halting  Criteria  
The study will be halted  in a given group if any of the following events occur  following booster 
dose only: 
Any subject experiences a n SAE after administration of the vaccine  that is considered related to 
vaccine . 
Any subject experiences laryngospasm, bronchospasm or anaphylaxis within 24 hours after 
administration of vaccine that is considered related to vaccine.  
Any subject experiences ulceration, abscess or necrosis at the injection site that is considered 
related to vaccine  administration.  
Two (2) or more subjects experience an allergic reaction such as generalized urticaria (defined as 
occurring at  three or  more body parts) within 72 hours after administration of vaccine that is 
considered related to vaccine . 
Three (3) or m ore subjects experience a Grade 3 AE ( unsolicited ) related to vaccine 
administration , in the same Preferred Terms based on the Medical Dictionary for Regulatory 
Activities ( MedDRA ) coding . 
7.1.2 Criteria for Continuation of Dosing and Redosing  
In the event a halting rule is met:   
an unscheduled safety analysis by the SMC  will be required for approval of further enrollment   
further administration of any study vaccine  boost within the specific group , is suspended for 
ALL subjects within that group  until an assessment by the SMC  takes place.  
7.1.3 Discontinuation of Study Intervention  
For Cohort 2, prior  to receiving the second  and third  vaccination, subjects  will be reassessed. The 
following events constitute contraindications to any further administrati on of study vaccines. If 
any of these events occur during the study  prior to the second vaccination , the subject  must not 
receive the second vaccin ation  but will be encouraged to continue study participation for safety 
and immun ogenicity evaluation s through 12 months after their last vaccination.  For Cohort 2, if 
any of these events occur after the second vaccination  and before the third vaccination  the 
subject must not receive the third vaccination but will be encouraged to continue study 
participation for safety and immunogenicity evaluations through 12 months after their last study 
vaccination.  See Table 5 for a schedule of evaluations in the 12 months after the last study 
vaccination.  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 50 of 97 • Any clinically significant medical condition that, in the opinion of the participating site 
PI or appropriate sub -investigator , pose s an additional risk to the subject  if he/she 
continues to participate in the study . 
• Confirmed  SARS -CoV -2 infection  (prior to Dose 2) . 
• Receipt of SARS -CoV -2 vaccine outside of study  
• Anaphylaxis or unexpected systemic hypersensitivity reaction following the 
administration of a prior study vaccination . 
• Any SAE judged to be related to vaccine . 
• Pregnancy . 
• New information becomes available that makes further participation unsafe  or interferes 
with the evaluation of  responses . 
• Termination of this trial.  
7.1.3.1  Delay of Study Vaccination  
If any of these events occur at the time scheduled for vaccination, the subject  may be vaccinated 
at a later date . 
• Acute moderate or severe infection with or without fever at the time of vac cination . 
• Fever, defined as oral temperature ≥38.0°C (100.4°F) at the time of vaccination . 
Subjects  with a minor illness without fever, as assessed by the participating site PI or appropriate 
sub-investigator , can be administered vaccines. Subjects  with an  oral temperature of 38.0°C 
(100.4°F) or higher  will be re -contacted within the window specified in the SOA  and re -
evaluated for eligibility.  
It is preferred that the vaccination still occur within the window specified in the SOA if possible 
but delays outside the windows are permitted (would still be a protocol deviation).  
7.1.4 Follow -up for Subjects that Discontinued Study Intervention  
Discontinuation of study intervention  does not require discontinuation from the study, and the 
remaining study proce dures should be completed as indicated by the SOA . If a clinically 
significant finding is identified , including, but not limited to , changes from baseline , after 
enrollment, the participating site PI  or qualified designee will determine if any change in subject  
management is needed. Any new clinically relevant finding will be reported as an AE.  
7.2 Subject  Withdrawal from the Study  and Replacement  
Subjects  are free to withdraw from participation in the study at any time upon request, without 
any consequence.  
A study subject will be discontinued from participation in the study if any of the following 
reasons occur prior to initial dosing:  
• Request by the subject to terminate participation . 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 51 of 97 • Initial v accine is not administered . 
A subject may be removed from the study for the following reasons post initial dosing; however, 
whenever possible the subject should be followed for safety and immunogenicity evaluations per 
protocol:  
• Subject becomes pregnant before receiving the second or third dose of vaccine . 
• Study non -compliance to protocol requirements that in the opinion of the participating 
site PI or appropriate sub -investigator  poses an increased risk  or compromises the validit y 
of the data.  
• Lost to follow -up. 
• If the subject  met an exclusion criterion for participation in the study (either newly 
developed or not previously recognized) that precludes further study participation . 
• Request of primary care provider , the IRB, FDA, or NIAID . 
• Medical disease or condition, or new clinical finding(s) for which continued 
participation, in the opinion of the participating site PI or appropriate sub -investigator 
might compromise the safety of the subject, interfere s with the subject ’s success ful 
completion of this study, or interfere s with the evaluation of responses . 
• If any AE or situation occurs such that continued participation in the study would not be 
in the best interest of the subject . 
• Any SAE judged to be related to vaccine . 
If the sub ject agrees, every attempt will be made to follow all AEs through resolution  or 
stabilization . 
Subjects who withdraw, or are withdrawn from this study, or are lost to follow -up after signing 
the informed consent form (ICF) and administration of the study p roduct will not be replaced.  
Subjects who withdraw, or are withdrawn from this study, or are lost to follow -up after signing 
the ICF but before administration of the study product may be replaced.  
The reason for subject  discontinuation or withdrawal from the study will be recorded on the 
appropriate DCF . 
7.3 Lost to Follow -Up 
A subject  will be considered lost to follow -up if he or she fails to appear for a follow -up 
assessment . Extensive effort (i.e., generally three documen ted contact attempts via telephone 
calls, e -mail, etc., made on separate occasions) will be made to locate or recall the  subject , or at 
least to determine the  subject’s  health status. These efforts will be documented in the subject ’s 
study file . 
  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 52 of 97 8 STUDY AS SESSMENTS AND PROCEDURES  
8.1 Screening and  Immunogenicity Assessments  
8.1.1 Screening or Enrollment/ Baseline Procedures  
There is a small amount of risk to subjects who report that they are in good health but have an 
unknown health problem at the time of the enrollment/ baseline visit . Screening assessments can 
occur u p to 28 days before or at the subject’s first vaccination  visit (Day 1 ). At the screening 
(optional) or enrollment/baseline  visit, and prior to any other study -related activities, t he 
participatin g site PI or appropriate sub -investigator  will provide the subject with detailed study 
information and will obtain written informed consent.  
Some or all of the following assessments are performed during the screening (optional) or 
enrollment/baseline visit to determine eligibility requirements as specified in the inclusion and 
exclusion criteria:  
• Obtain medical history . 
• Review pre -study medications and therapies at screening and record on the appropriate 
DCF . Review of adult vaccinations , including any other SARS -CoV -2 or other 
experimental coronavirus vaccines . 
• Review any participation in investigational trials in the last 6 months.  
• Measure vital signs (HR, BP, and oral temperature ), and height and weight for 
determination of BMI.  
• Targeted physical examination based upon  symptoms elicited in the  medical history  
• Review of birth control history with female subjects  of childbearing potential . 
• Counsel subjects to use adequate birth control methods required during the trial to avoid 
pregnancy . 
• Urine  pregnancy test (in women of childbearing potential) . If urine pregnancy is done at 
separate screening visit, repeat urine pregnancy test will be done  within 24 hours of study 
vaccine administration.  
• Review inclusion and exclusion criteria . 
The screening process can be suspended prior to complete assessment at any time if exclusions 
are identified by the study team.  
Study subjects who qualify for inclus ion will be contacted and scheduled for enrollment and first 
vaccination within the window for enrollment  unless the screening and vaccination are scheduled 
on the same day . 
If a physiologic parameter, e.g., vital signs , is outside of the protocol -specified range, then the 
measurement may be repeated once if, in the judgment of the participating  site PI or appropriate 
sub-investigator , the abnormality is the result of an acute, short -term, rapidly reversible condition 
(e.g., stress, anxiety or “white coat syndrome”)  or other source of error . A physiologic parameter 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 53 of 97 may also be repeated if there is a technical problem with the measurement caused by 
malfunctioning, or an inappropriate measuring device (i.e., inappropriate -sized BP cuff).  
A subject may be re -screened if there is a transient disease status (e.g., subject complained of a 
“cold or fever” and met a temporary delaying enrollment criterion of acute illness or fever), or if 
a protocol eligibility criterion that is not  met at the initial time of screening, will be met by 
rescreening at a later date (e.g., a medication taken within exclusionary window at the time of 
first screening that would not be within exclusionary window at a later rescreen).  
No subject s may be scre ened more than twice due to a screening failure result as defined above.  
Subjects  will be provided the results of abnormal clinical findings necessitating follow -up at the 
discretion of the participating  site PI or appropriate sub -investigator . Research la boratory results 
will not be provided to the subject . 
The screening and first vaccination procedures both can be conducted at the enrollment/ baseline 
visit.  
8.1.2 Immunogenicity Evaluations  
Serological Immunogenicity Assays : 
The following serological immunogenic ity assays may be performed:  
• IgG ELISA to SARS -CoV -2 protein s. 
• Neutralization assay s using different  strains of SARS -CoV -2 pseudovirus.  
• Neutralization assay using  different strains of  live SARS -CoV -2. 
• Quadriplex MSD assay ( Nucleo capsid protein , Receptor binding domain, spike protein 
and variant spike protein)  
Preparation of blood samples and shipping instructions for serological immunogenicity assays 
are outlined in the protocol -specific MOP. Inability (e.g., failure of venipuncture ) to collect a ll 
baseline samples on Day 1 will not exclude the subject from further participation in this study as 
long as a minimum of baseline serum for serological immunogenicity assays is collected.  
Cellular Immunology Assays : 
This trial may also investigate B and T cell immune responses using multiparametric flow 
cytometry.  
Refer to the protocol -specific  immune monitoring plan  for details . 
Preparation of blood samples and shipping instructions for cellular immunology assays are 
outlined in the  protocol -specific MOP . 
The volume of venous blood to be collected for immunogenicity evaluations is presented in  
Table 10, Table 11, and Table 12. 
Mucosal A ntibody Assays : 
Salivary and nasal mucosal samples collected from cohort 2 study participants will be evaluated  
for total and virus -specific  IgG and IgA immune responses using MSD assay.  Mucosal antibody 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 54 of 97 presence and magnitude will be correlated with serologic results. Preparation of the salivary and 
nasal samples and shipping instructions for immunogenicity assays are outlined in the protocol -
specific MOP.  
 
8.1.3 Samples for Illness Visit  
In the event that a subject develops symptoms compatible with COVID -19, the site will foll ow 
with an unscheduled Illness Visit. If a volunteer is asymptomatic but tests positive for COVID -
19, the site may follow -up with a study visit on an optional basis, as staff availability and 
resources allow. Wide discretion is given to sites for the asses sment of COVID -19 illness. 
Guidance can be found at the CDC website (2020 Interim Case Definition):  
https://wwwn.cdc.gov/nndss/conditions/coronavirus -disease -2019 -covid -19/case -
definition/2020/#:~:text=Clinical%20Criteria,of%20breath%2C%20or%20difficulty% 20breathin
g 
The following intervention will be performed in the event of an illness visit:  
Nasal or nasopharyngeal  (NP) swabs for PCR and sequencing  
Two nasal or NP swabs will be obtained for the purposes of 1) conducting qualitative analysis to 
assess for  the presence of SARS -CoV -2 virus, and 2) conducting PCR quantitation/sequencing in 
the event that nasal or NP swab #1 is positive for SARS -CoV -2.  
The first nasal or NP swab will be processed at the local level with results informing the 
disposition of th e second nasal  or NP  swab. The sites will freeze and store the second swab (refer 
to MOP for labeling, storage, and shipping instructions) for potential shipment to the central 
repository for processing.  
8.1.4 Samples for Genetic/Genomic Analysis  
8.1.4.1  Genetic/ Genomic Analysis  
DNA obtained from B -cells may be sequenced to identify B cell receptors and monoclonal 
antibodies.  The DNA data may be used to synthesize antigen -specific antibodies to characterize 
antibody binding. Secondary research samples may also be used for other genomic analysis , 
including, but not limited to,  single nucleotide polymorphisms (SNP) arrays , human leukocyte 
antigen ( HLA ) typing,  transcriptomic analysis, evaluat ion of  the immune response to the 
vaccine , and/or evaluation of any AE from the vaccine.  
8.1.4.2  Genetic Privacy and Confidentiality  
Any genetic data generated will be kept private . Informed consent permitting data sharing will be 
part of the consent process. Subjects will be informed that the evolution of genomic technology 
and analytical methods raises the risk of re -identification, even when specimens are de -
identified.  No data that may identify specific subjects will be kept with the genetic data.  
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 55 of 97 8.1.4.3  Management of Results  
All genetic testing in this protocol will b e performed for research purposes only and  is not 
performed in a Clinical Laboratory Improvement Amendments ( CLIA ) certified laboratory. 
Therefore, results will not be shared with the subjects.  
8.2 Safety and Other Assessments  
Study procedures are specified in the SOA . A study clinician , licensed to make medical 
diagnoses and listed on the Form FDA 1572 as the participati ng site PI or appropriate sub-
investigator, will be responsible for all study -related medical decisions.  
Medical history : 
A complete medical history will be obtained by interview of subjects at the screening 
(optional) or enrollment/ baseline visit. Subject s will be queried regarding a history of 
significant medical disorders.  
At all subsequent visits an interim medical history will be obtained by interview of 
subjects and any changes since the previous clinic visit or telephone call will be noted. 
The inter im medical history should include an assessment to identify intercurrent 
Protocol Specified AESIs, MAAEs , and NOCMCs.  
Physical examination : 
A symptom -directed (targeted) physical examination will be performed if indicated at 
any timepoint  at the discretion of the participating  site PI or appropriate sub -investigator , 
if necessary, to evaluate AEs. 
Reactogenicity assessments of solicited AEs, occurring from the time of  each vaccination 
through 7 days post  vaccination , will include an assessment of injection site reactions –
erythema, edema/ induration  and pain, as well as systemic reactions –fever, fatigue, chills, 
myalgia (exclusive of the injectio n site), arthralgia, headache, and nausea. Pre -
administration reactogenicity assessments will be performed immediately prior to each 
vaccination to establish baseline, then the vaccination will be given.  
Subjects will be observed in the clinic for at least  30 minutes post each vaccination. The 
vaccination site will be examined, post -administration reactogenicity assessments will be 
performed, and any AEs/SAEs will be recorded on the appropriate DCF  prior to 
discharge from the clinic. The vaccination site wi ll also be examine d 7 days after 
vaccination . 
Vital signs : Vital sign measurements will include systolic and diastolic BP, HR, and oral 
temperature. Vital signs will be measured at timepoints specified  in the SOA . On 
vaccination days, vital sign measurements will be collected prior to  vaccine 
administration. Vital signs assessed on Day 1 prior to the first vaccination will be 
considered as baseline. Subjects must not eat or drink anything hot or cold within 10 
minutes prior to taking oral temperature.  
Urine pregnancy test : Urine pregnancy test will be performed locally by the site 
laboratory  within 24 hours prior to  each vaccinat ion, and as needed at interim or 
DMID Protocol 21 -0012 Version  10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 56 of 97 unscheduled visits for all women of childbearing potential. Results must be confirmed as 
negative prior to enrollment  on Day 1 and administration of each vaccination  as 
applicable . 
Memory aid: 
All subjects will complete a Memory Aid from the time of each vaccination through 7 
days post each vaccination . Memory Aids will be reviewed with the subjects for any AEs 
(solicited injection site and systemic reactions , as well as unsolicited AEs), SAEs a nd 
concomitant medications  during telephone calls  7 days after each vaccination . Based on 
the information collected, subjects may be asked to return to the clinic for evaluation. 
Memory Aids will be review ed again , and subjects will be assessed for delayed  onset 
local reactions 14 days after booster vaccination  (initial vaccination in Cohort 1, delayed 
vaccination in Cohort 2) .  Memory aids will be review ed 7 days after each vaccination in 
Cohort 2.  
 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 57 of 97 Table 10: Venipu ncture Volumes for Cohort 1  (One Vaccination – EUA Dosed Cohort)  
Study Day  -28 to -1 1 8 15 29 91 181  
273 366 Early 
Termination 
Visit Total 
Volume of 
Blood 
Drawn (mL)  
Visit Window (±number of days)   0 1 2 2 7 14 28 28   
Study Visit  Screening 
(optional)  
00 01 02 03 04 05 06  
07 08   
Vaccination    X          
Serum for Serological Immunogenicity Assays1  16  16 16 16 16 16 16 162 96 
PBMCs (and Plasma)  for Cellular Immunology 
Assays   64  64   64  64 642 256 
Serum for Secondary Research   16  16 16 16 16 16 16 162 96 
Per Visit Blood Volume Total (mL)    96  96 32 32 96 32 96 962 448 
 
Cumulative Blood Volume (mL) (prior 56 
days)    96 96 192 224 32 96 32 96   
Running Blood Volume Total (mL)    96 96 192 224 256 352 384 480   
1 Inability (e.g., failure of venipuncture) to collect all baseline samples on Day 1 will not exclude the subject from further participation in this study as long as a 
minimum of baseline blood volume is collected.  Refer to the Blood Collection Summary Table in the MOP for the minimum number of expected aliquots for this blood 
draw volume and minimum aliquots required to completed  testing under the protocol  
2 These blood volumes are not included in the blood volume totals.  
  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 58 of 97 Table 11: Venipuncture Volumes for Cohort 2: (Up to Three Vaccinations)  
Study Day  -28 to -1 1 8 29 36 43 
Delayed Boost to occur > Day 181 (window +/- 30  days) from  Dose 
2 1B 8B 15B 29B 91B 181B 366B  Early Term -
ination Visit  Total 
Volume of 
Blood Drawn 
(mL)  
Visit Window (±number of days)   0 1 2 3 3 0 1 2 2 7 14 28   
Study Visit  Screening 
(optional)  
00 01 02 3 043 053 063  
073 084 094 104 114 124   
Vaccination     X    X      X         
Serum for Serological 
Immunogenicity Assays1   16   16   16 16  16 16 16 16 16 162 144 
PBMCs (and Plasma) for Cellular 
Immunology Assays     64   64  64  64  64 
  64 64 64  642 512 
Serum for Secondary Research   16  16  16 16  16 16 16 16 16 162 144 
Per Visit Blood Volume Total 
(mL)     96   96   96 96  96 32 96 96 96 962 800 
Cumulative Blood Volume (mL) 
(prior 56 days)     96 96 192 192 288 96  
96 192 224 96 96 96     
Running Blood Volume Total 
(mL)     96 96 192 192 288 384 384 480 512 608 704 800   
1 Inability (e.g., failure of venipuncture) to collect all baseline samples on Day 1 will not exclude the subject from further participation in this study as long as a 
minimum of baseline blood volume is collected.  Refer to the Blood Collection Summary Table in the MOP for the minimum number of expected aliquots for this blood 
draw volume and minimum aliquots required to completed testing under the protocol  
2 These blood volumes are not included in the blood volume totals.  
3 Visits 05 -07 windows should be based off the actual Visit 03 date.  
4 Visits 08 -12 windows should be based off the actual Visit 06 date. 
  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 59 of 97 Table 12: Venipuncture Volumes for Cohort 2: (Fourth Vaccination)  
 
Study Day  
Boost 
to 
occur ≥ 
120 
days ≤ 
366 
days 
from 
Dose 3  
 1C 8C 15C 29C 91C 181C  Illness/ 
Unscheduled Visit  Early Termination 
Visit  
Visit Number  13 14 15 16 17 18     
Window (+/ -) 01 12 22 22 72 142     
Immunoassays                  
Serum - Humoral Assays  32   32 32 32 32  323 
PBMC Cellular Assays & plasma  64   64     64  643 
Daily Volume (mL)  96   96 32 32 96  963 
Cumulative Volume (mL)  96   192 224 256 352    
Running Blood Volume Total 
(mL) 4  800  896 928 960 1056    
1 Visits 13 windows should be based off the actual Visit 06 date.  
2 Visits 14 -18 windows should be based off the actual Visit 13 date .  
3These blood volumes are not included in the blood volume totals.  
4Running blood volume continues after visit  11 for those receiving a 2nd booster in cohort 2 (will occur prior to originally planned visit 12).  For subjects who are boosted after visit 
10, the running blood volume will be 96 mL less.  
 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 60 of 97 8.2.1 Procedures to be Followed in the Event  of Abnormal Clinical Findings  
If a physiologic parameter, e.g., vital signs , is outside of the protocol -specified range, then the 
measurement may be repeated once if, in the judgment of the participating site PI or appropriate 
sub-investigator , the abnormality is the result of an acute, short -term, rapidly reversible condition 
(e.g., stress, anxiety or “white coat syndrome”) or other source of error. A physiologic parameter 
may also be repeated if there is a technical problem with the measurement caused by 
malfunctioni ng, or an inappropriate measuring device (i.e., inappropriate -sized BP cuff).  
All abnormal clinical findings that occur post vaccination will be considered  AEs. 
8.3 Adverse Events and Serious Adverse Events  
8.3.1 Definition of Adverse Event (AE)  
AE means any untoward medical occurrence associated with the use of an intervention in 
humans, whether or not considered intervention -related [21 CFR 312.32 (a) ]. An AE can 
therefore be any unfavorable and unintended sign, symptom or disease temporally assoc iated 
with the use of medicinal (investigational) product.  
Any medical condition that is present at the time that the subject is screened will be considered 
as baseline and not reported as an AE. However, if the severity of any pre -existing medical 
conditi on increases, it should be recorded as an AE.  
AEs can be further divided into solicited AEs and unsolicited AEs. Solicited AEs are those for 
which the study team will specifically query the subject  whether they occurred. Unsolicited AEs 
are those events th at the subject report occurring without being queried about the specific event.  
All AEs will be assessed for severity and relationship to study intervention ( Section 8.3.4 ). 
Reporting of all AEs, solicited and unsolicited, will occur during the period from study product 
administration on Day 1 through 28 days after each vaccin ation . After  28 days post last 
vaccination  through the end of planned study participation , only SAEs , Protocol Specified 
AESIs, MAAEs , and NOCMCs  will be reported  as AEs. 
All AEs, solicited and unsolicited, will be captured on the appropriate DCF . Solicited AEs will 
be regarded as related to the study product  and will not require separate entry into the AE log . 
Information to be collected for unsolicited AEs includes event description, date of onset, 
assessment of severity, relationship to study product and alternate etiology (assessed only by 
those with the training and authority to make a diagnosis and listed on the Form FDA 1572 as the 
participating site P I or appropriate sub -investigator ), date of resolution, seriousness , and 
outcome. AEs occurring during the study -collection and reporting period will be documented 
appropriately regardless of relationship.  
AEs will be followed t o resolution  or stabilizatio n. 
8.3.1.1  Solicited Adverse Events  
Solicited AEs are anticipated local and systemic AEs for which consistent collection of 
information is desired. Study c linicians will follow and collect resolution information for any 
reactogenicity symptoms that are not resolve d within 7 days.  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 61 of 97 Solicited AEs (i.e., reactogenicity) will be collected using a memory aid  and recorded on the 
appropriate DCF  from the time of each vaccination through  7 days post each vaccination . 
For this study, solicited AEs will be:  
• Injection site Pain 
• Injection site Erythema  
• Injection site Edema /Induration  
• Headache  
• Fatigue  
• Myalgia  
• Arthralgia  
• Nausea  
• Fever  
• Chills  
Subjects will also be assessed for delayed onset local reactions through 14 days post each 
vaccination.  
8.3.1.2  Unsolicited Adverse Events  
All AEs spontaneously reported by the subject and/or in response to an open question from study 
staff or revealed by observation, physical examination or other diagnostic procedures must be 
recorded on the appropriate DCF . 
Unsolicited AEs of all severities will be reported from the time of study product administration 
through 28 days post each vaccination . 
After 28 days post last vaccination  through the end of planned study participation , only  SAEs, 
AESIs, MAAEs, and NOCMCs (as detailed in  Section 8.3.9 ) will be reported  as AEs . 
8.3.1.3  Special Reporting of Adverse Events  
Not Applicable  
8.3.2 Definition of Serious Adverse Event (SAE)  
An SAE is defined in 21 CFR 312.32 as follows: “An AE or suspected adverse reaction is 
considered serious if, in the view of either the participating site PI or appropriate sub -investigator  
or the sponsor, it results in any of the following outcomes:  
• Death , 
• a life -threatening AE, 
• inpatient hospitalization or prolongation of existing hospitalization,  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 62 of 97 • a persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions,  
• or a congenital anomaly/birth defect.  
Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they 
may jeopardize the patient or subject and may require medical or surgical i ntervention to prevent 
one of the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatie nt hospitalization, or the development of drug 
dependency or drug abuse.”  
“Life -threatening” refers to an AE that at occurrence represents an immediate risk of death to a 
subject. An event that may cause death if it occurs in a more severe form is not cons idered life -
threatening. Similarly, a hospital admission for an elective procedure is not considered a n SAE.  
All SAEs, as with any AE, will be assessed for severity and relationship to study intervention . 
All SAEs will be recorded on the appropriate SAE DCF. 
All SAEs will be followed through resolution or stabilization by a study clinician,  licensed to 
make medical diagnoses and  listed on the Form FDA 1572 as the participating  site PI or 
appropriate s ub-investigator.  
All SAEs will be reviewed and evaluated by DMID and will be sent to the SMC ( for periodic 
review unless related) and IRB/IEC.  
8.3.3 Suspected Unexpected Serious Adverse Reactions (SUSAR)  
A SUSAR is any SAE where a causal relationship with the study product is at least reasonably 
possible but is not li sted in the Investigator ’s Brochure  (IB), Package Insert, and/or Summary of 
Product Characteristics.  
8.3.4 Classification of an Adverse Event  
The determination of seriousness, severity and causality will be made by an on -site investigator 
who is qualified (licen sed) to diagnose AE information, provide a medical evaluation of AEs and 
classify AEs based upon medical judgment. This includes , but is not limited to , physicians, 
physician assistants and nurse practitioners.  
8.3.4.1  Severity of Adverse Event s 
All AEs and SAEs will be assessed for severity, according to the toxicity grading scales in the 
FDA “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers En rolled in 
Preventive Vaccine Clinical Trials” . 
For AEs not included in the protocol -defined grading system, the following guidelines will be 
used to describe severity.  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 63 of 97 Mild (Grade 1) : Events that are usually transient and may require only minimal or no 
treatment or therapeutic intervention and generally do not interfere with the subject’s 
usual activities of daily living.  
Moderate (Grade 2) : Events that are usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual  activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research subject . 
Severe (Grade 3) : Events interrupt usual activities of daily living, or significantly affects 
clinical status, or may require intens ive therapeutic intervention. Severe events are 
usually incapacitating.  
Potentially Life Threatening (Grade 4) :  Events that lead to an ER visit or hospitalization. 
(recorded on Adverse Event log as a Serious Adverse Event (SAE) and to be reviewed by 
Medic al Monitor) . Death (Grade 5) :  Events that lead to death (recorded on Adverse Event log as 
a Serious Adverse Event (SAE) and to be reviewed by Medical Monitor). AEs characterized as 
intermittent require documentation of onset and duration of each episode. The start and stop date 
of each reported AE will be recorded on the appropriate DCF . Changes in the severity of an AE 
will be documented to allow an assessment of the duration of the event at each level of intensity.  
8.3.4.2  Relationship to Study Intervention  
For each reported adverse reaction, the participating site PI or qualified designee must assess the 
relationship of the event to the study product using the following guideline s: 
Related  – The AE is known to occur with the study intervention, there is a reasonable 
possibility that the study intervention caused the AE, or there is a temporal relationship 
between the study intervention and event. Reasonable possibility means that there is 
evidence to suggest a causal relationship between the stud y intervention and the AE.  
Not Related  – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study 
intervention and event onset, or an alternate etiology ha s been established.  
Solicited adverse events reported in the 7 days after each vaccination are considered related to 
study product unless they are also recorded as an unsolicited event, in which case the relationship 
to study product will be determined by the PI or qualified designee.  
8.3.5 Time Period and Frequency for Event Assessment and Follow -Up 
For this study:  
• solicited AEs will be collected for 7 days post each vaccination .  
• unsolicited AEs will be collected until 28 days after each  vaccination.  
• SAEs, AESIs, MAAEs , and NOCMCs will be collected from D ose 1  to end of planned 
study participation . 
8.3.6 Adverse Event Reporting  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 64 of 97 8.3.6.1  Investigators Reporting of AEs 
Information on all AEs should be recorded on the appropriate DCF . All clearly related s igns, 
symptoms and results of diagnostic procedures performed because of an AE should be grouped 
together and recorded as a single diagnosis. If the AE is a clinical laboratory abnormality that is 
part of a clinical condition or syndrome, it should be reco rded as the syndrome or diagnosis 
rather than the individual clinical laboratory abnormality. Each AE will also be described in 
terms of duration (start and stop date), severity, association with the study product, action(s) 
taken, and outcome.  
8.3.7 Serious Adv erse Event Reporting  
8.3.7.1  Investigators Reporting of SAEs  
Any AE that meets a protocol -defined criterion as an SAE must be submitted immediately 
(within 24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group, at 
the following address:  
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
6500 Rock Spring Dr. Suite 650  
Bethesda, MD 20817, USA  
SAE Hot Line: 1 -800-537-9979 (US) or 1 -301-897-1709 (outside US)  
SAE FAX Number: 1 -800-275-7619 (US) or 1 -301-897-1710 (outside US)  
SAE Email Address: PVG@dmidcroms.com  
In addition to the SAE form, select SAE data fields must also be entered into the SCHARP’s 
EDC system. Refer to  the protocol -specific MOP for details regarding this procedure.  
Other supporting documentation of the event may be requested by the DMID Pharmacovigilance 
Group and should be provided as soon as possible. The DMID Medical Monitor will review and 
assess th e SAE for regulatory reporting and potential impact on study subject safety and protocol 
conduct.  
At any time after completion of the study, if the participating site PI or appropriate sub -
investigator becomes aware of an SAE that is suspected to be relate d to study product, the 
participating site PI or appropriate sub -investigator will report the event to the DMID 
Pharmacovigilance Group.  
8.3.7.2  Regulatory Reporting of SAEs  
Following notification from the participating site PI or appropriate sub -investigator, DMI D, as 
the IND sponsor, will report any SUSAR in an IND safety report to the FDA and will notify all 
participating site PIs (i.e., all PIs to whom the sponsor is providing drug under its IND(s) or 
under any PI’s IND(s) ) of potential serious risks from clini cal studies or any other source, as 
soon as possible. DMID will report to the FDA any unexpected fatal or life -threatening 
suspected adverse reaction as soon as possible, but in no case later than 7 calendar days after the 
sponsor’s initial receipt of the information. If the event is not fatal or life -threatening , the IND 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 65 of 97 safety report will be submitted within 15 calendar days after the sponsor determines that the 
information qualifies for reporting as specified in 21 CFR Part 312.32. Relevant follow -up 
information to an IND safety report will be submitted as soon as the information is available. 
Upon request from FDA, DMID will submit to the FDA any additional data or information that 
the agency deems necessary, as soon as possible, but in no case later tha n 15 calendar days after 
receiving the request.  
SAEs that are not SUSARs will be reported to the FDA at least annually in a summary format 
which includes all SAEs . 
8.3.8 Reporting Events to Subjects  
Subjects  will be informed of any AEs or SAEs that occur as part of their participation in this 
trial. 
8.3.9 Adverse Events of Special Interest  (AESIs)  
Adverse Events of Special Interest (AESI s) represent any events for which additional data 
(besides the standard AE data) are  desired. An adverse event of special interest  (serious or 
nonserious) is one of scientific and medical concern specific to the sponsor’s product or 
program, for which ongoing monitoring and rapid communication by the investigator to the 
sponsor is required . Such an event may require  further investiga tion in order to characterize and 
understand it. Depending on the nature of the event, rapid communication by the trial sponsor to 
other parties (e.g., regulators) may also be required . These may be at the request of the regulatory 
agency, industry partner  or DMID, and driven by a regulatory requirement, or known or potential 
risk from the product or class. Non -structured data similar to SAEs will be collected for AESI s. 
AESI s encompass the following terms:  
Protocol Specified AESIs:  See Section 12. 
All suspected cases of anaphylaxis should be recorded . For reporting purposes, a 
participant who displays signs/symptoms consistent with anaphylaxis should be reported 
as a potential case of anaphylaxis.   
Thrombosis with Thrombocytopenia Syndrome (TTS) has been observed very rarely 
following vaccination with Ad26.COV2.S and is considered an AESI in this study. TTS 
is a syndrome characterized by a combination of both a thrombotic event and 
thrombocytopenia. Because this syndrome is rare and not completely understood, all 
cases of thrombosis and/or thrombocytope nia will be considered a suspected case of TTS 
until further adjudication can be performed. The investigator shall be responsible for 
reporting any suspected AESI of TTS using the SAE form. A suspected TTS case is 
defined as:  
•   Thrombotic events: suspect ed deep vessel venous or arterial thrombotic 
events as detailed in Section 12 
•   Thrombocytopenia, defined as platelet count below 150,000/µL  
Symp toms, signs, or conditions suggestive of a thrombotic event should be 
recorded and reported as a suspected AESI even if the final or definitive diagnosis 
has not yet been determined, and alternative diagnoses have not yet been eliminated 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 66 of 97 or shown to be les s likely. Follow -up information and final diagnoses, if applicable, 
should be submitted to the sponsor as soon as they become available.  
In the event of thrombocytopenia, study site personnel should report the absolute 
value for the platelet count and the reference range for the laboratory test used.  
For either a thrombotic event or thrombocytopenia, testing for anti -PF4 should be 
performed at the local laboratory or substitute local laboratory; repeat testing may 
be requested for confirmation upon sponsor  discretion.  
o All suspected cases of myocarditis and pericarditis must be  reported  as AESI.  
Symptoms of chest pain, shortness of breath or palpitations  may represent 
myocarditis or pericarditis . Typically, onset of symptoms has been within a few 
days follo wing receipt of the mRNA COVID -19 vaccines.  
  
o Guillain Barré Syndrome  has occurred in some people who have received the 
Jansse n COVID -19 Vaccine  and will be recorded as an AESI in this study .  In 
most circumstances, symptoms began within 42 days following receipt of dosing.  
 
NOCMCs  – defined as any new ICD diagnosis (per current International Statistical 
Classification of Diseases and Related Health Problems) that is applied to the subject 
during the course of the study, after receipt of the study agent, that is expected to 
continue f or at least 3 months and requires continued health care intervention.  
MAAEs  – defined as a hospitalization, emergency room visit or an otherwise 
unscheduled visit to or from medical personnel for any reason ; and considered related to 
study product . 
All AES Is are assessed, recorded, and followed as described above under AEs. AESI s that meet 
SAE criteria will be reported on an SAE form within 24 hours to the DMID Pharmacovigilance 
Group, at the following address:  
DMID Pharmacovigilance Group  
Clinical Research  Operations and Management Support (CROMS)  
6500 Rock Spring Dr. Suite 650  
Bethesda, MD 20817, USA  
SAE Hot Line: 1 -800-537-9979 (US) or 1 -301-897-1709 (outside US)  
SAE FAX Number: 1 -800-275-7619 (US) or 1 -301-897-1710 (outside US)  
SAE Email Address: PVG@dmi dcroms.com  
In addition,  for documentation and medical assessment purposes AESIs that do not meet SAE 
criteria will also be reported on an SAE form  and must be submitted immediately (within 24 
hours of site awareness)  to the DMID Pharmacovigilance Group ; however, the narrative will 
indicate that the AESI did not meet SAE criteria.  
8.3.10  Reporting of Pregnancy  
Pregnancy is not an AE. However, any pregnancy that occurs following the booster dose  
(through three months after boost er dose or through 12 months after the mRNA -1272 .211 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 67 of 97 booster dose ) should be reported to the sponsor on the appropriate DCF  Pregnancy form a nd 
pregnancy should be followed to outcome.  
8.4 Unanticipated Problems  
8.4.1 Definition of Unanticipated Problems (U Ps) 
The Department  of Health and Human Services (DHHS)  OHRP considers unanticipated 
problems involving risks to subjects  or others to include, in general, any incident, experience, or 
outcome that meets all of the following criteria:  
▪ Unexpected in terms of nature, severity,  or frequency given (a) the research procedures 
that are described in the protocol -related documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the subject  
population being studied;  
▪ Related or possibly related to participation in the research (“possibly related” means there 
is a reasonable possibility that the incident, experience, or outcome may have been 
caused by the procedures involved in the research); and  
▪ Suggests that the research places subjects  or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized.  
8.4.2 Unanticipated Problem Reporting  
To satisfy the requirement for prompt reporting, UPs will be reported using the following 
timeline:  
▪ UPs that are SAEs will be reported to the IRB and to the SDSU /study sponsor within 24 
hours of the participating site PI  or appropriate sub -investigator  becoming aware of the 
event  per the above -described  SAE reporting process . 
▪ UPs that are SAEs will be collected from Day 1 through the end of planned study 
participation . 
 
▪ Any other UP will be reported to the IRB and to the SDSU /study sponsor within 3 days  
of the participating site PI  or appropriate sub -investigator  becoming aware of the 
problem.  
▪ UPs that are not SAE s will be collected from Day 1  through  28 days after last 
vaccination . 
8.4.3 Reporting Unanticipated Problems to Subj ects 
Subjects will be informed of any UPs that occur as part of their participation in this trial.
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 68 of 97 9 STATISTICAL CONSIDERATIONS  
9.1 Statistical Hypotheses  
This is a phase 1/2, open -label,  multi -site clinical trial that is not designed to test a specific 
hypothesis. Rather, it is intended to obtain preliminary estimates in healthy adults of the safety, 
reactogenicity, and immunogenicity of  delayed heterologous  SARS -CoV -2 vaccine dosing 
(boost ) after receipt of EUA vaccines .  
9.2 Sample Size Determination  
9.2.1 Sample Size Calculation for the Safety Endpoint  
Rare AEs are not demonstrable in a clinical study of this size; however, the probabilities of 
observing one or more AEs given various true event rates are presented in Table 13. With the 
assumption that all enrolled subjects will likely complete immunizations and safety visits in this 
relatively short duration study, the following statistical considerations apply. With approximately 
50 subjects in each group  there is a 99.5%  chance of observing at least one AE of probability 
10%.  Similarly, with approximately 25 subjects in each of  the age subgroups, there is a 92.8% 
chance  of obser ving at least one AE of probability 10%.  Therefore, if no AEs of a given type 
occur in a Cohort 1 group , we can be relatively confident that they will occur in fewer than 10% 
of people once the vaccine is implemented .  
Probabilities of observing one or more  AEs, assuming an attrition rate of  approximately  10% (N 
= 45, N = 22), are also show n in Table 13. 
Due to the  surge in Omicron variant cases  at the  time of the writing of Version 6.0, it is 
anticipated that  a non -negligible proportion of vaccinated indiv iduals may be prone to 
asymptomatic breakthrough infections.  To allow for potential larger numbers of  participants 
enrolled in Stage 6 (Groups 15E -17E) that would subsequently be found to have serological  
evidence of prior infection , the sample size will b e expanded to N = 60/group (approximately 1:1 
age strata) for these groups.   
9.2.2 Sample Size Calculation for the Immunogenicity Endpoints  
A co -primary objective of this study is to evaluate the magnitude of SARS -CoV -2 specific 
antibody titers in serum samples . This objective is descriptive in nature and will be accomplished 
by estimating 95% confidence intervals (CI) for the geometric mean titer (GMT) at each 
timepoint when samples are collected.  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 69 of 97 Table 13: Probability of Observing an Adverse Event for Various Event Rates  in one 
vaccine  schedule group (or age subgroup), assuming no attrition (N = 50 or N = 25) or 
approximately 10% attrition (N = 45 or N = 22).  
N “True” Event 
Rate  Probability of Observing ≥ 
1 events (%)  N “True” Event 
Rate  Probability of Observing ≥ 
1 events (%)  
50 0.1%  4.9 
45 0.1%  4.4 
0.5%  22.2 0.5%  20.2 
1.0%  39.5 1.0%  36.4 
2.0%  63.6 2.0%  59.7 
3.0%  78.2 3.0%  74.6 
4.0%  87.0 4.0%  84.1 
5.0%  92.3 5.0%  90.1 
10.0%  99.5 10.0%  99.1 
15.0%  >99.9  15.0%  99.9 
20.0%  >99.9  20.0%  >99.9  
30.0%  >99.9  30.0%  >99.9  
N “True” Event 
Rate  Probability of Observing ≥ 
1 events (%)  N “True” Event 
Rate  Probability of Observing ≥ 
1 events  (%) 
25 0.1%  2.5 
22 0.1%  2.2 
0.5%  11.8 0.5%  10.4 
1.0%  22.2 1.0%  19.8 
2.0%  39.7 2.0%  35.9 
3.0%  53.3 3.0%  48.8 
4.0%  64.0 4.0%  59.3 
5.0%  72.3 5.0%  67.6 
10.0%  92.8 10.0%  90.2 
15.0%  98.3 15.0%  97.2 
20.0%  99.6 20.0%  99.3 
30.0%  >99.9  30.0%  >99.9  
 
The precision with which the GMT can be estimated from observed data depends on the standard 
deviation (SD) of the measurements, on the logarithmic scale, and the sample size. Table 14 
displays two -sided 95% confidence intervals for the GMT for several values of the observed 
antibody titer. Table 14 also shows results  assuming up to 10% attrition.  
 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 70 of 97 Table 14: Two -sided 95% confidence intervals based on observing a particular average 
loge-antibody titer in subjects’ vaccin e groups and age subgroups.  
Observed 
average log e 
antibody titer  SD of log e 
antibody 
titer 95% confidence interval of  
GMT in vaccine group  95% confidence interval of  
GMT in age subgroup  
N = 50  N = 45*  N = 25  N = 22*  
log e (5) 
0.5 (4.3, 5.8)  (4.3, 5.8) (4.1, 6.1)  (4, 6.2)  
log e (20) (17.4, 23.1)  (17.2, 23.2)  (16.3, 24.6)  (16, 25)  
log e (50) (43.4, 57.6)  (43, 58.1)  (40.7, 61.5)  (40.1, 62.4)  
log e (100)  (86.8, 115.3)  (86.1, 116.2)  (81.4, 122.9)  (80.1, 124.8)  
log e (250)  (216.9, 288.2)  (215.1, 290.5)  (203.4, 307.3)  (200.3, 312)  
log e (500)  (433.8, 576.3)  (430.3, 581)  (406.8, 614.6)  (400.6, 624.1)  
log e (1000)  (867.5, 1152.7)  (860.5, 1162.1)  (813.5, 1229.2)  (801.2, 1248.2)  
log e (5) 
1.0 (3.8, 6.6)  (3.7, 6.8)  (3.3, 7.6)  (3.2, 7.8)  
log e (20) (15.1, 26.6)  (14.8, 27)  (13.2, 30.2)  (12.8, 31.2)  
log e (50) (37.6, 66.4)  (37, 67.5)  (33.1, 75.6)  (32.1, 77.9)  
log e (100)  (75.3, 132.9)  (74, 135)  (66.2, 151.1)  (64.2, 155.8)  
log e (250)  (188.2, 332.2)  (185.1, 337.6)  (165.5, 377.8)  (160.5, 389.5)  
log e (500)  (376.3, 664.3)  (370.2, 675.2)  (330.9, 755.5)  (320.9, 779)  
log e (1000)  (752.6, 1328.7)  (740.5, 1350.4)  (661.8, 1511)  (641.9, 1558)  
*  Assumes approximately 10% attrition.
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 71 of 97 9.3 Populations for Analyses  
The safety analysis population includes all enrolled subjects who received at least one dose of  
study  vaccine. Analyses for the safety population will include safety reported through the end of 
the study . The modified intent -to-treat ( mITT) population includes all subjects who received at 
least one dose of vaccine and contributed both pre - and at least on e post -vaccination venous 
blood sample for immunogenicity testing for which valid results were reported.  
In the final analysis, protocol deviations  will be reviewed to determine which protocol deviations 
may affect the analysis. The per protocol (PP) popul ation will then be defined – and this includes 
all subjects in the mITT subset with the following exclusions:  
• Data from all available visits for subjects found to be ineligible at baseline.  
• Data from all visits subsequent to the protocol deviations  that ar e considered to affect the 
science . 
• Data from any visit that occurs substantially out of window.  
9.4 Statistical Analyses  
Interim analyses of safety, reactogenicity, and immunologic response data will be done, as 
needed.  
The final analysis will be performed after the final data lock and clinical study report (CSR) 
completed when all primary safety endpoint data and all secondary immunogenicity endpoint 
data are available  and received by the SDSU . The final CSR will be completed when all primary 
and secondary safety, clinical, and immunological endpoint data are available.  Available data 
from the exploratory endpoints at  the time of compilation of the final CSR may also be included. 
Other  remaining  exploratory endpoint data may be included in an addendum to the CSR, 
publication of manuscript(s), or other report (s).  Abbreviated analysis plans that describe planned 
analyse s to facilitate dissemination of study data for public health reasons, including  manuscript 
publication(s) , will be developed by the SDSU . A full statistical analysis plan (SAP)  will be 
developed by the SDSU and finalized prior to the primary data lock.  
9.4.1 General Approach  
Unless otherwise noted in the SAP, continuous variables will be summarized using the following 
descriptive statistics: n (non -missing sample size), mean, standard deviation, median, maximum 
and minimum. The frequency and percentages (based o n the non -missing sample size) of 
observed levels will be reported for all categorical measures.  
9.4.2 Analysis of the Primary Endpoint(s)  
Section 9.4.4  describes the analyses of Safety Endpoints, which is  one of  the co-primary 
endpoint s of this protocol.  
9.4.3 Analysis of the Co-Primary  Endpoint(s)  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 72 of 97 Descriptive summaries of immunogenicity data will be presented for the mITT population. If 
there are protocol devi ations  which may affect the analysis , a per -protocol (PP) analysis may 
also be performed.  
Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) from baseline of SARS -
CoV -2 specific antibody binding and neutralization titers will be calculated, al ong with 95% CIs, 
for all groups, at each timepoint. Summaries will also be displayed graphically. Rates of 
seroconversion, defined as a 4 -fold increase in antibody titer over baseline, will also be reported 
for all groups, at each timepoint, along with 95 % CIs.  
9.4.4 Safety Analyses  
Summaries and analysis of safety data will be presented for the Safety Analysis Population.  
Solicited AEs will be summarized by severity for each day post vaccination (Days 1 -8) and as 
the maximum severity over all 8 days. Additionally, solicited AEs will be analyzed using 
standard techniques, such as exact confidence intervals (CI), to summarize the proportion of 
subjects reporting each symptom, any application site symptom, an d any systemic symptom.  
Unsolicited non -serious AEs will be collected from the time of first vaccination through 28 days 
after the last vaccination. Unsolicited AEs will be coded by MedDRA for preferred term and 
system organ class (SOC). SAEs, Protocol Spe cified AESIs, MAAEs, and NOCMCs will be 
collected from the time of first vaccination  to end of planned study participation . The numbers of 
SAEs , AESIs , NOCMCs  and MAAEs will be reported by detailed listings showing the event 
description, MedDRA preferred t erm and SOC, relevant dates (vaccinations and AEs), severity, 
relatedness, and outcome for each event. Non -serious unsolicited AEs will be summarized as 
number and percentage of subjects reporting at least one event in each MedDRA preferred term 
and SOC, c ross tabulated by severity and relationship to study product. Additionally, the 
proportion of subjects and exact 95% CIs of AEs in aggregate and by MedDRA categories will 
be computed.  
9.4.5 Baseline Descriptive Statistics  
Summaries of demographic variables such as age, sex, ethnicity, and race will be presented by 
cohort and overall. Summaries of baseline clinical laboratory values will be presented by arm and 
cohort . 
9.4.6 Planned Interim and Early Analyses  
Data may be disseminated to public health officials and partners as needed  and included in 
publications and presentations to inform the global scientific community . Early analyses will 
include safety and immunogenicity as described in Sections 9.4.6.1 , 9.4.6.2  and 9.4.6.3 . Further, 
the protocol team will review data periodically to confirm no halting criteria have been met as 
described in Section 10.1.6.1 . 
Cumulative safety informat ion, study status, and primary endpoint results may be published,  
presented at a public forum , or presented as summaries aggregated by study arm at the discretion 
of the sponsor while the study is ongoing. Any ad -hoc analyses  jointly developed by the  study  
team and  SDSU will be executed by the SDSU  and SCHARP  as needed. None of the interim 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 73 of 97 analyses will include any formal statistical hypothesis testing; therefore, p value adjustment will 
not be made to any analyses.  
9.4.6.1  Interim Safety Analyses  
Given the need fo r rapid review and dissemination of study data for public health reasons, AEs 
and SAEs may  be reviewed as necessary outside of SMC reviews.  The SMC may not need to 
meet (unless halting  rules are met) , and materials will be provided electronically. Documentation 
of review and any concerns noted will be solicited electronically.  
The SMC will review separate cumulative AE data reports after all subjects within each booster 
product group  have been dosed an d completed Day 29 within Cohort 1 . At the time of the 
writing of Version 8.0 of the protocol  there are no scheduled mandatory review s by the SMC  
after participan ts in Cohort 2 receive the  prime, first boost or second boost vaccination s. This is 
due to the  safety database known for EUA vaccines  and vaccinations being administered  in 
accordance to CDC guidelines. SMC review s for Cohort 2 will occur if halting  rules are 
triggered , or as requested by the sponsor or PI .   
9.4.6.2  Interim Immunogenicity Review  
Interim data review of immunogenicity will be  performed as often as needed to inform public 
health decisions.  
Statistical analyses of secondary immunogenicity endpoints, by vaccine schedule group, may be 
performed when subjects have completed key immunogen icity visits. Immunogenicity reviews 
may be shared with the SMC , as determined by DMID.  
Data may be disseminated to public health officials and partners  as needed  and included in 
publications and presentations to inform the global scientific community . 
9.4.6.3  Interim Immunogenicity and Safety Review  
Interim analys es of safety, reactogenicity, and immunologic response data may be done , as 
needed . 
9.4.7 Sub-Group Analyses  
Subgrou p analyses, by age group, may be performed. For group 15E, which will enroll 
participants with one or two prior doses of Janssen, a subgroup analysis by this baseline 
characteristic may also be performed. Detailed information will be provided in the Statistical 
Analysis Plan.  
9.4.8 Tabulation of Individual Subject  Data  
In general, all data will be listed, sorted by arm and subject, and when appropriate by visit 
number within subject.  
9.4.9 Exploratory Analyses  
Summari es and analysis of cellular assay data will be presented for the mITT population. If there 
are protocol deviations  which may affect the analysis , a PP analysis may also be performed.  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 74 of 97 The magnitude, phenotype and percentage of innate immune cells and SARS -CoV-2 specific B 
cells will be summarized at each timepoint by arm.  
The magnitude, phenotype and percentage of cytokine producing S  protein -specific T cells will 
be summarized at each timepoint by arm. 
Breakthrough  NAAT -confirmed , SARS -CoV -2 infections will  be sequenced  to assess for the 
presence of variant spike lineage  proteins.  
Summari es of  mucosal immun e responses, from nasal and salivary  samples of participants in 
Cohort 2 who receive a second boost , will be summarized at each timepoint  post-boost . Also, the 
correlation between  the mucosal and the serological immune responses will be evaluated at each 
timepoint post -boost. The possibility  of conducting these analysis by status of prior infection (as 
given by N -protein ELISA assay) will be assessed .  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 75 of 97 10 SUPPORTING DOCUMENTATION AND 
OPERATIONAL CONSIDERATIONS  
10.1 Regulatory, Ethical, and Study Oversight Considerations  
This study will be conducted in conformity with the principles set forth in The Belmont Report: 
Ethical Principles and Guidelines for the Protection of Human Subjects of Research (US 
National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Resear ch; April 18, 1979), and the federal policy for the Protection of Human Subjects codified 
in 45 CFR Part 46, 21 CFR Part 50 (Protection of Human Subjects), and the ICH E6(R2).  
An OHRP -registered IRB will review and approve this protocol, associated informe d consent 
documents, recruitment material s, and handouts or surveys intended for the subjects, prior to the 
recruitment, screening and enrollment of subjects. The IRB review shall be in accordance with 
45 CFR 46 and 21 CFR 50, 21 CFR 56 ( IRBs), and other f ederal, state, and local regulations and 
policies, as applicable.  
Each institution engaged in this research will hold an OHRP -approved FWA.  
Any amendments to the protocol or informed consent documents  will be approved by the IRB 
before they are implemented . IRB review and approval will occur at least annually throughout 
the duration of the study. The participating site PI  will notify the IRB of deviations from the 
protocol and reportable SAEs, as applicable to the IRB policy.  
DMID must receive the documenta tion that verifies IRB  approval for this protocol, informed 
consent documents and associated documents , prior to the recruitment, screening and enrollment 
of subjects, and any IRB  approvals for continuing review or amendments as required by the 
DMID.  
10.1.1  Infor med Consent Process  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing throughout the individual’s trial participation. Investigators or designated 
research staff will obtain a subject’s  informed consent in accordance with the requirements of 45 
CFR 46, 21 CFR 50 and 21 CFR 56 for FDA -regulated studies, state and local regulations and 
policy, and ICH E6 GCP before any study procedures or data collection are performed. The 
participating  site PI or other study staff may obtain oral or written information for the purpose of 
screening, recruiting, or determining the eligibility of prospective subjects without the informed 
consent of the prospective subject if the process is approved by the IRB . 
At the first study visit, informed consent will be obtained and documented before any study 
procedures are performed. Subjects will receive a concise and focused presentation of key 
information about the clinical trial, verbally and with a written consen t form. The key 
information about the purpose of the study, the procedures and experimental aspects of the study, 
study interventions/products, risks and discomforts, the expected duration of the subject’s 
participation in the trial, any expected benefits to the subject, and alternative treatments and 
procedures that may be available to the subject. The explanation will be organized and presented 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 76 of 97 in lay terminology and language that facilitates understanding why one might or might not want 
to participate.  
Subjects will receive an explanation as to whether any compensation and any medical treatments 
are available if injury occurs, and, if so, what they consist of, or where further information may 
be obtained. Subjects will be informed of the anticipated fina ncial expenses, if any, to the subject 
for participating in the trial, as well as any anticipated prorated payments, if any, to the subject 
for participating in the trial. They will be informed of whom to contact (e.g., the participating  site 
PI) for answe rs to any questions relating to the research project. Information will also include the 
foreseeable circumstances and/or reasons under which the subject’s participation in the trial may 
be terminated. The subjects will be informed that participation is vol untary and that they are free 
to withdraw from the study for any reason at any time without penalty or loss of benefits to 
which the subject is otherwise entitled.  Subjects will be allowed sufficient time to consider 
participation in this research trial an d have the opportunity to discuss this trial with their family, 
friends or legally authorized representative, or think about it prior to agreeing to participate.  
Subjects will be informed that records identifying the subject will be kept confidential, and,  to 
the extent permitted by the applicable laws and/or regulations, will not be made publicly 
available. If the results of the trial are published, the subject’s identity will remain confidential. 
Subjects will be informed, even if identifiers are removed,  that information collected from this 
research and/or specimens may be used for  secondary  research , including the sharing of 
deidentified data . 
Subjects will be informed that the monitor(s), auditors(s), IRB, NIAID, and regulatory 
authority(ies) will be gr anted direct access to the subject’s original medical records for 
verification of clinical trial procedures and/or data without violating the confidentiality of the 
subject, to the extent permitted by the applicable laws and regulations, and that, by signi ng a 
written ICF, the subject is authorizing such access.  
ICFs will be IRB -approved,  and subjects will be asked to read and review the consent form. 
Subjects must sign the ICF prior to starting any study procedures being done specifically for this 
trial. Once signed, a copy of the ICF will be given to the subject for their records.  
New in formation will be communicated by the participating  site PI to subjects who consent to 
participate in this trial in accordance with IRB requirements. The informed consent document 
will be updated, and subjects will be re -consented per IRB requirements, if necessary.  
10.1.1.1  Requirements for Permission by Parents/Guardians and Assent by Children (in 
case of a minor)  
Not Applicable  
10.1.1.2  Other Informed Consent Procedures  
The rights and privacy of human subjects who participate in genomic or phenotypic research 
studies will  be protected at all times. The consent process, including relevant language in the 
ICF, will provide an explanation of the potential risks to the individual study subjects and their 
families. Clinical metadata, genomic, or other datasets or a subset of th e clinical and other 
metadata that may potentially identify human subjects will not be released in unrestricted 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 77 of 97 databases. Subjects will be informed that the evolution of genomic technology and analytical 
methods raises the risk of re -identification, even when specimens are de -identified.  
Subjects will be asked for consent to collect additional blood, nasal or NP swabs, the use of 
residual specimens, and the sharing of genetic information and samples for secondary research. 
This extra/residual blood and cor responding serum, plasma and PBMCs , and mucosal samples  
will be used as back -up specimens for PP defined assays or designated for secondary research 
use and stored indefinitely at a designated storage facility.  
Subject s will be asked to consent specificall y to genetic testing  on primary and secondary 
research  samples , including but not limited to transcriptomics and DNA sequencing. DNA 
sequencing data will be kept private. DNA data may be used to produce commercial antibody -
based therapeutics. Subjects will not share in profits or commercial rights to those products.  
If subjects  choose not to provide permission for extra  blood and secondary research use, they 
will not be eligible for enrollment into the study . 
Collection of extra/residual sample s during the course of the study will help facilitate rapid 
follow -on analyses, if warranted, to provide more comprehensive scientific insights into the 
impact (safety and immunological) of the vaccine  on the host response to vaccination. To 
maintain stati stical power in follow -on analyses it is important that ex tra blood collection and 
secondary research use be included in as many subjects as possible, due to the limited sample 
size per treatment arm.  
The stored samples will be labeled with barcodes to mai ntain confidentiality. Research with 
identifiable samples and data may occur as needed, however, subject confidentiality will be 
maintained as described for this protocol and with IRB approval.  
Samples designated for secondary research use may be used for additional immunological 
assessments that may include but are not limited to antibody epitope mapping, B and T cell 
repertoire determination, non -traditional immune assay development, determination of innate 
immune factors and the ability of vaccine -induce d antibodies to cross -react to different proteins 
and virus strains. These blood samples might be used in new or different immunological 
laboratory tests, to provide information for the development of new vaccines  or therapeutics , or 
for the studies of SAR S-CoV -2 or other infections. Secondary research using DNA may also be 
warranted to understand genetic factors involved in vaccination failures.  
Samples will not be sold for commercial profit.  Although the results of any future research may 
be patentable or  have commercial profit, subjects will have no legal or financial interest in any 
commercial development resulting from any future research.  
There are no direct benefits to the subject for extra specimens collected or from the secondary 
research. No result s from secondary research will be entered into the subject’s medical record.  
Incidental findings will not be shared with the subject, including medically actionable incidental 
findings, unless required by law.  
Risks are associated with the additional volum e of blood collected, such as anemia. Risks for 
loss of privacy and confidentiality are described below.  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 78 of 97 Subjects may withdraw permission to use samples for secondary use at any time. They will need 
to contact the participating  site and the samples will be removed from the study repository after 
this study is completed and documentation will be completed that outlines the reason for 
withdrawal of permission for secondary use of samples. Subjects who withdraw consent before 
the last visit will not have the extra  blood drawn for secondary use. 
Human Genetic Testing  
The research staff will seek the subjects’ consent for extra and residual specimens to be stored 
and used for secondary research , including genetic research,  evaluating human genomic and 
phenotypic markers . The rights and privacy of human subjects who participate in genomic or 
phenotypic research studies will be protected at all times.  
The consent process will include an explanation of the potential risks to the individua l subjects 
and their families associated with data submitted to an NIH data repository and subsequent 
sharing. Data that may potentially identify human subjects will not be released in unrestricted 
databases. Subjects will be informed that the evolution of  genomic technology and analytical 
methods raises the risk of re -identification, even when specimens are de -identified. The consent 
will include whether individual subject data will be shared through a NIH controlled access data 
repository. Data for genomi c or phenotypic research will be submitted to a controlled access data 
repository, therefore, informed consent permitting the data sharing must be documented, even if 
the specimens are de -identified.  
10.1.2  Study Termination  and Closure  
In Section 7 Study Intervention Discontinuation and Subject  Discontinuation/Withdrawal, 
describes the temporary halting of the study.  
This study may be prematurely terminated if there is suff icient reasonable cause, including , but 
not limited to:  
Determination of unexpected, significant, or unacceptable risk to subjects  
Results of interim analysis  
Insufficient compliance to protocol requirements  
Data that are not sufficiently complete and/or not evaluable  
Regulatory authorities  
If the study is prematurely terminated, the PI will promptly inform study subjects  and the IRB as 
applicable. Study subjects  will be contacted, as applicable, and be inform ed of changes to study 
visit schedule. The PI will assure appropriate follow -up for the subjects, as necessary.  
The sponsor will notify regulatory authorities as applicable.  
10.1.3  Confidentiality and Privacy  
Subject confidentiality is strictly held in trust by t he participating investigators, their staff, and 
the sponsor(s) and their agents. This confidentiality is extended to cover clinical information 
relating to subjects , test results of biological samples and genetic tests, and all other information 
generated  during participation in the study. No identifiable information concerning subjects  in 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 79 of 97 the study will be released to any unauthorized third party. Subject confidentiality will be 
maintained when study results are published or discussed in conferences.  
The study monitor, other authorized representatives of the sponsor, representatives of the IRB, 
and/or regulatory agencies may inspect all documents and records required to be maintained by 
the participating site PI , including , but not limited to, medical reco rds (office, clinic, or hospital) 
and pharmacy records for the subjects  in this study. The participating site will permit access to 
such records.  
All source records , including electronic data , will be stored in secured systems in accordance 
with institutio nal policies and federal regulations.  
All study data and research specimens that leave the participating site (including any electronic 
transmission of data) will be identified only by a coded number that is linked to a subject through 
a code key maintaine d at the participating  site. Names or readily identifying information will not 
be released unless DMID approves and it aligns with the consent form, or according to laws for 
required reporting.  
Because it may be possible to re -identify de -identified genomi c data, even if access to data is 
controlled and data security standards are met, confidentiality cannot be guaranteed, and re -
identified data could potentially be used to discriminate against or stigmatize subjects , their 
families, or groups. In addition,  there may be unknown risks.  
As this research is funded by the NIH, it is covered by NIH policy which effectively issues the 
research a Certificate of Confidentiality  (COC) . By this policy, researchers cannot be forced to 
disclose or provide, in any Federa l, State, or local civil, criminal, administrative, legislative, or 
other proceeding, the name of such individual or any such information, document, or 
biospecimen that contains identifiable, sensitive information about the individual and that was 
created or compiled for purposes of the research, unless such disclosure or use is made with the 
consent of the individual to whom the information, document, or biospecimen pertains.  
The Certificate cannot be used to resist a demand for information from personnel of the United 
States Government that is used for auditing or evaluation of federally funded projects, like this 
study, or for information that must be released in order to meet the requirements of the FDA.  
A COC  does not prevent subject s from voluntarily r eleasing information about themselves or 
their involvement in this research. If any person or agency obtains a written consent to receive 
research information, then the researchers may not use the Certificate to withhold that 
information.  
The COC  does not prevent the researchers from reporting , without the subject’s consent, 
information that would identify the subject as a subject  in the research project in the case of 
matters that must be legally reported , including child and elder abuse, sexual abuse, or wanting 
to harm themselves or others.  
The release of individual private information or specimens for other research will only occur if 
consent was obtained from the individual to whom the information, document, or biospecimen 
pertains, or that the release is in compliance with applicable Federal regulations governing the 
protection of human subjects in research.  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 80 of 97 10.1.4  Secondary Use of Stored Specimens and Data  
Secondary Human Subject Research is the re -use of identifiable data or identifiable 
biospecimens that were collected from some other ‘‘primary’’ or ‘‘initial’’ activity, such as the 
data and samples collected in this protocol. This section will detail the samples and data 
available for secondary research. Any use of the secondary  sample or data,  however, will be 
presented in a separate protocol and require separate IRB approval.  
10.1.4.1  Samples for Secondary Research  
The following types of  samples will be stored an d used for secondary research:  
Residual Research Sample : Any leftover Primary Research Sample after the laboratory testing 
specified in this protocol is completed will be stored for future studies with the subject’s consent.  
Repository Research Sample : Samples will be collected with the subject ’s consent in this 
protocol with the intent to store for additional research (i.e. , samples collected beyond those 
needed for primary research) and will be used in future studies.  Amendments to this protocol 
with addi tional assays may use repository research samples . 
Samples will be stored indefinitely at a DMID -designated storage facility. Each sample will be 
encoded (labeled) only with a barcode and a unique tracking number to protect subject 
confidentiality. Seconda ry research with coded samples and data may occur, however, subject 
confidentiality will be maintained as described for this protocol. An IRB review of the secondary 
research using coded specimens is required.  
Residual/Repository Research Samples, upon wri tten request and approval from DMID  and any 
approvals required by the site or network , may be shared for secondary research with 
investigators at the participating site, with researchers at other Infectious Disease Clinical 
Research Consortium ( IDCRC ) sites or other institutions, or company -designated research 
laboratories. The samples will not be sold or used directly for production of any commercial 
product. DMID will authorize shipment from the DMID CMS.  
Reports from secondary research will not be kept i n the subjects’ health records or shared with 
subjects, unless required by law. Reports will not be sent to the specimen repository.  
The subject’s decision can be changed at any time by notifying the study doctors or nurses in 
writing. To participate in this study, subjects must consent for storage of samples for secondary 
use. If the subject subsequently changes his/her decision, the s amples will be destroyed if the 
samples have not been used for research or released for a specific research project.  
10.1.4.2  Data Sharing for Secondary Research  
Data from this study may be used for secondary research. All of the individual subject  data 
collected during this study  will be made available after de -identification. The SAP and Analytic 
Code will also be made available. Data will be available immediatel y following publication, with 
no end date. Upon written request, with provision of a methodologically sound proposal, and 
approval from DMID and any approvals required by the site or network , data may be shared for 
secondary research with investigators /researchers . The data will be available for only the purpose 
outlined in the approved proposal.  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 81 of 97 For access to genomic data in the NIH designated controlled access database, an investigator (or 
data requestor) must submit a Data Access Request which certifies adherence to the NIH 
Security Best Practices for Controlled -Access data subject to the NIH Genomic Data Sharing 
(GDS ) Policy.  
The participating  site PI  may request removal of data on individual study subjects from NIH data 
repositories in the event that a research subject withdraws or changes his or her consent. 
However, some data that have been distributed for approved research use cannot be retrieved.  
10.1.5  Key Roles and Study Governance  
This study is sponsored by DMID. Decisions related to th is study will be m ade by the protocol 
team, which includes representatives from the participating site (PI), DMID (sponsor), VRC, and 
ModernaT X, Inc. Key Roles are noted in the protocol -specific MOP.  
10.1.6  Safety Oversight  
10.1.6.1  Safety Monitoring Committee  (SMC)  
The SMC is an independent group of at least 2-3 experts that monitors subject safety and advises 
DMID. SMC members will be separate and independent of study staff participating in this trial 
and should not have scientific, financial, or other conflicts of interest related to this trial. The 
SMC will consist of members with appropriate expertise to contribute to the interpretation of 
data from this trial. A quorum will consist of a simple majority.  
The SMC will hold an organizational meeting or electronic re view  prior to enrollment. At this 
meeting, the SMC will review the charter, protocol, ICF, IB, and safety report template s. 
Given the frequency and urgency to review data, the SMC will not need to meet (unless halting  
rules are met ), and materials will be provided electronically . Documentation of review and any 
concerns noted will be solicited electronically . 
The SMC will review separate cumulative AE data reports after all subjects within each product  
booster group  have been dosed and completed Day 29 within Cohort 1 . At the time of writing of 
Version 8.0 of the protocol, there is no additional scheduled  mandatory review by the SMC for 
Cohort 2, unless halting rules are triggered. Ad hoc reviews will occur when trial halting criteria 
are met, or as requested by the sponsor or PI.  
Procedures for SMC reviews/meetings will be defined in the SMC charter. The SMC will review 
applicable data , including, but not limited to, enrollment, demographics, dosing  data,  clinical  
laboratory data , and safety data , at scheduled timepoints during this trial as defined in the SMC 
charter.  
Additional data may be requested by the SMC, and interim statistical reports may be generated 
as deemed necessary and appropriate by DMID. As an outcome of each review/meeting, the 
SMC will make a recommendation as to the advisability of proceeding with study product  
administration, and to continue, modify, or terminate this trial.  
10.1.7  Clinical Monitoring  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 82 of 97 Clinical site monitoring is conducted to ensure that the rights and well -being of trial  subjects  are 
protected, that the reported trial data are accurate, complete, and verifiable. Clinical Monitoring 
also ensures conduct of the trial is in compliance with the currently approved protocol/  
amendment(s), ICH, GCP , and with applicable regulator y requirement(s) and sponsor 
requirements. Clinical monitoring will also verify that any critical study procedures are 
completed following specific instructions in the protocol -specific MOP . 
Monitoring for this study will be performed by DMID. Details of c linical site monitoring are 
documented in a CMP. The CMP describes in detail who will conduct the monitoring, at what 
frequency monitoring will be done, at what level of detail monitoring will be performed, and the 
distribution of monitoring reports. Monit oring visits will include, but are not limited to, review 
of regulatory files, accountability records, electronic case report forms ( eCRFs ), ICFs, medical 
and laboratory reports, site study intervention storage records, training records, and protocol and 
GCP compliance. Site monitors will ha ve access to each participating  site, study staff and all 
study documentation according to the DMID -approved CMP . Study monitors will meet with all 
participa ting site PIs to discuss any problems and outstanding issues and  will document site visit 
findings and discussions.  
10.1.8  Quality Control (QC) and Quality Assurance  (QA)  
To ensure the reliability of study data, the participating site will develop a Clinical Quality 
Manageme nt Plan (CQMP). The CQMP will describe : 
• routine internal quality control (QC) and QA activities  
o for the purposes of measuring, documenting and reporting study conduct, protocol 
adherence, human subjects’ protections, and reliability of the protocol -driven data 
collected;  
o independent of sponsor site monitoring.  
• a process for addressing data quality issues (i.e., collecting, recording), and reporting 
findings in a timely manner); systemic issues (i.e., protocol conduct, non -compliance, 
human subject protectio ns), and implementation and evaluation of Corrective and 
Preventative Action Plan (CAPA) procedures.  
10.1.9  Data Handling and Record Keeping  
10.1.9.1  Data Collection and Management Responsibilities  
Data collection is the responsibility of the study staff at the participati ng site under the 
supervision of the  participating  site PI. The participating site PI must maintain complete and 
accurate source documentation.  
Clinical research data from source do cumentation , including, but not limited to, AEs/SAEs, 
concomitant medications, medical history, physical assessments, and clinical laboratory data , 
will be entered by the participating site into eCRFs via a 21 CFR Part 11 -compliant internet data 
entry syst em provided by SCHARP . The data system includes password protection and internal 
quality checks, such as automatic range checks, to identify data that appear inconsistent, 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 83 of 97 incomplete, or inaccurate. AEs and concomitant medications will be coded according t o the most 
current versions of MedDRA and WhoDrug, respectively.  
The IDCRC SDSU and SCHARP  will be responsible for data management, quality review, 
analysis, and reporting of the study data.  
The IND sponsor is responsible for review of data collection tool s and processes, and review of 
data and reports.  
AEs will be coded according to the MedDRA dictionary version  23.0 or higher . 
A separate study specific Study Data Standardization Plan (SDSP) appendix will be developed 
which describes the technical recommen dations for the submission of human study data and 
related information in a standardized electronic format throughout product development.  
At the end of the study, a copy of all datasets , including annotated CRFs  and data dictionary , will 
be provided to DMID.  
10.1.9.2  Study Record Retention  
Study -related records, including the regulatory file, study product accountability records, consent 
forms, subject source documents and electronic records , should be maintained for a period of 2 
years follo wing the date a marketing application is approved for the investigational product for 
the indication for which it is being investigated; or, if no application is to be filed or if the 
application is not approved for such indication, until 2 years after the  investigation is 
discontinued and FDA is notified. These documents should be retained for a longer period, 
however, if required by local policies or regulations. No records will be destroyed without the 
written consent of DMID. Consent forms with specimen  retention linked to identifiable 
specimens will be maintained for as long as the specimens remain in identifiable format, and a 
minimum of three years after use of the identifiable specimens in nonexempt human subject 
research.  
10.1.9.3  Source Records  
Source data are all information in original records (and certified copies of original records) of 
clinical findings, observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial. Source data should be attributable,  legible, 
contemporaneous, original, accurate, a nd complete. Each participating  site will maintain 
appropriate medical and research records for this trial, in compliance with ICH GCP, regulatory, 
and institutional requirements. Study data will be collected  on paper CRFs and entered the eCRF 
or data will be entered directly into the eCRF.  Data recorded in the eCRF derived from source 
documents should be consistent with the data recorded on the source documents.  Data entered 
directly into the eCRFS will be co nsidered the source document.  
Interview of subjects is sufficient for obtaining medical history. Solicitation of medical records 
from the subject’s primary care provider is not required.  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 84 of 97 10.1.9.4  Protocol Deviations  
A protocol deviation is any non -compliance with t he clinical trial protocol, any process that is 
noted in the protocol and refers to details in the  protocol -specific  MOP or GCP requirements , or 
any critical study procedures with specific instructions in ancillary documents referenced in the 
protocol such  as a protocol -specific MOP . 
The non -compliance may be either on the part of the subject, the participating site PI  or the study 
staff. Following a deviation(s), corrective actions should be developed by the participating site 
and implemented promptly. All individual protocol deviations will be addressed in subject study 
records.  
It is the responsibility of the participating  site PI and study staff  to use continuous vigilance to 
identify and report deviations within five working days of identif ication of the protocol 
deviation, or within five working days of the scheduled protocol -required activity. All deviations 
must be promptly reported to DMID per the protocol deviation reporting procedures. Protocol 
deviations must be sent to the local IRB/ IEC per their guidelines. The participating site PI and 
study staff  are responsible for knowing and adhering to their IRB requirements. A completed 
copy of the DMID Protocol Deviation Form must be maintained in the Regulatory File, as well 
as in the subjec t’s chart if the deviation is subject specific.  
10.1.9.5  Publication and Data Sharing Policy  
Analyses will be conducted as data become available while the study is ongoing at the discretion 
of the sponsor. Analyses of data will be available for publication to infor m the scientific 
community. Data will be available immediately following publication, with no end date, with 
data sharing at the discretion of the PI. Publication of manuscripts may occur at the discretion of 
the sponsor in accordance with DMID’s Expanded Distribution of Clinical  Research Endpoint 
Data Policy.  
10.1.9.6  Human Data Sharing Plan  
This study will be conducted in accordance with the following publication and data sharing 
policies and regulations:  
• NIH Public Access Policy, which ensures that the public has  access to the published 
results of NIH funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central upon 
acceptance for publication.  
10.1.9.7  Genomic Data Sharing  (GDS)  Plan 
This study will comply with the NIH GDS  Policy, which applies to all NIH -funded research that 
generates large -scale human or non -human genomic data, as well as the use of these data for 
subsequent research. Large -scale data include genome -wide associati on studies (GWAS), SNP 
arrays, and genome sequence, transcriptomic, epigenomic, and gene expression data.  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 85 of 97 10.1.9.8  Publication  
At intervals throughout the study at the discretion of the sponsor and following completion of the 
study, the lead PI is expected to publi sh the results of this research in a scientific journal. This 
study will adhere to the following publication and data sharing policies and regulations:  
• NIH Public Access Policy, which ensures that the public has access to the published 
results of NIH funded research. As such, the final peer -reviewed journal manuscripts will 
be accessible to the public on PubMed Central no later than 12 months after publication.  
10.1.9.9  Conflict of Interest Policy  
The independence of this study from any actual or perceived influence, such as by the 
pharmaceutical industry, is critical. Therefore, any actual conflict of interest of persons who have 
a role in the design, conduct, analysis, publication, or any aspect of this trial will be disclosed 
and managed. Furthe rmore, persons who have a perceived conflict of interest will be required to 
have such conflicts managed in a way that is appropriate to their participation in the design and 
conduct of this trial. DMID has established policies and procedures for all study  team members 
to disclose all conflicts of interest and will establish a mechanism for the management of all 
reported dualities of interest.  
10.2 Additional Considerations  
10.2.1  Research Related Injuries  
For any potential research related injury, the participating site PI or designee will assess the 
subject. Study staff will try to reduce, control and treat any complications from this trial. 
Immediate medical treatment may be provided by the participating site , such as giving 
emergency medications to stop immediate al lergic reactions to the vaccine . As needed, referrals 
to appropriate health care facilities will be provided to the subject. The participating site PI 
should then determine if an injury occurred as a direct result of the tests or treatments that are 
done f or this trial.  
If it is determined by the participating  site PI that an injury occurred to a subject as a direct result 
of the tests or treatments that are done for this trial, then referrals to appropriate health care 
facilities will be provided to the su bject. Study staff will try to reduce, control and treat any 
complications from this trial. Immediate medical treatment may be provided by the participating 
site, such as giving emergency medications to stop immediate allergic reactions to the vaccine. 
No financial compensation will be provided to the subject by NIAID, NIH , the vaccine 
manufacturer , or the participating site for any injury suffered due to participation in this trial.  
For this protocol, the study vaccine s are covered under the PREP Act, as described in Section 
2.1.1 . 
10.3 Abbreviations  
Table 15: Abbreviations  
ACIP  Advisory Committee on  Immunization  Pract ices 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 86 of 97 Ad Adenovirus  
AE Adverse Event  
AESI  Adverse Event of Special Interest  
AIDS  Acquired Immunodeficiency Syndrome  
PBMC  Peripheral Blood Mononuclear Cell  
BMI  Body Mass Index  
BP Blood Pressure  
°C Degrees Celsius  
CAPA  Corrective and Preventative Action Plan  
CFR  Code of Federal Regulations  
CI Confidence Interval  
CICP  Countermeasures Injury Compensation Program  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Clinical Monitoring Plan  
CMS  Clinical Material Services  
COC  Certificate of Confidentiality  
COPD  Chronic Obstructive Pulmonary Disease  
CoV  Coronavirus  
COVID -19 Coronavirus Disease 2019  
CRF  Case Report Form  
CROMS  Clinical Research Operations and Management Support  
CSR  Clinical Study Report  
CQMP  Clinical Quality Management Plan  
DCF  Data Collection Form  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases  
DNA  Deoxyribonucleic Acid  
DSPC  1,2-distearoyl -sn-glycero -3-phosphocholine  
EC Ethics Committee  
eCRF  Electronic Case Report Form  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 87 of 97 EDC  Electronic Data Capture  
eGFR  Estimated Glomerular Filtration Rate  
ELISA  Enzyme -Linked Immunosorbent Assay  
EUA  Emergency Use Authorization  
°F Degrees Fahrenheit  
FDA  Food and Drug Administration  
FWA  Federal Wide Assurance  
GCP  Good Clinical Practice  
GDS  Genomic Data Sharing  
GLP  Good Laboratory Practices  
GMFR  Geometric Mean Fold Rise  
GMT  Geometric Mean Titer  
GWAS  Genome -Wide Association Studies  
HEENT  Head, Ears, Eyes, Nose, and Throat  
HHS  Health and Human Services  
HIV Human Immunodeficiency Virus  
HLA  Human Leukocyte Antigen  
HR Heart Rate  
HRSA  Health Resources and Services Administration  
IB Investigator’s Brochure  
ICD International Classification of Diseases  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
IDCRC  Infectious Disease Clinical Research Consortium  
IDE Investigational Device Exemption  
IEC Independent or Institutional Ethics Committee  
IM Intramuscular  
IND Investigational New Drug Application  
IRB Institutional Review Board  
IV Intravenous  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 88 of 97 kg Kilogram  
LNP  Lipid Nanoparticle  
m Meter  
MAAE  Medically Attended  Adverse Event  
mcg Microgram  
MedDRA  Medical Dictionary for Regulatory Activities  
MERS  Middle East Respiratory Syndrome  
mg Milligrams  
MI Myocardial Infarction  
min Minute  
mITT  Modified Intent -To-Treat  
mL Milliliter  
mm Hg  Millimeter of Mercury  
MOP  Manual of Procedures  
mRNA  Messenger Ribonucleic Acid  
N Number (typically refers to subjects)  
MSD  MesoScale Discovery  
NAAT  Nucleic Acid Amplification Test 
NaCl  Sodium Chloride  
NDA  New Drug Application  
NEUT  Neutralizing  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
NOCMC  New -Onset Chronic Medical Condition  
NP Nasopharyngeal  
OHRP  Office for Human Research Protections  
PBMC  Peripheral Blood Mononuclear Cell  
OWS  Operation Warp Speed  
PCR  Polymerase Chain Reaction   
PEG  Polyethylene Glycol  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 89 of 97 PHI Protected Health Information  
PI Principal Investigator  
PIMMC  Potential Immune -Mediated Medical Conditions  
PP Per Protocol  
PREP  Act Public Readiness and Emergency Preparedness Act  
QA Quality Assurance  
QC Quality Control  
RBD  Receptor Binding Domain  
RNA  Ribonucleic Acid 
SAE  Serious Adverse Event  
SAGE  Strategic Advisory Group of Experts on Immunization  
SAP Statistical Analysis Plan  
SARS  Severe Acute Respiratory Syndrome  
SARS -CoV  SARS Coronavirus  
SARS -CoV -2 SARS Coronavirus 2  
SCHARP  Statistical Center for HIV/AIDS Research and Prevention  
SD Standard Deviation  
SDSP  Study Data Standardization Plan  
SDSU  Statistical and Data Science Unit 
SMC  Safety Monitoring Committee  
SNP Single Nucleotide Polymorphisms  
SOA  Schedule of Activities  
SOC  System Organ Class  
SOP Standard Operating Procedure  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
Th T helper  
TTS Thrombosis with Thrombocytopenia Syndrome  
UP Unanticipated Problem  
US United States  
USP United States Pharmacopeia  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 90 of 97 vp Viral Particles  
VRC  Vaccine Research Center  
VRBPAC  Vaccine and Related Biological Product Advisory Committee  
WBC  White Blood Cell  
WHO  World Health Organization  
WIV1  Chinese Horseshoe Bat Coronavirus WIV1  
 
10.4 Protocol Amendment History  
Table 16: Protocol Amendment History  
Version 2.0 of the  protocol was amended 22 June 2021.  
Version 3.0 of the protocol was amended 1 5 July 2021  
Version 4.0 of the protocol was amended 20 August 2021  
Version 5.0 of the protocol was amended 10 November 2021  
Version 6.0 of the protocol was amended 0 9 February 2022  
Version 7.0 of the protocol was amended 04 April 2022  
Version 8.0 of the protocol was a mended 29 September 2022  
Version  9.0 of the protocol was amended 26 October  2022  
Version 10.0 of the protocol was amended 06 April 2023  
 
11 REFERENCES  
 
1. WHO. World Health Organization, Weekly Operational Update on COVID -19. 2020a. 
https://www.who.int/emergencies/diseases/novel -coronavirus -2019/situation -reports .  Accessed 
on 20 January 2022.  
2. JHU. COVID -19 Dashboard, Center for Systems Science and Engine ering (CCSE) at 
Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html . Accessed January 20, 
2022. 2021.  
3. Corbett KS, Edwards DK, Leist SR, et al. SARS -CoV -2 mRNA vaccine design enabled 
by prototype pathogen preparedness. Nature 2020;586:56 7-71. 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 91 of 97 4. Bos R, Rutten L, van der Lubbe JEM, et al. Ad26 vector -based COVID -19 vaccine 
encoding a prefusion -stabilized SARS -CoV -2 Spike immunogen induces potent humoral and 
cellular immune responses. npj Vaccines 2020;5:91.  
5. Heath PT, Galiza EP, Baxter D N, et al. Safety and Efficacy of NVX -CoV2373 Covid -19 
Vaccine. N Engl J Med 2021;385:1172 -83. 
6. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX -CoV2373 in Adults 
in the United States and Mexico. N Engl J Med 2021.  
7. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe 
acute respiratory syndrome -related coronavirus 2 (SARS -CoV -2) lineage with multiple spike 
mutations in South Africa. medRxiv 2020:2020.12.21.20248640.  
8. Callaway E, Mallapaty S. Novavax of fers first evidence that COVID vaccines protect 
people against variants. Nature 2021;590:17.  
9. Cohen J. One -dose COVID -19 vaccine offers solid protection against severe disease. 
Science 2021.  
10. Wang P, Nair MS, Liu L, et al. Increased Resistance of SARS -CoV -2 Variants B.1.351 
and B.1.1.7 to Antibody Neutralization. bioRxiv 2021.  
11. Wu K, Werner AP, Moliva JI, et al. mRNA -1273 vaccine induces neutralizing antibodies 
against spike mutants from global SARS -CoV -2 variants. bioRxiv 2021.  
12. Spencer AJ, McKa y PF, Belij -Rammerstorfer S, et al. Heterologous vaccination regimens 
with self -amplifying RNA and Adenoviral COVID vaccines induce robust immune responses in 
mice. bioRxiv 2021:2021.01.28.428665.  
13. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety an d immunogenicity of an 
rAd26 and rAd5 vector -based heterologous prime -boost COVID -19 vaccine in two formulations: 
two open, non -randomised phase 1/2 studies from Russia. Lancet 2020;396:887 -97. 
14. Zent O, Arras -Reiter C, Broeker M, Hennig R. Immediate all ergic reactions after 
vaccinations --a post -marketing surveillance review. Eur J Pediatr 2002;161:21 -5. 
15. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA -1273 SARS -
CoV -2 Vaccine. N Engl J Med 2021;384:403 -16. 
16. Walsh EE, Frenck RW, Jr., Falsey AR, et al. Safety and Immunogenicity of Two RNA -
Based Covid -19 Vaccine Candidates. N Engl J Med 2020;383:2439 -50. 
17. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA 
Covid -19 Vaccine. N Engl J Med 202 0;383:2603 -15. 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 92 of 97 18. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS -CoV -2 
- Preliminary Report. N Engl J Med 2020;383:1920 -31. 
19. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and Immunogenicity of SARS -
CoV -2 mRNA -1273 Vaccine  in Older Adults. N Engl J Med 2020;383:2427 -38. 
20. Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled 
phase 2 trial of the safety and immunogenicity of mRNA -1273 SARS -CoV -2 vaccine. Vaccine 
2021.  
21. Brown CM, Vostok J, John son H, et al. Outbreak of SARS -CoV -2 Infections, Including 
COVID -19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - 
Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1059 -
62. 
22. Rosenberg ES, Holtgra ve DR, Dorabawila V, et al. New COVID -19 Cases and 
Hospitalizations Among Adults, by Vaccination Status — New York, May 3 –July 25, 2021. 
MMWR Morb Mortal Wkly Rep 2021;70.  
23. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer -BioNTech and M oderna 
Vaccines in Preventing SARS -CoV -2 Infection Among Nursing Home Residents Before and 
During Widespread Circulation of the SARS -CoV -2 B.1.617.2 (Delta) Variant — National 
Healthcare Safety Network, March 1 –August 1, 2021. MMWR Morb Mortal Wkly Rep 202 1;70.  
24. Fowlkes A, Gaglani M, Groover K, et al. Effectiveness of COVID -19 Vaccines in 
Preventing SARS -CoV -2 Infection Among Frontline Workers Before and During B.1.617.2 
(Delta) Variant Predominance - Eight U.S. Locations, December 2020 -August 2021. MMWR  
Morb Mortal Wkly Rep 2021;70:1167 -9. 
25. Falsey AR, Frenck RW, Jr., Walsh EE, et al. SARS -CoV -2 Neutralization with 
BNT162b2 Vaccine Dose 3. N Engl J Med 2021.  
26. Chu L, Montefiori D, Huang W, et al. Immune Memory Response After a Booster 
Injection of mR NA-1273 for Severe Acute Respiratory Syndrome Coronavirus -2 (SARS -CoV -
2). medRxiv 2021.  
27. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS -CoV -2 variant 
mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med 2021.  
28. Janssen  Biotech I. FDA Briefing Document - Janssen Ad26.COV2.S Vaccine for the 
Prevention of COVID -19 Vaccines and Related Biological Products Advisory Committee 
MeetingFebruary 26, 2021  
29. Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1 -2a Trial of 
Ad26.COV2.S Covid -19 Vaccine. N Engl J Med 2021.  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 93 of 97 30. Sadoff J, Le Gars M, Cardenas V, et al. Durability of antibody responses elicited by a 
single dose of Ad26.COV2.S and substantial increase following late boosting. MedRxiv 2021.  
31. Keech C, Al bert G, Cho I, et al. Phase 1 -2 Trial of a SARS -CoV -2 Recombinant Spike 
Protein Nanoparticle Vaccine. N Engl J Med 2020;383:2320 -32. 
  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 94 of 97 12 APPENDIX A: Adverse Events of Special Interest (AESIs) 
Terms  
Investigators should report all events which fall into th e following categories as an AESI per the 
reporting processes specified in the protocol. The following AESIs are medical concepts that  
may be related to COVID -19 or are of interest in COVID -19 vaccine safety surveillance . Even if 
the events below occur in the setting of a COVID infection, the event should still be reported as 
an AESI if it is one of the medical concepts below.  
 
Medical Concept  Additional Notes  
Anosmia, Ageusia  • New onset COVID associated or idiopathic events 
without other etiology excluding congenital etiologies or 
trauma  
Subacute thyroiditis  • Including but not limited to events of: atrophic 
thyroiditis, autoimmune thyroiditis, immune -mediated 
thyroiditis, silent thyroiditis, thyrotoxicosis and 
thyroiditis  
Acute pancreatitis  • Includ ing but not limited to events of: autoimmune 
pancreatitis, immune -mediated pancreatitis, ischemic 
pancreatitis, edematous pancreatitis, pancreatitis, acute 
pancreatitis, hemorrhagic pancreatitis, necrotizing 
pancreatitis, viral pancreatitis, and subacute p ancreatitis  
• Excluding known etiologic causes of pancreatitis 
(alcohol, gallstones, trauma, recent invasive procedures)  
Appendicitis  • Include any event of appendicitis  
Rhabdomyolysis  New onset rhabdomyolysis without known etiology 
such as excessive exercise or trauma  
Acute respiratory distress 
syndrome (ARDS)  Including but not limited to new events of ARDS 
and respiratory failure  
Coagulation disorders  Including but not limited to thromboembolic and 
bleeding disorders, disseminated intravascular 
coagulation, pulmonary embolism, deep vein 
thrombosis  
Acute cardiovascular injury  Including but not limited to myocarditis, pericarditis, 
microangiopathy, coronary artery disease, 
arrhythmia, stress cardiomyopathy, heart failure , or 
acute myocardial infarction  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 95 of 97 Acute kidney injury  Include events with idiopathic or autoimmune etiologies  
Exclude events with clear alternate etiology (trauma, 
infection, tumor, or iatrogenic causes such as medications or 
radiocontrast etc .) 
Include al l cases that meet the following criteria :  
Increase in serum creatinine by ≥ 0.3 mg/dl (≥26.5 umol/l) 
within 48 hours;  
OR Increase in serum creatinine to ≥ 1.5 times baseline, 
known or presumed to have occurred within prior 7 days  
OR Urine volume ≤0.5 ml/ kg/ hour for 6 hours  
Acute liver injury  Include events with idiopathic or autoimmune 
etiologies  
Exclude events with clear alternate etiology (trauma, 
infection, tumor, etc .) 
Include all cases that meet the following criteria  
> 3-fold elevation above t he upper normal limit for 
ALT or AST  
OR • > 2 -fold elevation above the upper normal limit 
for total serum bilirubin or GGT or ALP  
Dermatologic findings  • Chilblain -like lesions  
• Single organ cutaneous vasculitis  
• Erythema multiforme  
• Bullous rashes  
• Severe cutaneous adverse reactions including but not 
limited to: Stevens -Johnson Syndrome (SJS), Toxic 
Epidermal Necrolysis (TEN), Drug Reaction with 
Eosinophilia and Systemic Symptoms (DRESS) and 
fixed drug eruptions  
Multisystem inflammatory 
disorders  Multisystem inflammatory syndrome in adults (MIS -
A) 
Multisystem inflammatory syndrome in children 
(MIS -C) 
Kawasaki’s disease  
Thrombocytopenia  and/or 
Thrombosis with 
Thrombocytopenia Syndrome 
(TTS)  • Platelet counts < 150 x10^9  
• Thrombotic events:  Suspected deep vessel venous or 
arterial thrombotic events  
• Including but not limited to TTS (default operative 
diagnosis if boosted with Ad26.COV2.S), immune 
thrombocytopenia, platelet production decreased, 
thrombocytopenia, thrombocytopenic purpura, 
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 96 of 97 throm botic thrombocytopenic purpura, or HELLP 
syndrome  
Acute aseptic arthritis  New onset aseptic arthritis without clear alternate 
etiology (e.g., gout, osteoarthritis, and trauma)  
New onset of or worsening of 
neurologic disease  Including but not limited to : 
Guillain -Barre Syndrome  
Acute disseminated encephalomyelitis (ADEM)  
Peripheral facial nerve palsy (Bell’s palsy)  
Transverse myelitis  
Encephalitis/Encephalomyelitis  
Aseptic meningitis  
Febrile seizures  
Generalized seizures/convulsions  
Stroke (Hemorrhagic and non -hemorrhagic)  
Narcolepsy  
Anaphylaxis  Anaphylaxis is an acute hypersensitivity reaction 
with multi -organ -system involvement that can 
present as, or rapidly progress to, a severe life -
threatening reaction. It may occur following 
exposure  to allergens from a variety of sources. 
Anaphylaxis is a clinical syndrome characterized by:  
o sudden onset AND  
o rapid progression of signs and symptoms AND  
o involving two or more organ systems, as follows:  
o Skin/ mucosal: urticaria (hives), generalized 
erythema, angioedema, generalized pruritus with 
skin rash, generalized prickle sensation, red and 
itchy eyes  
o Cardiovascular: measured hypotension, clinical 
diagnosis of uncompensated shock, loss of 
consciousness or decreased level of 
consciousn ess, evidence of reduced peripheral 
circulation  
o Respiratory: bilateral wheeze (bronchospasm), 
difficulty breathing, stridor, upper airway 
swelling (lip, tongue, throat, uvula, or larynx), 
respiratory distress, persistent dry cough, hoarse 
voice, sensation of throat closure, sneezing, 
rhinorrhea  
o Gastrointestinal: diarrhea, abdominal pain, 
nausea, vomiting  
Follow reporting procedures in protocol.  
DMID Protocol 21 -0012 Version 10.0 
Delayed Boost   06 April 2023  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 97 of 97 Myocarditis and/or pericarditis  Symptoms and diag nostic findings include but ar e not limited to:  
Chest pain  
Dyspnea  
ST or T wave changes on ECG  
Elevated cardiac enzymes  
Abnormal echocardiography or other cardiac imaging.  
Other syndromes  Fibromyalgia  
Postural Orthostatic Tachycardia Syndrome  
Chronic Fatigue Syndrome (Includes Myalgic 
encephalomyelitis and Post viral fatigue syndrome)  
Myasthenia gravis  
 